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Czwartek, 20 maja 2010 roku
15.00–16.00 PREZENTACJA PLAKATÓW przy kawie (prosimy Autorów o obecność przed plakatami)
Sale: Tatry, Rysy, Zawrat, Giewont, Morskie Oko
16.00–16.15 UROCZYSTE OTWARCIE KONFERENCJI (Sala Tatry)
16.15–19.45 SESJA 1. Postępowanie w wolu guzkowym (Sala Tatry)
Przewodniczący: A. Milewicz, J. Nauman
16.15–16.40 Update on European guidelines in thyroid nodules (WYKŁAD NA ZAPROSZENIE)
Ralf Paschke (Lipsk, Niemcy)
16.45–17.00 Kryteria i standardy w BACC raka tarczycy stanowisko Polskiego Towarzystwa
Ultrasonograficznego
W. Jakubowski (Warszawa)
17.05–17.15 Elastografia — nowa technika ultrasonograficzna w diagnostyce guzów tarczycy
M. Gietka-Czernel, M. Kochman, K. Bujalska, E.Stachlewska-Nasfeter, W. Zgliczyński (Warszawa)
17.20–17.30 Ocena wartości ultrasonografii wysokiej rozdzielczości do oceny fałdów głosowych
u pacjentów przed i po tyroidektomii — prospektywne badanie pilotażowe
M. Dedecjus, Z. Adamczewski, J. Brzeziński, A. Lewiński (Łódź)
17.35–17.45 Czy powtórna ocena preparatów cytologicznych biopsji aspiracyjnej cienkoigłowej (BAC)
tarczycy ma wpływ na wybór metody leczenia chorych z guzami tarczycy?
D. Lange, E. Stobiecka, A. Stanek-Widera, D. Banaś, M. Wesołowski (Gliwice)
17.50–18.00 Retrospektywna kategoryzacja rozpoznań z BAC/USG tarczycy
J. Sygut, A. Kowalska, J. Kopczyński, D. Gąsior-Perczak, R. Mężyk, K. Niemyska (Kielce)
18.05–18.15 Trudności diagnostyczne w ocenie histologicznej nowotworów tarczycy. Podobieństwa
i różnice w ocenie preparatów parafinowych w oparciu o konsultacje Polskiej Grupy ds.
Nowotworów Endokrynnych
A. Konturek, M. Barczyński, M. Stopa, P. Richter, W. Nowak (Kraków)
18.20–18.35 Nowe możliwości diagnostyczne w ultrasonografii
Prezentacja sponsorowana SIEMENS
18.35–18.50 Przerwa na kawę
KONFERENCJA OKRĄGŁEGO STOŁU — Postępowanie diagnostyczne i terapeutyczne
w wolu guzkowym
POLSKA GRUPA ds. NOWOTWORÓW ENDOKRYNNYCH
Moderatorzy: A. Lewiński, J. Nauman
18.50–19.05 Polskie Rekomendacje Raka Tarczycy: prezentacja części dotyczącej diagnostyki
cytologicznej guzków tarczycy i rozpoznania histopatologicznego raka tarczycy
S. Sporny (Łódź)
19.05–19.45 Dyskusja
W. Jakubowski, A. Kulig, D. Lange, W. Olszewski, L. Pomorski, D. Słowińska-Klencka, J. Sowiński
20.00–21.00 Koktail powitalny i dyskusja przed plakatami (prosimy Autorów o obecność przed plakatami)
PROGRAM SZCZEGÓŁOWY ZJAZDU
IV Konferencja „Rak tarczycy”
Zakopane, 20–22 maja 2010 roku
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21.00–22.05 SESJA 2. Omówienie doniesień plakatowych „Ciekawe przypadki raka tarczycy”
Dyskusja ( Sala Tatry)
Postery (Sala Tatry)
Przewodniczący: Z. Szybiński, R. Junik
21.00–21.03 Analiza genu PDS w rodzinie z zespołem Pendreda i współwystępującym
rakiem brodawkowatym tarczycy
K. Łącka, A. Paradowska, E. Korman, J. Rajewska, B. Stawny, J.K. Łącki (Poznań)
21.05–21.08 Trudności w diagnostyce i leczeniu pacjenta z przewlekłym autoimmunologicznym
zapaleniem tarczycy i współistniejącym guzkiem tarczycy
M. Niedziela, D. Bręborowicz, B. Rabska-Pietrzak, E. Trejster, J. Harasymczuk (Poznań)
21.10–21.13 Rodzinne występowanie nowotworu oksyfilnego tarczycy, analiza genu GRIM 19
J. Maceluch, B. Rabska-Pietrzak, A. Rojek, J. Harasymczuk, E. Trejster, M. Warzywoda, D. Bręborowicz,
J. Bręborowicz, M. Niedziela (Poznań)
21.15–21.18 Guz tarczycy jako pierwsza manifestacja ziarnicy złośliwej
M. Ruchała, E. Szczepanek, P. Majewski, J. Sowiński (Poznań)
21.20–21.23 Opis przypadku chłoniaka Hodgkina wywodzącego się z grasicy imitującego
wole zamostkowe
M. Dedecjus, A. Kędzierska, J. Kozak, G. Stróżyk, R. Kordek, J. Brzeziński (Łódź)
21.25–21.28 Zróżnicowany rak tarczycy u kobiet w ciąży — dylematy kliniczne
M. Koziołek, E. Wentland-Kotwicka, A. Syrenicz (Szczecin)
21.30–21.33 Wariant kolumnowokomórkowy raka brodawkowatego tarczycy w wolu jajnika
— opis przypadku
B. Szcześniak-Kłusek, E. Stobiecka, A. Smok-Ragankiewicz, J. Krajewska, A. Czarniecka, D. Lange (Gliwice)
21.35–21.38 Leczenie sorafenibem w zaawansowanym raku tarczycy — opis przypadku
J. Krajewska, T. Olczyk, J. Roskosz, A. Śmietana, B. Kaczmarek-Borowska, E. Paliczka-Cieślik,
S. Szpak-Ulczok, B. Jarząb (Gliwice)
21.40–21.43 Przypadek pacjenta z akromegalią i rozsianym rakiem pęcherzykowym tarczycy
A. Bałdys-Waligórska, F. Gołkowski, A. Krzentowska, A. Stefańska, O. Halytskyy,
A. Hubalewska-Dydejczyk (Kraków)
21.45–21.48 Izolowany przerzut raka jasnokomórkowego nerki do tarczycy — opis przypadku
M. Bilski, G. Kamiński (Warszawa)
21.50–21.53 Przerzut raka piersi do tarczycy — prezentacja dwóch przypadków
E. Skowrońska-Jóźwiak, Z. Adamczewski, K. Krawczyk-Rusiecka, A. Gumińska, S. Sporny,
A Kulig, M. Dedecjus, J. Brzeziński, A. Lewiński (Łódź)
21.55–21.58 Współistnienie gruczolaków przytarczyc u pacjentki hemodializowanej z rakiem tarczycy
— opis przypadku
J. Skrobisz, R. Wieczorek (Poznań)
22.00–22.03 Współwystępowanie raka jasnokomórkowego nerki i pęcherzykowego tarczycy
— opis przypadku
M. Bilski, G. Kamiński (Warszawa)
Piątek, 21 maja 2010 roku
8.30–10.30 SESJA 3. Leczenie operacyjne raka tarczycy
Sesja im. Prof. Jana Skrzypka (Sala Tatry)
Przewodniczący: J. Brzeziński, J. Włoch
8.30–8.45 Molekularne i kliniczne czynniki rokownicze i ich miejsce w strategii
chirurgicznej raka tarczycy
A. Czarniecka, J. Włoch (Gliwice)
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8.48–9.03 Przed-, śród- i pooperacyjny monitoring funkcji nerwów krtaniowych wstecznych
w chirurgicznym leczeniu raka tarczycy
M. Dedecjus, J. Brzeziński (Łódź)
9.06–9.15 Ocena wartości klinicznej śródoperacyjnego neuromonitoringu
wyników leczenia operacyjnego raka tarczycy
M. Barczyński, A. Konturek, S. Cichoń, W. Nowak (Kraków)
9.18–9.27 Ryzyko niezamierzonego wycięcia przytarczycy w czasie operacji raka tarczycy
L. Pomorski, K. Paduszyńska, S. Mikosiński, E. Rogowska, K. Kaczka (Łódź)
9.30–9.39 Skojarzone leczenie zróżnicowanego raka tarczycy (ZRT) u dzieci: ocena powikłań
A. Kropińska, J. Roskosz, J. Włoch, J. Krajewska, A. Krawczyk, T. Olczyk, E. Paliczka-Cieślik, J. Kozielski,
A. Krzywiecki, J. Szczasny, K. Steinhof-Radwańska, W. Przeorek, D. Handkiewicz-Junak (Gliwice)
9.42–9.51 Odcinkowa rekonstrukcja tchawicy przy zastosowaniu wolnego płata promieniowego
i podporowego stelaża pierścieni biodegradowalnych na przykładzie 3 przypadków
A. Maciejewski, C. Szymczyk, J. Wierzgoń, M. Grajek, M. Dobrut, R. Szumniak, S. Półtorak,
Ł. Krakowczyk, P. Jędrzejewski (Gliwice)
9.54–10.20 Advances in thyroid cancer surgery (WYKŁAD NA ZAPROSZENIE)
Michele Minuto (Piza, Włochy)
10.30–10.45 Przerwa na kawę
10.45–12.45 SESJA 4. Badania molekularne raka tarczycy i udziału hormonów tarczycy
w kancerogenezie
Sesja im. Prof. Jana Steffena (Sala Tatry)
Przewodniczący: A. Nauman, K. Łącka
10.45–11.10 Molecular biology of thyroid cancer (WYKŁAD NA ZAPROSZENIE)
Clara Alvarez (Santiago de Compostela, Hiszpania)
11.15–11.24 Kariometryczna charakterystyka raka brodawkowatego tarczycy i jej związek ze zmianami
w profilu ekspresji genów
M. Chekan, M. Świerniak, M. Jarząb, M. Oczko-Wojciechowska, D. Rusinek, M. Śnietura, B. Jarząb (Gliwice)
11.27–11.36 Charakterystyka transkryptomu mikrodyssekowanych tyreocytów
raka brodawkowatego tarczycy
M. Oczko-Wojciechowska, A. Rusin, D. Rusinek, M. Kowalska, M. Kowal, T. Tyszkiewicz, M. Chekan,
A. Czarniecka, E. Gubała, B. Jarząb (Gliwice)
11.39–11.48 Przewidywanie ryzyka przerzutów odległych w raku brodawkowatym tarczycy za pomocą
profilu ekspresji genów
S. Szpak-Ulczok, M. Jarząb, M. Oczko-Wojciechowska, M. Kowalska, M. Kowal, T. Tyszkiewicz, A. Pfeifer,
A. Czarniecka, J. Włoch, B. Jarząb (Gliwice)
11.51–12.00 Ekspresja genów związanych z wiekiem chorego w tarczycy i nowotworach gruczołu
tarczowego na podstawie badania ich profilu metodą mikromacierzy oligonukleotydowych
M. Jarząb, M. Oczko-Wojciechowska, M. Świerniak, S. Szpak-Ulczok, D. Handkiewicz-Junak, M. Kowal,
T. Tyszkiewicz, D. Lange, M. Chekan, A. Pfeifer, T. Tyszkiewicz, A. Czarniecka, B. Jarząb, Z. Krawczyk (Gliwice)
12.03–12.12 Rola mikroRNA w zaburzeniach ekspresji jodotyroninowej dejodynazy typu I w raku nerki
typu jasnokomórkowego (ccRCC)
J. Bogusławska, A. Master, A. Piekiełko-Witkowska, A. Wójcicka, P. Popławski, Z. Tański, A. Nauman (Warszawa)
12.15–12.24 Zaburzenia ekspresji receptora hormonu tarczycy TR1 w raku nerki człowieka
A. Piekiełko-Witkowska, A. Master, A. Wójcicka, J. Bogusławska, P. Popławski, H. Wiszomirska, Z. Tański,
V.M. Darras, G.R. Williams, A. Nauman (Londyn)
12.27–12.36 Wpływ reakcji Fentona na oksydacyjne uszkodzenia lipidów błon komórkowych
i jądrowego DNA w tarczycy wieprzowej — potencjalny udział w inicjacji kancerogenezy
J. Stępniak, A. Kokoszko, K. Zasada, J. Szosland, M. Milczarek, A. Gesing, A. Lewiński,
M. Karbownik-Lewińska (Łódź)
579
M
A
T
ER
IA
ŁY
Z
JA
Z
D
O
W
E
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 61 (5)
12.45–14.15 Przerwa obiadowa
14.15–15.15 SESJA 5. Leczenie uzupełniające raka tarczycy (Sala Tatry)
Przewodniczący I. Kozłowicz-Gudzińska, M. Gryczyńska
14.15–14.24 Ocena skuteczności uzupełniającego leczenia jodem promieniotwórczym po radykalnym
leczeniu operacyjnym u chorych na zróżnicowane raki tarczycy (ZRT)
J. Krajewska, M. Jarząb, A. Czarniecka, J. Roskosz, A. Kukulska, E. Paliczka-Cieślik,
Z. Puch, D. Handkiewicz-Junak, B. Jarząb (Gliwice)
14.27–14.36 Leczenie uzupełniające jodem promieniotwórczym chorych na zróżnicowanego raka
tarczycy: porównanie efektów leczenia uzupełniającego 131-I przy zastosowaniu
aktywności 30, 60 i 100 mCi — ocena późna
A. Kukulska, J. Krajewska, Z. Puch, M. Gawkowska-Suwińska, E. Paliczka-Cieślik, J. Roskosz,
D. Handkiewicz-Junak, M. Jarząb, E. Gubała, B. Jarząb (Gliwice)
14.39–14.48 Porównanie dwóch grup pacjentów ze zróżnicowanym rakiem tarczycy leczonych
radiojodem 131-I po stymulacji endogennej i egzogennej TSH
A. Bałdys-Waligórska, F. Gołkowski, A. Krzentowska, A. Hubalewska-Dydejczyk (Kraków)
14.51–15.00 Analiza kliniczna wydalania jodu z moczem u chorych
na zróżnicowane raki tarczycy (ZRT)
B. Michalik, J. Roskosz, A. Stanjek-Cichoracka, A. Kochańska-Dziurowicz, B. Jarząb (Gliwice)
15.03–15.12 Stężenie TSH u chorych na zróżnicowanego raka tarczycy (ZRT) podczas leczenia
supresyjnego L-tyroksyną: ocena dotychczasowej praktyki klinicznej
A. Kropińska, J. Roskosz, Z. Puch, J. Krajewska, A. Krawczyk, T. Olczyk, H. Lewandowska, A. Antosz,
M. Dobrakowski, E. Gubała, B. Jarząb (Gliwice)
15.15–15.45 Przerwa na kawę
15.45–16.45 SESJE 6A–6D. OMÓWIENIE DONIESIEŃ PLAKATOWYCH
Sesja 6A. Biologia molekularna raka tarczycy
Dyskusja (Sala Rysy)
Postery (Sala Rysy)
Przewodniczący: M. Karbownik-Lewińska, M. Niedziela
Sesja 6B. Postępy w wykrywaniu raka tarczycy
Dyskusja (Sala Tatry)
Postery (Sala Giewont)
Przewodniczący: K. Kuzdak, M. Ruchała
Sesja 6C. Biopsje aspiracyjne cienkoigłowe, tyreologia ogólna
Dyskusja (Sala Zawrat)
Postery (Sala Zawrat)
Przewodniczący: A. Kulig, A. Syrenicz
Sesja 6D. Rak rdzeniasty tarczycy
Dyskusja (Sala Morskie Oko)
Postery (Sala Morskie Oko)
Przewodniczący: L. Pomorski, B. Kos-Kudła
16.45–17.15 Przerwa na kawę
15.45–16.38 Sesja 6A. Biologia molekularna raka tarczycy
Dyskusja (Sala Rysy)
Postery (Sala Rysy)
Przewodniczący: M. Karbownik-Lewińska, M. Niedziela
580
Tytuł artykułu Autor i wsp.
M
A
T
ER
IA
ŁY
Z
JA
Z
D
O
W
E
15.45–15.48 Geny naprawy DNA w liniach nowotworowych i guzach tarczycy
J. Janik, K. Hanusek, B. Czarnocka (Warszawa)
15.50–15.53 Analiza ekspresji mRNA genu NDRG2 w pierwotnym raku brodawkowatym tarczycy
oraz w przerzutach tego raka do regionalnych węzłów chłonnych
A. Mordalska, J. Latek, T. Ferenc, L. Pomorski, A. Zygmunt, E. Gałecka, A. Lewiński (Łódź)
15.55–15.58 Model zwierzęcy raka brodawkowatego tarczycy indukowanego mutacją BRAFV600E
D. Rusinek, E. Chmielik, M. Kowal, E. Gubała, W. Widłak (Gliwice)
16.00–16.03 Ocena transkryptomu raka brodawkowatego tarczycy w stosunku do tarczycy
niezmienionej nowotworowo na podstawie profilu ekspresji genów
M. Świerniak, M. Jarząb, M. Oczko-Wojciechowska, A. Pfeifer, K. Unger, C. Maenhaut, G. Thomas,
B. Jarząb (Gliwice)
16.05–16.08 Próba zastosowania techniki lasów losowych (Random Forests) do dyskryminacji typów
histologicznych nowotworów tarczycy
T. Stokowy, M. Jarząb, K. Fujarewicz, M. Oczko-Wojciechowska, A. Pfeifer, R. Paschke, M. Eszlinger (Gliwice)
16.10–16.13 Ekspresja genów odpowiedzi immunologicznej w nowotworach tarczycy
— analiza transkryptomu
M. Jarząb, M. Oczko-Wojciechowska, M. Kowal, M. Olakowski, A. Rusin, M. Kowalska, D. Rusinek, A. Pfeifer,
M. Świerniak, A. Czarniecka, E. Chmielik, E. Stobiecka, D. Lange, J. Jarząb, Z. Krawczyk (Gliwice)
16.15–16.18 Porównanie profilu ekspresji genów w gruczolakach tarczycy i innych gruczolakach
wewnątrzwydzielniczych
J. Żebracka-Gala, M. Oczko-Wojciechowska, M. Kowalska, A. Kukulska, A. Czarniecka, E. Gubała, D. Larysz,
A. Rudnik, J. Waler, J. Gawrychowski, A. Pfeifer, M. Świerniak, M. Jarząb, E. Chmielik, D. Lange,
K. Fujarewicz, A. Świerniak, B. Jarząb (Gliwice)
16.20–16.23 Ekspresja ghreliny i obestatyny w ludzkiej zdrowej tarczycy i nowotworach tarczycy
E. Gurgul, M. Ruchała, M. Biczysko, J. Surdyk-Zasada, A. Kasprzak, A. Łukaszyk, J. Sowiński (Poznań)
16.25–16.28 Chip diagnostyczny oparty o inhibitory enzymów — wstępne badania
W. Balcerzak, A. Czernicka, S. Deja, P. Młynarz, P. Kafarski (Wrocław)
16.30–16.33 Ryzyko wystąpienia oraz obraz kliniczny raka brodawkowatego tarczycy
a polimorfizm genu CHEK2A
M. Kalemba, Z. Puch, D. Kula, M. Kowalska, M. Kowal, T. Tyszkiewicz, D. Handkiewicz-Junak, J. Roskosz,
K. Drosik, M. Żydek, A. Sikora, A. Chróst, E. Gubała, B. Jarząb (Gliwice)
16.35–16.38 Opis przypadku chorej z rakiem brodawkowatym tarczycy, u której diagnostykę
tyreologiczną podjęto ze względu na obecność mutacji CHEK2
K. Lizis-Kolus, A. Kowalska, B. Kozak-Klonowska, M. Siołek, J. Słuszniak, J. Lubiński, C. Cybulski (Kielce)
16.45–17.15 Przerwa na kawę
15.45–16.33 Sesja 6B. Postępy w wykrywaniu raka tarczycy
Dyskusja (Sala Tatry)
Postery (Sala Giewont)
Przewodniczący: K. Kuzdak, M. Ruchała
15.45–15.48 Analiza obrazów ultrasonograficznych raków wielkości do 15 mm w aspekcie typowania
zmian do BAC w wolu wieloguzkowym
J. Pankowski, E. Kaznowska, B. Maksymiuk (Zakopane)
15.50–15.53 Analiza przydatności oznaczania steżenia PTH w materiale uzyskanym podczas biopsji
aspiracyjnej cienkoigłowej zmian ogniskowych szyi w lokalizowaniu przytarczyc
B. Popowicz, J. Jankiewicz-Wika, S. Sporny, M. Klencki, E. Woźniak, E. Sewerynek, E.J. Komorowski,
D. Słowińska-Klencka (Łodź)
15.55–15.58 Wykorzystanie elastografii opartej na metodzie obrazowania harmonicznego na podstawie
Dopplera tkankowego w diagnostyce zmian ogniskowych w tarczycy — badanie pilotażowe
Z. Adamczewski, K. Krawczyk-Rusiecka, M. Dedecjus, J. Brzeziński, A. Lewiński (Łódź)
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16.00–16.03 Nowe metody ultrasonograficzne w wizualizacji mikrozwapnień w diagnostyce zmian
ogniskowych tarczycy
R.Z. Słapa, W. Jakubowski, K.T. Szopiński, A. Szcześniak, J. Bierca, J. Słowińska-Srzednicka (Warszawa)
16.05–16.08 Zalety i wady ultrasonografii trójwymiarowej guzów tarczycy z uwzględnieniem
rekonstrukcji cienkiej warstwy
R.Z. Słapa, W. Jakubowski, J. Słowińska-Srzednicka, K.T Szopiński (Warszawa)
16.10–16.13 Częstość występowania oraz charakterystyka zmian ogniskowych u pacjentów
z hemiagenezją tarczycy
M. Ruchała, E. Szczepanek, J. Sowiński (Poznań)
16.15–16.18 Wole nawrotowe poza typową lokalizacją płatów bocznych — analiza ponad 60 przypadków
E. Woźniak, M. Klencki, B. Popowicz, S. Sporny, D. Słowińska-Klencka (Łódź)
16.20–16.23 Występowanie zmian nowotworowych w tarczycy u pacjentów po leczeniu radiojodem
z powodu zmian łagodnych
M.H. Listewnik, B. Birkenfeld, K. Niedziałkowska, M. Chosia, B. Elbl, M. Sawrymowicz (Szczecin)
16.25–16.28 Zastosowanie badania SPECT/CT z MIBI-Tc99m i porównanie z metodą subtrakcji
w diagnostyce zmian guzkowych w tarczycy
M.H. Listewnik, B. Birkenfeld, K. Cichoń-Bańkowska, K. Niedziałkowska, L. Iglińska-Wagner, W. Watrak,
W. Smolira, P. Zorga, H. Piwowarska-Bilska, B. Elbl, M. Sawrymowicz (Szczecin)
16.30–16.33 Analiza wyników badania histopatologicznego tarczycy po reperacjach z powodu raka
tarczycy w rozpoznaniach po strumektomii
J. Skrobisz (Poznań)
16.45–17.15 Przerwa na kawę
15.45–16.38 Sesja 6C. Biopsje aspiracyjne cienkoigłowe, tyreologia ogólna
Dyskusja (Sala Zawrat)
Postery (Sala Zawrat)
Przewodniczący: A. Kulig, A. Syrenicz
15.45–15.48 Analiza zgodności wyników biopsji aspiracyjnej cienkoigłowej celowanej (BACC)
z badaniem histopatologicznym u pacjentów ze zmianami ogniskowymi tarczycy
w materiale własnym
M. Rzeszutko, W. Rzeszutko, T. Tomkalski (Wrocław)
15.50–15.53 Ocena zgodności przed- i pooperacyjnych rozpoznań nowotworów złośliwych
gruczołu tarczowego
P. Furga, J. Łapiński, K. Paśnik (Warszawa)
15.55–15.58 Biopsja celowana aspiracyjna cienkoiglowa a badanie śródoperacyjne tarczycy
w materiale własnym oddzialu chirurgii onkologicznej
D. Bisz, J. Albiński, S. Borczewski, P. Ciszewski (Warszawa)
16.00–16.03 Cytodiagnostyka niskozróżnicowanego raka tarczycy
J. Sygut, W. Rezner, J. Kopczyński, J. Słuszniak, A. Kowalska (Kielce)
16.05–16.08 Rola biopsji aspiracyjnej cienkoigłowej w rozpoznawaniu przerzutów nowotworowych
do tarczycy — spostrzeżenia własne
G. Buła, J. Waler, A. Niemiec, H. Koziołek, W. Bichalski, J. Gawrychowski (Bytom)
16.10–16.13 Morphological diagnostics of solitary cystic thyroid nodules
V.N. Marina, V.I. Kolomiytsev, V.I. Vovk, O.V. Lukavetsky, M.P. Pavlovsky (Lwów, Ukraina)
16.15–16.18 Etyczno-ekonomiczne aspekty biopsji tarczycy — obserwacje ośrodka terenowego
M. Maciejewski, M. Gąsiorek, M. Słomian, A. Sawicka, K. Marczewski (Zamość)
16.20–16.23 Ocena wyników stężenia IL-6 u pacjentów z chorobą Graves-Basedowa
bez aktywnej oftalmopatii
D. Zalewska-Rydzkowska, A. Nowicka, J. Kwaśniewska-Błaszkowska, S. Manysiak,
G. Odrowąż-Sypniewska, R. Junik (Bydgoszcz)
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16.25–16.28 Zaburzenia czynności tarczycy wykrywane w badaniu przesiewowym w kierunku
wrodzonej niedoczynności tarczycy
M. Kumorowicz-Czoch, D. Tylek-Lemańska, J. Starzyk (Kraków)
16.30–16.33 Udział polimorfizmu Pro12Ala genu PPAR-g w orbitopatii endokrynnej
J. Daroszewski, E. Pawlak, M. Bolanowski, I. Rydecka (Wrocław)
16.35–16.38 Identyfikacja markerów immunologicznych (CD54, CD95, CD134, CD152) na tyreocytach
pacjentów z immunologicznymi i nieimmunologicznymi schorzeniami tarczycy przy
wykorzystaniu hodowli komórkowych
A. Bossowski, E. Iłendo, K. Ratomski, B. Czarnocka, J. Dadan (Białystok)
16.45–17.15 Przerwa na kawę
15.45–16.13 Sesja 6D. Rak rdzeniasty tarczycy
Dyskusja (Sala Morskie Oko)
Postery (Sala Morskie Oko)
Przewodniczący: L. Pomorski, B. Kos-Kudła
15.45–15.48 Analiza transkryptomu raka rdzeniastego tarczycy
M. Oczko-Wojciechowska, J. Włoch, J. Żebracka-Gala, A. Pfeifer, M. Kowalska, Z. Wygoda, A. Czarniecka,
E. Gubała, B. Jarząb (Gliwice)
15.50–15.53 Rola badań PET-CT z analogiem somatostatyny znakowanym galem-68 (68Ga-DOTA-TATE
PET-CT) w diagnostyce rozsiewu raka rdzeniastego tarczycy (MTC)
I. Pałyga, A. Kowalska, D. Gąsior-Perczak, J. Słuszniak. J. Sygut, M. Tarnawska-Pierścińska,
S. Góźdź (Kielce)
15.55–15.58 Ocena przydatności oznaczeń stężenia prokalcytoniny w obserwacji chorych z rakiem
rdzeniastym tarczycy (RRT)
D. Gąsior-Perczak, A. Kowalska, I. Pałyga, G. Antczak, A. Słuszniak, S. Góźdź (Kielce)
16.00–16.03 Ocena wartości prognostycznej czasu podwojenia stężenia markerów nowotworowych
raka rdzeniastego tarczycy
T. Gawlik, A. d’Amico, E. Gubała, A. Chorąży, K. Gorczewski, B. Jarząb (Gliwice)
16.05–16.08 Fenotyp nosicieli mutacji w eksonie 10 protoonkogenu RET
S. Szpak-Ulczok, E. Gubała, A. Pawlaczek, M. Oczko-Wojciechowska, B. Jarząb (Gliwice)
16.10–16.13 Guzy chromochłonne wsród nosicieli mutacji germinalnych protoonkogenu RET
K. Hasse-Lazar, A. Krawczyk, S. Szpak-Ulczok, A. Pawlaczek, J. Ziaja, B. Jarząb (Gliwice)
16.45–17.15 Przerwa na kawę
17.15–20.00 SESJA 7. Nowoczesne leczenie raka tarczycy (Sala Tatry)
Przewodniczący: M. Gembicki, I. Kinalska
17.15–17.45 Recent Advances in Management of Thyroid Cancer (WYKŁAD NA ZAPROSZENIE)
Paul Ladenson
17.50–18.10 Terapia celowana w zaawansowanym raku tarczycy
B. Jarząb (Gliwice)
18.15–18.30 Nowe możliwości diagnostyczne w medycynie nuklearnej
Prezentacja sponsorowana SIEMENS
KONFERENCJA OKRĄGŁEGO STOŁU Leczenie raka tarczycy
Polska Grupa ds. Nowotworów Endokrynnych
Moderatorzy: S. Zgliczyński, B. Jarząb
18.30–18.40 Polskie Rekomendacje Raka Tarczycy: prezentacja części dotyczącej
leczenia operacyjnego raka tarczycy
K. Kuzdak, J. Brzeziński, J. Włoch (Gliwice)
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18.50–19.00 Polskie Rekomendacje Raka Tarczycy: prezentacja części dotyczącej
leczenia izotopowego raka tarczycy
B. Jarząb, J. Sowiński, I. Kozłowicz-Gudzińska (Gliwice)
19.10–19.20 Polskie Rekomendacje Raka Tarczycy: prezentacja części dotyczącej
raka rdzeniastego tarczycy
L. Pomorski, J. Włoch, B. Jarząb (Gliwice)
19.20–20.00 Dyskusja
J. Brzeziński, I. Kozłowicz-Gudzińska, K. Kuzdak, A. Lewiński, L. Pomorski, J. Sowiński, J. Włoch
20.30 SPOTKANIE TOWARZYSKIE
Sobota, 22 maja 2010 roku
9.00–10.45 SESJA 8. Obrazowanie i leczenie izotopowe raka tarczycy (Sala Tatry)
Przewodniczący: J. Sowiński, T. Bednarczuk
9.00–9.08 Wartość kliniczna badania PET z 18F-fluorodeoksyglukozą u chorych z podejrzeniem
wznowy zróżnicowanego raka tarczycy
A. d’Amico, T. Gawlik, J. Roskosz, A. Kukulska, B. Jarząb (Gliwice)
9.11–9.19 Rola badań obrazowych w diagnostyce przerzutów odległych zróżnicowanego raka tarczycy
R. Czepczyński, M. Gryczyńska, A. Czepczyńska, M. Stajgis, J. Sowiński (Poznań)
9.22–9.30 Scyntygrafia receptorowa PET z użyciem znakowanych galem pozytonowym analogów
somatostatyny w raku rdzeniastym tarczycy
Z. Wygoda, A. d’Amico, D. Hankiewicz-Junak, B. Jurecka-Lubieniecka, K. Hasse-Lazar, B. Jarząb (Gliwice)
9.33–9.41 Prokalcytonina — nowy marker u chorych z rakiem rdzeniastym tarczycy
K. Kaczka, S. Mikosiński, L. Pomorski (Łódź)
9.44–10.10 Advances in radioiodine treatment of thyroid cancer (WYKŁAD NA ZAPROSZENIE)
Markus Luster (Ulm, Niemcy)
10.15–10.40 Nuclear medicine for medullary thyroid cancer (WYKŁAD NA ZAPROSZENIE)
Lisa Bodei (Mediolan, Włochy)
10.45–11.00 Przerwa na kawę
11.00–12.00 SESJE 9A–9C. OMÓWIENIE DONIESIEŃ PLAKATOWYCH
Sesja 9A. Wspomaganie wykrywania raka tarczycy
Dyskusja (Sala Tatry)
Postery (Sala Giewont)
Przewodniczący: S. Sporny, M. Puzianowska-Kuźnicka
Sesja 9B. Klinika raka tarczycy
Dyskusja (Sala Rysy)
Postery (Sala Rysy)
Przewodniczący: S. Cichoń, M. Zieliński
Sesja 9C. Leczenie i monitorowanie raka tarczycy
Dyskusja (Sala Zawrat)
Postery (Sala Zawrat)
Przewodniczący: M. Gryczyńska, M. Grzywa
12.00–13.15 Przerwa obiadowa
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11.00–11.48 Sesja 9A. Wspomaganie wykrywania raka tarczycy
Dyskusja (Sala Tatry)
Postery (Sala Giewont)
Przewodniczący: S. Sporny, M. Puzianowska-Kuźnicka
11.00–11.03 Guzy pęcherzykowe i oksyfilne tarczycy — doświadczenia własne
J. Waler, G. Buła, A. Niemiec, W. Truchanowski, R. Mucha, N. Waler, J. Gawrychowski (Bytom)
11.05–11.08 Zastosowanie nienadzorowanych metod analizy do interpretacji zmienności ekspresji
genów w zbiorze guzów pechęrzykowych
A. Pfeifer, M. Eszlinger, T. Musholt, S. Hauptmann, M. Oczko-Wojciechowska, M. Jarząb, M. Świerniak,
D. Lange, R. Paschke, B. Jarząb (Gliwice)
11.10–11.13 Ocena ekspresji genu COX-2 u pacjentów z rakiem brodawkowatym gruczołu tarczowego
w materiale pobranym w badaniu BAC tarczycy
K. Krawczyk-Rusiecka, K. Wojciechowska-Durczyńska, A. Cyniak-Magierska, Z. Adamczewski, A. Lewiński (Łódź)
11.15–11.18 Ocena poziomu ekspresji genu PIK3CA w raku brodawkowatym tarczycy
K. Wojciechowska-Durczyńska, K. Krawczyk-Rusiecka, A. Cyniak-Magierska, A. Zygmunt, A. Lewiński (Łódź)
11.20–11.23 Endogenna aktywność biotynowo-awidynowa w badaniach immunohistochemicznych
chorób tarczycy
B. Nikiel, M. Chekan, M. Jarząb, D. Lange (Gliwice)
11.25–11.28 Ocena występowania rearanżacji RET/PTC1 i RET/PTC3 w bioptatach tarczycy pobranych
od pacjentów z przewlekłym autoimmunologicznym zapaleniem tego gruczołu
A. Cyniak-Magierska, K. Wojciechowska-Durczyńska, K. Rusiecka-Krawczyk, A. Zygmunt, A. Lewiński (Łódź)
11.30–11.33 Identyfikacja immunohistochemiczna ogniska pierwotnego oraz przerzutów węzłowych
raka brodawkowatego tarczycy
A. Konturek, M. Barczyński, M. Stopa, P. Richter, W. Nowak (Kraków)
11.35–11.38 Ocena korelacji ekspersji metalotioneiny i ekspresji antygenu Ki-67 w łagodnych
i złośliwych chorobach tarczycy
A. Królicka, P. Domosławski, B. Wojtczak, J. Dawiskiba, Ch. Kobierzycki, A. Piotrowska, M. Podhorska-Okołów,
P. Dzięgiel, T. Łukieńczuk, K. Kaliszewski, J. Daroszewski (Wrocław)
11.40–11.43 Ocena swoistości potencjalnych genów markerowych FN1, KRT19, DPP4, MET,
CDH3 w różnicowaniu raka brodawkowatego i guzków łagodnych tarczycy
W. Truchanowski, M. Kowalska, M. Oczko-Wojciechowska, M. Kowal, T. Tyszkiewicz, A. Kukulska,
A. Czarniecka, J. Włoch, J. Waler, G. Buła, M. Kucharzewski, B. Jarząb, J. Gawrychowski (Bytom)
11.45–11.48 Ekspresja genu LGALS3BP w tkance gruczołu tarczowego i limfocytach krwi obwodowej
jako potencjalny czynnik prognostyczny raka brodawkowatego tarczycy o wysokiej
złośliwości — 5 lat obserwacji
K. Kaliszewski, T. Łukieńczuk, W. Bednarz, W. Balcerzak, B. Wojtczak, T. Dobosz, M. Kaliszewska,
J. Dawiskiba (Wrocław)
12.00–13.15 Przerwa obiadowa
11.00–11.58 Sesja 9B. Klinika raka tarczycy
Dyskusja (Sala Rysy)
Postery (Sala Rysy)
Przewodniczący: S. Cichoń, M. Zieliński
11.00–11.03 Ocena zawansowania raka tarczycy: czy obserwujemy różnice w ciągu ostatniego
dziesięciolecia?
B. Michalik, J. Kern-Bałaga, M. Kalemba, B. Włodarczyk-Marciniec, B. Zemła (Gliwice)
11.05–11.08 Zapadalność na raka tarczycy w obszarze epidemiologicznym Olsztyna i dawnych
granicach województwa olsztyńskiego w latach 1993–2008
E. Bandurska-Stankiewicz, E. Aksamit-Białoszewska, A. Stankiewcz, D. Shafie (Olsztyn)
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11.10–11.13 Ocena częstości przerzutów raka brodawkowatego tarczycy do węzłów chłonnych
kompartymentu centralnego szyi u chorych poddawanych elektywnej limfadenektomii
M. Barczyński, A. Konturek, M. Stopa, P. Richter, W. Nowak (Kraków)
11.15–11.18 Znaczenie rokownicze przerzutów do węzłów chłonnych zróżnicowanych raków tarczycy
(ZRT) w zależności od zakresu leczenia operacyjnego i zaawansowania miejscowego
A. Czarniecka, M. Jarząb, J. Krajewska, E. Chmielik, E. Stobiecka, B. Szcześniak-Kłusek, R. Kokot, A. Sacher,
S. Półtorak, J. Włoch (Gliwice)
11.20–11.23 Przerzuty przeskakujące w raku brodawkowatym tarczycy — częstość występowania
i wpływ na leczenie operacyjne
L. Pomorski, M. Dobrogowski, S. Mikosiński, K. Kaczka (Zgierz)
11.25–11.28 Nowotwory tarczycy u dzieci i młodzieży operowanych z powodu wola guzkowego
w uniwersyteckim szpitalu pediatrycznym w ostatnim 40-leciu
A. Kalicka-Kasperczyk, G. Drabik, J. Skirpan, W. Mieżyński, J. Starzyk (Kraków)
11.30–11.33 Rak tarczycy wykryty przypadkowo w pooperacyjnym badaniu parafinowym
R. Anielski, S. Cichoń, A. Hubalewska-Dydejczyk, M. Buziak-Bereza, P. Orlicki, A. Bałdys-Waligórska (Kraków)
11.35–11.38 Rak tarczycy leczony w trybie ostrodyżurowym — 10 lat doświadczeń I Katedry i Kliniki
Chirurgii Ogólnej Gastroenterologicznej i Endokrynologicznej Akademii Medycznej
we Wrocławiu
K. Kaliszewski, T. Łukieńczuk, W. Bednarz, P. Domosławski, B. Knychalski, M. Kaliszewska, K. Sutkowski (Wrocław)
11.40–11.43 Rak brodawkowaty tarczycy teraz i 10 lat temu — analiza w oparciu o materiał I Katedry
i Kliniki Chirurgii Ogólnej, Gastroenterologicznej i Endokrynologicznej Akademii
Medycznej we Wrocławiu
K. Kaliszewski, T. Łukieńczuk, W. Bednarz, W. Balcerzak, Z. Forkasiewicz, J. Spodzieja, M. Kaliszewska,
T. Dawiskiba, M. Napierała, W. Podhorski (Wrocław)
11.45–11.48 Zastosowanie nowej techniki operacyjnej z dostępu szyjnego z uniesieniem rękojeści
mostka w leczeniu operacyjnym wola ekotopowego
M. Zielinski, J. Pankowski, M. Skrobot, L. Hauer, T. Nabialek, A. Szlubowski (Zakopane)
11.50–11.53 Występowanie innych nowotworów złośliwych u chorych
ze zróżnicowanym rakiem tarczycy
E. Mikina, J. Sygut, A. Kowalska (Kielce)
11.55–11.58 Przebieg kliniczny niskozróżnicowanego raka tarczycy (ca insulare) — obserwacja własna
A. Walczyk, A. Kowalska (Kielce)
12.00–13.15 Przerwa obiadowa
11.00–11.58 Sesja 9C. Leczenie i monitorowanie raka tarczycy
Dyskusja (Sala Zawrat)
Postery (Sala Zawrat)
Przewodniczący: M. Gryczyńska, M. Grzywa
11.00–11.03 Prospektywna analiza wskazań do leczenia 131I u chorych na mikroraka brodawkowatego
po niecałkowitym wycięciu tarczycy
T. Olczyk, A. Kropińska, A. Krawczyk, J. Krajewska, D. Handkiewicz-Junak, B. Jarząb (Gliwice)
11.05–11.08 Leczenie jodem promieniotwórczym chorych na zaawansowanego zróżnicowanego raka
tarczycy (ZRT)
D. Handkiewicz-Junak, E. Paliczka-Cieślik, J. Roskosz, K. Hasse-Lazar (Gliwice)
11.10–11.13 Wpływ obecności przerzutów odległych i/lub do węzłów chłonnych na częstość uzyskania
pełnej remisji u chorych ze zróżnicowanym rakiem tarczycy (DTC)
T. Trybek, A. Kowalska (Kielce)
11.15–11.18 Wydalanie jodu z moczem u chorych na zróżnicowanego raka tarczycy leczonych jodem
promieniotwórczym z użyciem rhTSH
A. Stanjek-Cichoracka, B. Michalik, A. Kochańska-Dziurowicz, J. Roskosz (Gliwice)
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11.20–11.23 Wysokie stężenia osoczowe TSH po podaniu rhTSH u chorych ze zróżnicowanym rakiem
tarczycy (ZRT) i nieodwracalną niewydolnością nerek (NN) — opis 3 przypadków
A. Kowalczyk, G. Kamiński (Warszawa)
11.25–11.28 Biochemiczne wykrywanie nawrotu zróżnicowanego raka tarczycy (ZRT)
E. Gubała, A. Kropińska, R. Deja, B. Jarząb (Gliwice)
11.30–11.33 Czy leczenie supresyjne L-tyroksyną ma wpływ na serce u młodych chorych
na zróżnicowanego raka tarczycy?
A. Kropińska, J. Krajewska, K. Zawisza, H. Lewandowska, A. Antosz, M. Dobrakowski, B. Jarząb,
D. Handkiewicz-Junak (Gliwice)
11.35–11.38 Porównanie wyników oznaczeń tyreoglobuliny i przeciwciał przeciw tyreoglobulinie
otrzymanych metodą TRACE i ECLIA u pacjentów leczonych z powodu zróżnicowanego
raka tarczycy (ZRT)
R. Deja, Z. Kołosza, E. Gubała, B. Masłyk (Gliwice)
11.40–11.43 Obrazowanie przerzutów do kośćca w zróżnicowanych rakach tarczycy
B. Jurecka-Lubieniecka, A. d’Amico, K. Steinhof-Radwańska, J. Szczasny, Z. Wygoda,
B. Bobek-Billewicz, B. Jarząb (Gliwice)
11.45–11.48 Opieka psychoonkologiczna nad chorymi na zróżnicowane raki tarczycy — identyfikacja
kluczowych punktów interwencji
A. Syska-Bielak, A. Kropińska, M. Jarząb, A. Heyda, M. Jarząb, E. Wojtyna, J. Życińska,
D. Handkiewicz-Junak, K. Hasse-Lazar, A. Czarniecka, T. Olczyk, B. Jarząb (Gliwice)
11.50–11.53 Objawy zaburzeń lękowych i depresyjnych i jakość życia u młodych dorosłych leczonych
w wieku dziecięcym z powodu zróżnicowanego raka tarczycy
M. Jarząb, A. Syska-Bielak, A. Kropińska, D. Handkiewicz-Junak, M. Jarząb, K. Hasse-Lazar, A. Heyda,
A. Król, P. Gorczyca, R.T. Hese (Tarnowskie Góry)
11.55–11.58 Leczenie uzupełniające izotopem jodu 131 u chorych z mikrorakiem
brodawkowatym tarczycy
A. Klimowicz, J. Fischbach, M. Gryczyńska, M. Matysiak-Grześ, P. Gut, M. Pisarek, B. Więckowska,
J. Sowiński (Poznań)
12.00–13.15 Przerwa obiadowa
13.15–14.45 SESJA 10. Patogeneza i rozpoznanie raka tarczycy (Sala Tatry)
Przewodniczący: B. Czarnecka, D. Lange
13.15–13.35 Molecular diagnosis of thyroid nodules (WYKŁAD NA ZAPROSZENIE)
Markus Eszlinger (Leipzig, Niemcy)
13.40–13.48 Profil molekularny raka tarczycy indukowanego promieniowaniem jonizującym
D. Handkiewicz-Junak, M. Świerniak, M. Jarząb, D. Rusinek, M. Oczko-Wojciechowska, M. Kowal, B. Jarząb (Gliwice)
13.51–13.59 Przydatność biomarkerów nowotworu tarczycy (RET/PTC 1, RET/PTC 3, AKAP9/BRAF,
PAX8/PPARg, BRAF) w analizie aspiratów z biopsji guzków tarczycy u dzieci
M. Niedziela, J. Maceluch (Poznań)
14.02–14.10 „Zmiana pęcherzykowa” w BAC tarczycy — analiza 130 zweryfikowanych
histopatologicznie przypadków
Ł. Koperski, B. Górnicka, M. Bogdańska, E. Wilczek, A. Wasiutyński (Warszawa)
14.13–14.21 Wartość diagnostyczna oznaczania PTH w popłuczynach z igły po biopsji cienkoigłowej
zmian ogniskowych nieznanego pochodzenia zlokalizowanych w obrębie gruczołu tarczowego
S. Mikosiński, P. Jarek, J. Makarewicz, S. Sporny, L. Pomorski (Łódź)
14.24–14.32 Zastosowanie oznaczenia stężenia parathormonu z materiału uzyskanego w biopsji
aspiracyjnej cienkoigłowej zmian ogniskowych na szyi w diagnostyce pacjentów
z pierwotną nadczynnością przytarczyc i negatywnym wynikiem scyntygrafii SPECT
Z. Adamczewski, M. Dedecjus, J. Brzeziński, A. Lewiński (Łódź)
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14.35–14.43 Badanie predyspozycji genetycznej do raka brodawkowatego tarczycy
B. Jarząb, D. Kula, Z. Puch, M. Kalemba, D. Handkiewcz-Junak, M. Kowalska, T. Tyszkiewicz, M. Kowal (Gliwice)
14.45–15.15 Przerwa na kawę
KONFERENCJA OKRĄGŁEGO STOŁU Rak tarczycy: stan aktualny i nowe perspektywy
POLSKA GRUPA ds. NOWOTWORÓW ENDOKRYNNYCH
Moderator: A. Lewiński, B. Jarząb
15.15–16.45 Dyskusja
M. Gembicki, B. Jarząb, M. Karbownik-Lewińska, A. Lewiński, A. Milewicz, J. Nauman, A. Syrenicz, Z. Szybiński
16.45–17.00 OGŁOSZENIE WYNIKÓW KONKURSU I WRĘCZENIE NAGRÓD
ZAMKNIĘCIE KONFERENCJI
19.00 Góralska kolacja przy ognisku
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Thursday, 21 May 2010
15.00–16.00 Poster session (Rooms: Tatry, Rysy, Zawrat, Giewont, Morskie Oko)
16.00–16.15 WELCOME AND OPENING (Room: Tatry)
16.15–19.45 Session 1. Management of nodular goiter (Room: Tatry)
Chairman: A. Milewicz, J. Nauman
16.15–16.40 Update on European guidelines in thyroid nodules (INVITED LECTURE)
Ralf Paschke (Lipsk Germany)
16.45–17.00 Criteria and Standards in FNB of thyroid cancer
W. Jakubowski (Warsaw)
17.05–17.15 Elastography — new development in ultrasound in evaluating thyroid nodules
M. Gietka-Czernel, M. Kochman, K. Bujalska, E.Stachlewska-Nasfeter, W. Zgliczyński (Warsaw)
17.20–17.30 Vocal cords examination by use of real time, high-resolution ultrasonography
— a prospective pilot study in patients before and after thyroidectomy
M. Dedecjus, Z. Adamczewski, J. Brzeziński, A. Lewiński (Lodz)
17.35–17.45 Does second opinion on thyroid fine-needle aspiration (FNA) cytology change
clinical treatment?
D. Lange, E. Stobiecka, A. Stanek-Widera, D. Banaś, M. Wesołowski (Gliwice)
17.50–18.00 Retrospective categorization of diagnoses by ultrasound-guided FNAB of the thyroid gland
J. Sygut, A. Kowalska, J. Kopczyński, D. Gąsior-Perczak, R. Mężyk, K. Niemyska (Kielce)
18.05–18.15 Difficulties in pathological evaluation of thyroid carcinomas — results of verification
by the Polish Working-Group for Endocrine Tumors
A. Konturek, M. Barczyński, M. Stopa, P. Richter, W. Nowak (Krakow)
18.20–18.35 New diagnostic possibilities in ultrasonography
Sponsored session SIEMENS
18.35–18.50 Coffee break
Round Table Conference Management of nodular goiter: diagnostic and therapy
Polish Working-Group for Endocrine Tumors
Moderators: A. Lewiński, J. Nauman
18.50–19.05 Polish Recommendations in Thyroid Cancer: cythological diagnostic of thyroid nodules
and histopathological evaluation of thyroid cancer
S. Sporny (Lodz)
19.05–19.45 Discussion
W. Jakubowski, A. Kulig, D. Lange, W. Olszewski, L. Pomorski, D. Słowińska-Klencka, J. Sowiński
20.00–21.00 Wellcome coctail and poster discussion
21.00–22.05 SESSION 2. Interesting cases of thyroid cancer poster presentation
Discussion (Room Tatry)
Posters (Room Tatry)
Chairman: Z. Szybiński, R. Junik
21.00–21.03 PDS gene analysis in family with Pendred’s syndrome associated with thyroid papillary cancer
K. Łącka, A. Paradowska, E. Korman, J. Rajewska, B. Stawny, J.K. Łącki (Poznan)
PROGRAME OF THE CONFERENCE
IV Conference „Thyroid cancer”
Zakopane, 20–22 May 2010 roku
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21.05–21.08 Difficulties in diagnosis and therapy of the patient with chronic autoimmune thyroiditis
and the coexisting thyroid nodule
M. Niedziela, D. Bręborowicz, B. Rabska-Pietrzak, E. Trejster, J. Harasymczuk (Poznan)
21.10–21.13 Familial case of oxyphilic thyroid neoplasm GRIM-19: gene analysis
J. Maceluch, B. Rabska-Pietrzak, A. Rojek, J. Harasymczuk, E. Trejster, M. Warzywoda, D. Bręborowicz,
J. Bręborowicz, M. Niedziela (Poznan)
21.15–21.18 Thyroid lesion as first manifestation of Hodgkin’s lymphoma
M. Ruchała, E. Szczepanek, P. Majewski, J. Sowiński (Poznan)
21.20–21.23 A case of Hodgkin lymphoma of the thymus imitating retrosternal goiter retrospective
analysis of the diagnostic process
M. Dedecjus, A. Kędzierska, J. Kozak, G. Stróżyk, R. Kordek, J. Brzeziński (Lodz)
21.25–21.28 Differentiated thyroid cancer in pregnant women — clinical dilemmas
M. Koziołek, E. Wentland-Kotwicka, A. Syrenicz (Szczecin)
21.30–21.33 Columnar cell variant of papillary thyroid carcinoma in ovarian struma — case report
B. Szcześniak-Kłusek, E. Stobiecka, A. Smok-Ragankiewicz, J. Krajewska, A. Czarniecka, D. Lange (Gliwice)
21.35–21.38 Treatment with Sorafenib in advanced thyroid cancer a case report
J. Krajewska, T. Olczyk, J. Roskosz, A. Śmietana, B. Kaczmarek-Borowska, E. Paliczka-Cieślik, S. Szpak-Ulczok,
B. Jarząb (Gliwice)
21.40–21.43 Case of a patient with acromegaly and a disseminated follicular thyroid carcinoma
A. Bałdys-Waligórska, F. Gołkowski, A. Krzentowska, A. Stefańska, O. Halytskyy,
A. Hubalewska-Dydejczyk (Krakow)
21.45–21.48 Solitary metastasis of the clarocellular renal carcinoma to the thyroid gland — case report
M. Bilski, G. Kamiński (Warszawa)
21.50–21.53 Metastases of breast cancer to the thyroid gland in two patients — a case report
E. Skowrońska-Jóźwiak, Z. Adamczewski, K. Krawczyk-Rusiecka, A. Gumińska, S. Sporny, A Kulig,
M. Dedecjus, J. Brzeziński, A. Lewiński (Lodz)
21.55–21.58 A case of a patient with secondary hyperparathyroidism and thyroid cancer
J. Skrobisz, R. Wieczorek (Poznan)
22.00–22.03 Coincidence of the clarocellular renal and follicular thyroid carcinomas: case report
M. Bilski, G. Kamiński (Warszawa)
Friday, 21 May 2010
8.30–10.30 SESSION 3. Surgical treatment of thyroid cancer
Session of Prof. Jan Skrzypek (Room Tatry)
Chairmen: J. Brzeziński, J. Włoch
8.30–8.45 Molecular and clinical prognostic factors and their role in thyroid cancer surgery planning
A. Czarniecka, J. Włoch (Gliwice)
8.48–9.03 Pre-, intra- and postsurgical monitoring of recurrent laryngeal nerve after thyroidectomy
M. Dedecjus, J. Brzeziński (Lodz)
9.06–9.15 Clinical value of intraoperative neuromonitoring of the recurrent laryngeal nerves
in improving outcomes of surgery for thyroid cancer
M. Barczyński, A. Konturek, S. Cichoń, W. Nowak (Krakow)
9.18–9.27 The risk of inadvertent parathyroid excision during thyroid cancer surgery
L. Pomorski, K. Paduszyńska, S. Mikosiński, E. Rogowska, K. Kaczka (Lodz)
9.30–9.39 The treatment of differentiated thyroid cancer (DTC) in children:
evaluation of permanent side effects
A. Kropińska, J. Roskosz, J. Włoch, J. Krajewska, A. Krawczyk, T. Olczyk, E. Paliczka-Cieślik, J. Kozielski,
A. Krzywiecki, J. Szczasny, K. Steinhof-Radwańska, W. Przeorek, D. Handkiewicz-Junak (Gliwice)
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9.42–9.51 Tracheal reconstruction with the use of radial forearm free flap and biodegradative mesh
suspension description of three cases
A. Maciejewski, C. Szymczyk, J. Wierzgoń, M. Grajek, M. Dobrut, R. Szumniak, S. Półtorak,
Ł. Krakowczyk, P. Jędrzejewski (Gliwice)
9.54–10.20 Advances in thyroid cancer surgery (INVITED LECTURE)
Michele Minuto (Pisa, Italy)
10.30–10.45 Coffee break
10.45–12.45 SESSION 4. Molecular analyses of thyroid cancer and the role of thyroid hormones
in carcinogenesis
Session of Prof. Jan Steffen (Room Tatry)
Chairman: A. Nauman, K. Łącka
10.45–11.10 Molecular biology of thyroid cancer (INVITED LECTURE)
Clara Alvarez (Santiago de Compostela, Spain)
11.15–11.24 Karyometric characteristics of papillary thyroid carcinoma and its relation to gene
expression profile of tumor tissue
M. Chekan, M. Świerniak, M. Jarząb, M. Oczko-Wojciechowska, D. Rusinek, M. Śnietura, B. Jarząb (Gliwice)
11.27–11.36 Transcriptome of microdissected papillary thyroid cancer cell
M. Oczko-Wojciechowska, A. Rusin, D. Rusinek, M. Kowalska, M. Kowal, T. Tyszkiewicz, M. Chekan,
A. Czarniecka, E. Gubała, B. Jarząb (Gliwice)
11.39–11.48 Prediction of the papillary thyroid cancer distant metastases risk by gene expression profiling
S. Szpak-Ulczok, M. Jarząb, M. Oczko-Wojciechowska, M. Kowalska, M. Kowal, T. Tyszkiewicz, A. Pfeifer,
A. Czarniecka, J. Włoch, B. Jarząb (Gliwice)
11.51–12.00 Expression of age-related genes in thyroid and thyroid neoplasms by oligonucleotide
microarray profiling
M. Jarząb, M. Oczko-Wojciechowska, M. Świerniak, S. Szpak-Ulczok, D. Handkiewicz-Junak, M. Kowal,
T. Tyszkiewicz, D. Lange, M. Chekan, A. Pfeifer, T. Tyszkiewicz, A. Czarniecka, B. Jarząb, Z. Krawczyk (Gliwice)
12.03–12.12 The role of miRNA in reduction of type I 5-iodothyronine deiodinase expression and
mRNA level in renal clear cell carcinoma (ccRCC)
J. Bogusławska, A. Master, A. Piekiełko-Witkowska, A. Wójcicka, P. Popławski, Z. Tański, A. Nauman (Warsaw)
12.15–12.24 Disturbances of expression of thyroid hormone receptor TR-beta-1 in human renal cancer
A. Piekiełko-Witkowska, A. Master, A. Wójcicka, J. Bogusławska, P. Popławski, H. Wiszomirska, Z. Tański,
V.M. Darras, G.R. Williams, A. Nauman (Londyn)
12.27–12.36 Effects of Fenton reaction on oxidative damage to membrane lipids and nuclear DNA
in porcine thyroid potential role in cancer initiation
J. Stępniak, A. Kokoszko, K. Zasada, J. Szosland, M. Milczarek, A. Gesing, A. Lewiński,
M. Karbownik-Lewińska (Lodz)
12.45–14.15 Lunch break
14.15–15.15 SESSION 5. Complementary treament of thyroid cancer (Room Tatry)
Chairman: I. Kozłowicz-Gudzińska, M. Gryczyńska
14.15 14.24 The assessment of the efficacy of radioiodine remnant ablation after radical surgery
in patients with differentiated thyroid cancer (DTC)
J. Krajewska, M. Jarząb, A. Czarniecka, J. Roskosz, A. Kukulska, E. Paliczka-Cieślik, Z. Puch,
D. Handkiewicz-Junak, B. Jarząb (Gliwice)
14.27–14.36 Radioiodine remnant ablation in patients with differentiated thyroid carcinoma (DTC):
comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
A. Kukulska, J. Krajewska, Z. Puch, M. Gawkowska-Suwińska, E. Paliczka-Cieślik, J. Roskosz,
D. Handkiewicz-Junak, M. Jarząb, E. Gubała, B. Jarząb (Gliwice)
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14.39–14.48 Comparison of two groups of patients with differentiated thyroid carcinoma treated with
radioiodine 131-I following endogenous and exogenous stimulation of TSH
A. Bałdys-Waligórska, F. Gołkowski, A. Krzentowska, A. Hubalewska-Dydejczyk (Krakow)
14.51–15.00 Clinical analysis of urinary iodine excretion in patients with differentiated thyroid cancer (DTC)
B. Michalik, J. Roskosz, A. Stanjek-Cichoracka, A. Kochańska-Dziurowicz, B. Jarząb (Gliwice)
15.03–15.12 L-thyroxin suppressive treatment in patients with differentiated thyroid cancer (DTC):
Evaluation of our clinical practice
A. Kropińska, J. Roskosz, Z. Puch, J. Krajewska, A. Krawczyk, T. Olczyk, H. Lewandowska, A. Antosz,
M. Dobrakowski, E. Gubała, B. Jarząb (Gliwice)
15.15–15.45 Coffee break
15.45–16.45 SESSIONS 6A–6D. POSTER PRESENTATION
Session 6A. Molecular biology of thyroid cancer
Discussion (Room Rysy)
Posters in (Room Rysy)
Chairmen: M. Karbownik-Lewińska, M. Niedziela
Session 6B. Progress in thyroid cancer detection
Discussion (Room Tatry)
Posters (Room Giewont)
Chairman: K. Kuzdak, M. Ruchała
Session 6C. Fine needle aspiration biopsies, general thyroidology
Discussion (Room Zawrat)
Posters (Room Zawrat)
Chairman: A. Kulig, A. Syrenicz
Session 6D. Medullary thyroid cancer
Discussion (Room Morskie Oko)
Posters (Room Morskie Oko)
Chairman: L. Pomorski, B. Kos-Kudła
16.45–17.15 Coffee break
15.45–16.38 Session 6A. Molecular biology of thyroid cancer
Discussion (Room Rysy)
Posters in (Room Rysy)
Chairmen: M. Karbownik-Lewińska, M. Niedziela
15.45–15.48 DNA repair genes in the thyroid cell lines and human tumors
J. Janik, K. Hanusek, B. Czarnocka (Warsaw)
15.50–15.53 Analysis of NDRG2 mRNA expression in primary papillary thyroid carcinoma
and in its metastases to regional lymph nodes
A. Mordalska, J. Latek, T. Ferenc, L. Pomorski, A. Zygmunt, E. Gałecka, A. Lewiński (Lodz)
15.55–15.58 Animal model of the papillary thyroid carcinoma induced by BRAFV600E mutation
— preliminary
D. Rusinek, E. Chmielik, M. Kowal, E. Gubała, W. Widłak (Gliwice)
16.00–16.03 Scale of differences between transcriptomes of papillary thyroid carcinoma and normal
thyroid — analysis of gene expression profile
M. Świerniak, M. Jarząb, M. Oczko-Wojciechowska, A. Pfeifer, K. Unger, C. Maenhaut, G. Thomas,
B. Jarząb (Gliwice)
16.05–16.08 Application of Random Forests technique for discrimination of histological types
of thyroid tumor
T. Stokowy, M. Jarząb, K. Fujarewicz, M. Oczko-Wojciechowska, A. Pfeifer, R. Paschke, M. Eszlinger (Gliwice)
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16.10–16.13 Expression of immunity-related genes in thyroid cancer — transcriptome analysis
M. Jarząb, M. Oczko-Wojciechowska, M. Kowal, M. Olakowski, A. Rusin, M. Kowalska, D. Rusinek, A. Pfeifer,
M. Świerniak, A. Czarniecka, E. Chmielik, E. Stobiecka, D. Lange, J. Jarząb, Z. Krawczyk (Gliwice)
16.15–16.18 Gene expression profile of follicular adenoma in comparison to other endocrine adenomas
J. Żebracka-Gala, M. Oczko-Wojciechowska, M. Kowalska, A. Kukulska, A. Czarniecka, E. Gubała, D. Larysz,
A. Rudnik, J. Waler, J. Gawrychowski, A. Pfeifer, M. Świerniak, M. Jarząb, E. Chmielik, D. Lange,
K. Fujarewicz, A. Świerniak, B. Jarząb (Gliwice)
16.20–16.23 Exression of ghrelin and obestatin in human thyroid gland and thyroid tumors
E. Gurgul, M. Ruchała, M. Biczysko, J. Surdyk-Zasada, A. Kasprzak, A. Łukaszyk, J. Sowiński (Poznan)
16.25–16.28 Diagnostic chip based on enzyme inhibitors — preliminary approach
W. Balcerzak, A. Czernicka, S. Deja, P. Młynarz, P. Kafarski (Wroclaw)
16.30–16.33 CHEK2 polymorphism and its association with occurrence and staging of papillary
thyroid cancer
M. Kalemba, Z. Puch, D. Kula, M. Kowalska, M. Kowal, T. Tyszkiewicz, D. Handkiewicz-Junak, J. Roskosz,
K. Drosik, M. Żydek, A. Sikora, A. Chróst, E. Gubała, B. Jarząb (Gliwice)
16.35–16.38 Case report of the woman with papillary thyroid carcinoma, which was thyreological
diagnosed because of presence CHEK2 mutation in genetic examinations
K. Lizis-Kolus, A. Kowalska, B. Kozak-Klonowska, M. Siołek, J. Słuszniak, J. Lubiński, C. Cybulski (Kielce)
16.45–17.15 Coffee break
15.45–16.33 Session 6B. Progress in thyroid cancer detection
Discussion (Room Tatry)
Posters (Room Giewont)
 Chairman: K. Kuzdak, M. Ruchała
15.45–15.48 Analysis of ultrasound images of thyroid cancers of diameter less then 15 mm for selection
of Fine Needle Aspiration for patients with multinodular goiter
J. Pankowski, E. Kaznowska, B. Maksymiuk (Zakopane)
15.50–15.53 Analysis of usefulness of PTH concentration measurement in the material obtained during
fine needle aspiration biopsy of neck focal lesions in the identification of parathyroids
B. Popowicz, J. Jankiewicz-Wika, S. Sporny, M. Klencki, E. Woźniak, E. Sewerynek, E.J. Komorowski,
D. Słowińska-Klencka (Lodz)
15.55–15.58 Elastography based on tissue Doppler in the diagnosis of thyroid nodules — a pilot study
Z. Adamczewski, K. Krawczyk-Rusiecka, M. Dedecjus, J. Brzeziński, A. Lewiński (Lodz)
16.00–16.03 Nowe metody ultrasonograficzne w wizualizacji mikrozwapnień w diagnostyce zmian
ogniskowych tarczycy
R.Z. Słapa, W. Jakubowski, K.T. Szopiński, A. Szcześniak, J. Bierca, J. Słowińska-Srzednicka (Warsaw)
16.05–16.08 Advantages and disadvantages of 3D ultrasound of thyroid nodules including thin slice
volume rendering
R.Z. Słapa, W. Jakubowski, J. Słowińska-Srzednicka, K.T Szopiński (Warsaw)
16.10–16.13 The incidence and characteristics of thyroid focal lesions in patients with thyroid
hemiagenesis
M. Ruchała, E. Szczepanek, J. Sowiński (Poznan)
16.15–16.18 The recurrent goiter beyond the typical lateral lobes localization — the analysis of over 60 cases
E. Woźniak, M. Klencki, B. Popowicz, S. Sporny, D. Słowińska-Klencka (Lodz)
16.20–16.23 The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to
benign thyroid diseases
M.H. Listewnik, B. Birkenfeld, K. Niedziałkowska, M. Chosia, B. Elbl, M. Sawrymowicz (Szczecin)
16.25–16.28 The application of SPECT/CT scintigraphy with MIBI-Tc99m and a comparison with the
subtraction method in the diagnostics of nodular goiter in the thyroid
M.H. Listewnik, B. Birkenfeld, K. Cichoń-Bańkowska, K. Niedziałkowska, L. Iglińska-Wagner, W. Watrak,
W. Smolira, P. Zorga, H. Piwowarska-Bilska, B. Elbl, M. Sawrymowicz (Szczecin)
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16.30–16.33 Analysis of the results of histopathological examination of the thyroid gland after
reoperations caused by thyroid cancer diagnosed after strumectomy
J. Skrobisz (Poznan)
16.45–17.15 Coffee break
15.45–16.38 Session 6C. Fine needle aspiration biopsies, general thyroidology
Discussion (Room Zawrat)
Posters (Room Zawrat)
Chairman: A. Kulig, A. Syrenicz
15.45–15.48 The analysis of value of ultrasound-guided fine-needle aspiration biopsy (US-FNAB)
of thyroid nodules patients with nodular goiter
M. Rzeszutko, W. Rzeszutko, T. Tomkalski (Wroclaw)
15.50–15.53 Compliance of pre and postoperative diagnosis of malignant thyroid neoplasms
P. Furga, J. Łapiński, K. Paśnik (Warsaw)
15.55–15.58 Thyroid fine-needle aspiration (FNA) cytology versus frozen section examination (FS)
in the experience of the Surgical Oncology Department
D. Bisz, J. Albiński, S. Borczewski, P. Ciszewski (Warsaw)
16.00–16.03 Diagnostic cytology of poorly differentiated thyroid carcinoma
J. Sygut, W. Rezner, J. Kopczyński, J. Słuszniak, A. Kowalska (Kielce)
16.05–16.08 Role of fine-needle aspiration biopsy in diagnosing tumor metastases to thyroid gland
— personal observation
G. Buła, J. Waler, A. Niemiec, H. Koziołek, W. Bichalski, J. Gawrychowski (Bytom)
16.10–16.13 Morphological diagnostics of solitary cystic thyroid nodules
V.N. Marina, V.I. Kolomiytsev, V.I. Vovk, O.V. Lukavetsky, M.P. Pavlovsky (Lwow, Ukraine)
16.15–16.18 Ethically-economic aspects of thyroid biopsy observation from local center
M. Maciejewski, M. Gąsiorek, M. Słomian, A. Sawicka, K. Marczewski (Zamosc)
16.20–16.23 Evaluation of the results of IL-6 levels in patients with Graves-Basedow disease without
active ophthalmopathy
D. Zalewska-Rydzkowska, A. Nowicka, J. Kwaśniewska-Błaszkowska, S. Manysiak, G. Odrowąż-Sypniewska,
R. Junik (Bydgoszcz)
16.25–16.28 Thyroid dysfunctions in children detected in mass screening for congenital hypothyroidism
M. Kumorowicz-Czoch, D. Tylek-Lemańska, J. Starzyk (Krakow)
16.30–16.33 The contribution of Pro12Ala PPAR-g gene polymorphism to Graves orbitopathy
J. Daroszewski, E. Pawlak, M. Bolanowski, I. Rydecka (Wroclaw)
16.35–16.38 Identification of immune markers (CD54, CD95, CD134, CD152) on the thyroid follicular
cells in patients with immune and non-immune thyroid diseases using cellular culture
A. Bossowski, E. Iłendo, K. Ratomski, B. Czarnocka, J. Dadan (Bialystok)
16.45–17.15 Coffee break
15.45–16.13 Session 6D. Medullary thyroid cancer
Discussion (Room Morskie Oko)
Posters (Room Morskie Oko)
Chairman: L. Pomorski, B. Kos-Kudła
15.45–15.48 The analysis of transcriptome of medullary thyroid carcinoma
M. Oczko-Wojciechowska, J. Włoch, J. Żebracka-Gala, A. Pfeifer, M. Kowalska, Z. Wygoda, A. Czarniecka,
E. Gubała, B. Jarząb (Gliwice)
15.50–15.53 The role of gallium-68 labelled somatostatine analogue PET-CT (68Ga-DOTA-TATE
PET-CT) in diagnosing of patients with disseminated medullary thyroid carcinoma (MTC)
I. Pałyga, A. Kowalska, D. Gąsior-Perczak, J. Słuszniak. J. Sygut, M. Tarnawska-Pierścińska, S. Góźdź (Kielce)
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15.55–15.58 Diagnostic performance evaluation of procalcitonin measurments during the follow-up
of patients with medullary thyroid carcinoma (MTC)
D. Gąsior-Perczak, A. Kowalska, I. Pałyga, G. Antczak, A. Słuszniak, S. Góźdź (Kielce)
16.00–16.03 Prognostic impact of the doubling time of medullary thyroid carcinoma tumor markers
T. Gawlik, A. d’Amico, E. Gubała, A. Chorąży, K. Gorczewski, B. Jarząb (Gliwice)
16.05–16.08 Phenotype of exon 10 RET gene mutations carriers
S. Szpak-Ulczok, E. Gubała, A. Pawlaczek, M. Oczko-Wojciechowska, B. Jarząb (Gliwice)
16.10–16.13 Pheochromocytomas in the RET protooncogene mutations carriers
K. Hasse-Lazar, A. Krawczyk, S. Szpak-Ulczok, A. Pawlaczek, J. Ziaja, B. Jarząb (Gliwice)
16.45–17.15 Coffee break
17.15–20.00 SESSION 7. Modern thyroid cancer treatment (Room Tatry)
Chair: M. Gembicki, I. Kinalska
17.15–17.45 Recent Advances in Management of Thyroid Cancer (INVITED LECTURE)
Paul Ladenson
17.50–18.10 Therapy in advanced thyroid cancer
B. Jarząb (Gliwice)
18.15–18.30 New diagnostic methods in nuclear medicine
Sponsored presentation SIEMENS
ROUND TABLE CONFERENCE: Thyroid cancer treatment
Polish Working-Group for Endocrine Tumors
Moderators: S. Zgliczyński, B. Jarząb
18.30–18.40 Polish Recommendations in Thyroid Cancer: surgical treatment of thyroid cancer
K. Kuzdak, J. Brzeziński, J. Włoch (Gliwice)
18.50–19.00 Polish Recommendations in Thyroid Cancer: isotope treatment of thyroid cancer
B. Jarząb, J. Sowiński, I. Kozłowicz-Gudzińska (Gliwice)
19.10–19.20 Polish Recommendations in Thyroid Cancer: medullary thyroid cancer
L. Pomorski, J. Włoch, B. Jarząb (Gliwice)
19.20–20.00 Discussion
J. Brzeziński, I. Kozłowicz-Gudzińska, K. Kuzdak, A. Lewiński, L. Pomorski, J. Sowiński, J. Włoch
20.30 GET-TOGETHER PARTY
Saturday, 22 May 2010
9.00–10.45 SESSION 8. Imaging and isotope treatment of thyroid cancer (Room Tatry)
Chairman: J. Sowiński, T. Bednarczuk
9.00–9.08 The clinical value of PET with 18F-fluorodeoxyglucose in patients with suspected recurren-
ce of differentiated thyroid carcinoma
A. d’Amico, T. Gawlik, J. Roskosz, A. Kukulska, B. Jarząb (Gliwice)
9.11–9.19 Role of different imaging modalities in diagnosis of differentiated thyroid carcinoma
metastases
R. Czepczyński, M. Gryczyńska, A. Czepczyńska, M. Stajgis, J. Sowiński (Poznan)
9.22–9.30 Receptor PET scintigraphy with positon-gallium labeled somatostatin analogues
in medullary thyroid carcinoma
Z. Wygoda, A. d’Amico, D. Hankiewicz-Junak, B. Jurecka-Lubieniecka, K. Hasse-Lazar, B. Jarząb (Gliwice)
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9.33–9.41 Procalcitonin — a new marker for medullary thyroid cancer patients?
K. Kaczka, S. Mikosiński, L. Pomorski (Lodz)
9.44–10.10 Advances in radioiodine treatment of thyroid cancer (INVITED LECTURE)
Markus Luster (Ulm, Germany)
10.15–10.40 Nuclear medicine for medullary thyroid cancer (INVITED LECTURE)
Lisa Bodei (Milan, Italy)
10.45–11.00 Coffee break
11.00–12.00 SESSION 9A–9C. POSTER SESSION
Session 9A. Assisted detection of thyroid cancer
Discussion (Room Tatry)
Posters (Room Giewont)
Chairman: S. Sporny, M. Puzianowska-Kuźnicka
Session 9B. Clinics of thyroid cancer
Discussion (Room Rysy)
Posters (Room Rysy)
Chairman: S. Cichoń, M. Zieliński
Session 9C. Treatment and monitoring of thyroid cancer
Discussion (Room Zawrat)
Posters (Room Zawrat)
Chairman: M. Gryczyńska, M. Grzywa
12.00–13.15 Lunch break
11.00–11.48 Session 9A. Assisted detection of thyroid cancer
Discussion (Room Tatry)
Posters (Room Giewont)
Chairman: S. Sporny, M. Puzianowska-Kuźnicka
11.00–11.03 Follicular tumors and oxyphilic tumors of thyroid gland in own experience
J. Waler, G. Buła, A. Niemiec, W. Truchanowski, R. Mucha, N. Waler, J. Gawrychowski (Bytom)
11.05–11.08 Applying unsupervised analysis to interpret the variability of gene expression in the
set of follicular tumours
A. Pfeifer, M. Eszlinger, T. Musholt, S. Hauptmann, M. Oczko-Wojciechowska, M. Jarząb, M. Świerniak,
D. Lange, R. Paschke, B. Jarząb (Gliwice)
11.10–11.13 COX-2 expression in thyroid papillary cancer in material obtained by FNAB
K. Krawczyk-Rusiecka, K. Wojciechowska-Durczyńska, A. Cyniak-Magierska, Z. Adamczewski, A. Lewiński (Lodz)
11.15–11.18 Assessment of PIK3CA gene expression in papillary thyroid cancer
K. Wojciechowska-Durczyńska, K. Krawczyk-Rusiecka, A. Cyniak-Magierska, A. Zygmunt, A. Lewiński (Lodz)
11.20–11.23 EABA in immunohistochemical study of thyroid lesions
B. Nikiel, M. Chekan, M. Jarząb, D. Lange (Gliwice)
11.25–11.28 Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy
specimens collected from patients with Hashimoto thyroiditis
A. Cyniak-Magierska, K. Wojciechowska-Durczyńska, K. Rusiecka-Krawczyk, A. Zygmunt, A. Lewiński (Lodz)
11.30–11.33 Immunohistochemical characterization of a primary papillary thyroid carcinoma
and co-existing thyroid metastases in cervical lymph node
A. Konturek, M. Barczyński, M. Stopa, P. Richter, W. Nowak (Krakow)
11.35–11.38 Correlation of metallothionein expression with antigen Ki-67 in benign and malignant
thyroid lesions
A. Królicka, P. Domosławski, B. Wojtczak, J. Dawiskiba, Ch. Kobierzycki, A. Piotrowska, M. Podhorska-Okołów,
P. Dzięgiel, T. Łukieńczuk, K. Kaliszewski, J. Daroszewski (Wroclaw)
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11.40–11.43 Evaluation of specificity of potential papillary thyroid cancer (PTC) marker genes FN1,
KRT19, DPP4, MET and CDH3
W. Truchanowski, M. Kowalska, M. Oczko-Wojciechowska, M. Kowal, T. Tyszkiewicz, A. Kukulska,
A. Czarniecka, J. Włoch, J. Waler, G. Buła, M. Kucharzewski, B. Jarząb, J. Gawrychowski (Bytom)
11.45–11.48 Expression of LGALS3BP gene in thyroid tissues and peripherial blood lymphocytes as
a potential prognostic factor for high malignancy type of papillary thyroid cancer
five-year follow up
K. Kaliszewski, T. Łukieńczuk, W. Bednarz, W. Balcerzak, B. Wojtczak, T. Dobosz, M. Kaliszewska, J. Dawiskiba
(Wroclaw)
12.00–13.15 Lunch break
11.00–11.58 Session 9B. Clinics of thyroid cancer
Discussion (Room Rysy)
Posters (Room Rysy)
Chairman: S. Cichoń, M. Zieliński
11.00–11.03 Does differentiated thyroid cancer (DTC) staging change within the last ten years?
B. Michalik, J. Kern-Bałaga, M. Kalemba, B. Włodarczyk-Marciniec, B. Zemła (Gliwice)
11.05–11.08 Incidence rate of thyroid cancer in Olsztyn Region in the years 1993–2008
E. Bandurska-Stankiewicz, E. Aksamit-Białoszewska, A. Stankiewcz, D. Shafie (Olsztyn)
11.10–11.13 The prevalence of central compartment of the neck lymph nodes involvement following
elective clearance for papillary thyroid cancer
M. Barczyński, A. Konturek, M. Stopa, P. Richter, W. Nowak (Krakow)
11.15–11.18 Prognostic value of differentiated thyroid cancer (DTC) lymph node metastases in relation
to the extent of surgical treatment
A. Czarniecka, M. Jarząb, J. Krajewska, E. Chmielik, E. Stobiecka, B. Szcześniak-Kłusek, R. Kokot, A. Sacher,
S. Półtorak, J. Włoch (Gliwice)
11.20–11.23 Skip metastases in papillary thyroid carcinoma — incidence and impact on surgery
L. Pomorski, M. Dobrogowski, S. Mikosiński, K. Kaczka (Zgierz)
11.25–11.28 Thyroid neoplasms in children and adolescents operated on due to nodular goiter
in a single institution within the past 40 years
A. Kalicka-Kasperczyk, G. Drabik, J. Skirpan, W. Mieżyński, J. Starzyk (Krakow)
11.30–11.33 Differentiated thyroid carcinoma diagnosed incidentally in postoperative histopathology
R. Anielski, S. Cichoń, A. Hubalewska-Dydejczyk, M. Buziak-Bereza, P. Orlicki, A. Bałdys-Waligórska (Krakow)
11.35–11.38 Thyroid cancer treated in emergency mode — 10 years experience of I Department of
General Gastroenterological and Endocrinological Surgery Medical University of Wroclaw
K. Kaliszewski, T. Łukieńczuk, W. Bednarz, P. Domosławski, B. Knychalski, M. Kaliszewska, K. Sutkowski
(Wroclaw)
11.40–11.43 Papillary thyroid cancer now and 10 years ago — the analysis of material of 1st Department
of General, Gastroenterological and Endocrinological Surgery Medical University
of Wroclaw
K. Kaliszewski, T. Łukieńczuk, W. Bednarz, W. Balcerzak, Z. Forkasiewicz, J. Spodzieja, M. Kaliszewska,
T. Dawiskiba, M. Napierała, W. Podhorski (Wrocław)
11.45–11.48 The use of transervical approach with elevation of the sternal manubrium for surgery
of mediastinal ectopic goiter, mediastinal parathyroid tumors and the mediastinal
metastases of the thyroid cancer
M. Zielinski, J. Pankowski, M. Skrobot, L. Hauer, T. Nabialek, A. Szlubowski (Zakopane)
11.50–11.53 Incidence of other malignant neoplasms in patient with thyroid carcinoma
E. Mikina, J. Sygut, A. Kowalska (Kielce)
597
M
A
T
ER
IA
ŁY
Z
JA
Z
D
O
W
E
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 61 (5)
11.55–11.58 The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma)
— own observation
A. Walczyk, A. Kowalska (Kielce)
12.00–13.15 Lunch break
11.00–11.58 Session 9C. Treatment and monitoring of thyroid cancer
Discussion (Room Zawrat)
Posters (Room Zawrat)
Chairman: M. Gryczyńska, M. Grzywa
11.00–11.03 Prospective analysis of 131-I treatment in patients with papillary microcarcinoma operated
by subtotal thyroidectomy
T. Olczyk, A. Kropińska, A. Krawczyk, J. Krajewska, D. Handkiewicz-Junak, B. Jarząb (Gliwice)
11.05–11.08 Radioiodine treatment of advanced differentiated thyroid cancer (DTC)
D. Handkiewicz-Junak, E. Paliczka-Cieślik, J. Roskosz, K. Hasse-Lazar (Gliwice)
11.10–11.13 The influence of presence distant and/or regional nodal metastases on frequency
of complete remission at patients with differentiated thyroid carcinoma (DTC)
T. Trybek, A. Kowalska (Kielce)
11.15–11.18 Urinary iodine excretion in patients with differentiated thyroid cancer (DTC) treated
with recombinant human TSH
A. Stanjek-Cichoracka, B. Michalik, A. Kochańska-Dziurowicz, J. Roskosz (Gliwice)
11.20–11.23 High serum TSH concentration after rhTSH administration in patients with differentiated
thyroid carcinoma (DTC) and irreversible renal failure(RF) — 3 cases study
A. Kowalczyk, G. Kamiński (Warszawa)
11.25–11.28 Biochemical detection of relapse of differentiated thyroid cancer (DTC)
E. Gubała, A. Kropińska, R. Deja, B. Jarząb (Gliwice)
11.30–11.33 Does the suppressive treatment of L-thyroxine impair heart function in young patients with
differentiated thyroid cancer (DTC)?
A. Kropińska, J. Krajewska, K. Zawisza, H. Lewandowska, A. Antosz, M. Dobrakowski, B. Jarząb,
D. Handkiewicz-Junak (Gliwice)
11.35–11.38 Comparison of results of thyroglobulin (Tg) and Tg autoantibodies (aTg) measurements
obtained with TRACE and ECLIA methods in patients with differentiated thyroid carcinoma
R. Deja, Z. Kołosza, E. Gubała, B. Masłyk (Gliwice)
11.40–11.43 Detection of bone metastases in differentiated thyroid cancer
B. Jurecka-Lubieniecka, A. d’Amico, K. Steinhof-Radwańska, J. Sczasny, Z. Wygoda, B. Bobek-Billewicz,
B. Jarząb (Gliwice)
11.45–11.48 Psycho-oncological care over patients suffering from differentiated thyroid cancer
— identification of crucial points of intervention
A. Syska-Bielak, A. Kropińska, M. Jarząb, A. Heyda, M. Jarząb, E. Wojtyna, J. Życińska, D. Handkiewicz-Junak,
K. Hasse-Lazar, A. Czarniecka, T. Olczyk, B. Jarząb (Gliwice)
11.50–11.53 Depressive symptoms, anxiety and quality of life in young adults, treated in childhood
due to differentiated thyroid cancer
M. Jarząb, A. Syska-Bielak, A. Kropińska, D. Handkiewicz-Junak, M. Jarząb, K. Hasse-Lazar, A. Heyda,
A. Król, P. Gorczyca, R.T. Hese (Tarnowskie Gory)
11.55–11.58 Complementary treatment by 131I at patients with thyroid papillary microcancer
A. Klimowicz, J. Fischbach, M. Gryczyńska, M. Matysiak-Grześ, P. Gut, M. Pisarek, B. Więckowska,
J. Sowiński (Poznan)
12.00–13.15 Lunch break
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13.15–14.45 SESSION 10. Pathiogenesis and diagnosis of thyroid cancer (Room Tatry)
Chairman: B. Czarnocka, D. Lange
13.15–13.35 Molecular diagnosis of thyroid nodules (INVITED LECTURE)
Markus Eszlinger (Leipzig, Germany)
13.40–13.48 Radioiodine treatment of advanced differentiated thyroid cancer (DTC)
D. Handkiewicz-Junak, M. Świerniak, M. Jarząb, D. Rusinek, M. Oczko-Wojciechowska, M. Kowal,
B. Jarząb (Gliwice)
13.51–13.59 Usefulness of biomarkers of thyroid neoplasm (RET/PTC-1, RET/PTC-3, AKAP9/BRAF,
PAX8/PPARg, BRAF) in analysis of aspirates from biopsy of thyroid nodules in children
M. Niedziela, J. Maceluch (Poznan)
14.02–14.10 Follicular lesion in thyroid FNAB — a study of histopathologically verified 129 cases
Ł. Koperski, B. Górnicka, M. Bogdańska, E. Wilczek, A. Wasiutyński (Warsaw)
14.13–14.21 The diagnostic value of PTH concentration in the needle washout after fine-needle biopsy
of foci of unknown origin localized within thyroid gland
S. Mikosiński, P. Jarek, J. Makarewicz, S. Sporny, L. Pomorski (Lodz)
14.24–14.32 Estimation of Parathyroid Hormone level in patients with primary hyperparathyroidism
(PHPT) and negative SPECT scans in the material obtained during fine needle aspiration
biopsy (FNAB) of the focal neck lesions
Z. Adamczewski, M. Dedecjus, J. Brzeziński, A. Lewiński (Lodz)
14.35–14.43 Analysis of genetic predisposition to papillary thyroid cancer
B. Jarząb, D. Kula, Z. Puch, M. Kalemba, D. Handkiewcz-Junak, M. Kowalska, T. Tyszkiewicz, M. Kowal (Gliwice)
14.45–15.15  Coffee break
ROUND TABLE CONFERENCE: Thyroid cancer: present situation and new perspectives
Polish Working-Group for Endocrine Tumors
Moderators: A. Lewiński, B. Jarząb
15.15–16:45 Discussion
M. Gembicki, B. Jarząb, M. Karbownik, Lewińska, A. Lewinski, A. Milewicz, J. Nauman, A. Syrenicz,
Z. Szybiński
16.45–17.00 ANNOUNCEMENT OF BEST POSTER PRIZE WINNERS FARAWELL
19.00 Dinner by the bonfire
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Molecular biology of thyroid cancer
C. Alvarez
Department of Physiology, School of Medicine, University of Santiago
de Compostela (USC), Santiago de Compostela, Spain
Follicular thyroid tumors are the most common neoplasias of the
endocrine system and, in this moment, thyroid carcinoma repre-
sents the seventh cancer in incidence in females. Advances in bio-
medical research tools have been constant in the last years, from
the use of genetic platforms where thousands of genes could be
analyzed in minutes to the generation of complex mouse models
where a gene could be shut off or replaced in a specific tissue with-
in an organ. However, much of this research remains far off the
clinical application because the preclinical models where mecha-
nisms should be demonstrated do not correspond well with the
human patient. This has happened in the thyroid: most of the hu-
man cell lines used to test new drugs or to explain molecular mech-
anisms of mutated genes are not of thyroid phenotype.
During the last ten years, and after careful standardization, we had
developed a Bank of Thyroid Tumors in Culture (BANTTIC) where
we collected primary follicular cultures obtained from surgery piec-
es of thyroid operations from normal, hyperplastic goiter, adenoma,
multinodular goiter, carcinoma and metastasis. We have groups of
cultures coming from a common pathological origin but from dif-
ferent individual patients, reducing the risk of finding spurious
results coming from a single unimportant mutation.
Using the BANTTIC as a tool to look for cell mechanisms common
to all follicular cancer cells against normal cells we have investigat-
ed the role of TGF beta in human thyroid. This factor has a dual
anti-tumor action both as an anti-proliferative and a pro-apoptotic
factor. Although in previous models it was thought that both ac-
tions were affected in thyroid cancer, we have discovered that the
anti-proliferative action is maintained and this could well explain
the paucity of growth of the human papillary thyroid carcinoma.
Molecular diagnosis of thyroid nodule
M. Eszlinger
III Medical Department, University of Leipzig, Leipzig, Germany
Fine-needle aspiration biopsy (FNAB) is currently the most sensitive
and specific tool for the presurgical differential diagnosis of thyroid
malignancy, but has also substantial limitations. While approximately
75% of FNAB reveal benign lesions and 5% already cytologically
prove malignancy, up to 20% of FNAB show follicular proliferation
for which follicular adenoma, follicular carcinoma, and follicular vari-
ant of papillary carcinoma can only be distinguished histologically,
thus requiring thyroid surgery. However, new biomarkers that might
improve the accuracy of FNAB come along with the discovery of
more and more details of the molecular etiology of thyroid tumors.
So far molecular testing for somatic mutations is most promising (e.g.,
BRAF, RAS, RET/PTC, and PAX8/PPARG), since the proposed biom-
arkers from mRNA and miRNA expression studies need further eval-
uation, especially in FNAB samples. Nevertheless, the application of
molecular markers will significantly improve thyroid tumor diagno-
sis and thus it will help to prevent unnecessary surgeries and it will
also help to guide mutation-specific targeted therapies.
Recent advances in management of thyroid cancer
P. Ladenson
Johns Hopkins University School of Medicine, Baltimore, USA
The incidence of thyroid carcinoma is rising worldwide. Manage-
ment of thyroid cancer has undergone major changes in the past
decade, including discovery of molecular mechanisms of thyroid car-
cinogenesis, implementation of novel approaches to detection and
localization of residual disease, and guidelines for radioiodine and
TSH-suppressive therapies. Cytologically indeterminate thyroid
nodules remain a diagnostic challenge. There is still the need for
better prediction of which thyroid cancer patients are more likely to
suffer recurrent disease. Highly sensitive serum thyroglobulin test-
ing, particularly after TSH stimulation, has identified a substantial
cohort of patients with previously unsuspected residual disease; but
use of cervical sonography and other anatomic and metabolic imag-
ing techniques identified the site of this remaining disease in only
one-fourth of serologically positive patients. Since most residual dis-
ease is not iodine-avid, the management paradigm has changed from
repeated radioiodine therapy to surgery. For patients with nonre-
sectable and progressive metastatic disease, novel tyrosine kinase
inhibitor therapy offers promise for disease remission, but not cure.
Consequently, there remain important challenges for physicians and
surgeons caring for patients with thyroid cancer.
Advances in thyroid cancer surgery
M. Minuto
Department of Surgery, University of Pisa, Italy
The philosophy of limiting the surgical accesses, introduced by the
laparoscopic surgical techniques, fits perfectly the essential goals
Invited lectures
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of endocrine surgery: the removal of a tumor that can be hyper-
functioning, benign or malignant. An operation on the neck is felt
as a brutal aggression on the patient’s self-image and for this rea-
son several techniques have been set up and proposed to the sur-
gical community, aiming at avoiding the traditional Kocher’s inci-
sion that was felt necessary for every thyroid disease in the past.
The innovations that play a significant role in the treatment of thy-
roid cancer, and that allow to reduce the incisions in the neck nev-
ertheless performing a radical operation, can be divided into dif-
ferent categories: 1) the TOOLS allowing to section structures with-
out the necessity of tying knots; 2) the techniques that allow to
perform a radical operation through a single or multiple limited
incision(s), or with a robot-assistance; 3) The newest developments
on the use of percutaneous energy that can be utilized for the abla-
tion of hyperfunctioning benign tumors. The common rule of any
of those three categories is to demonstrate the same efficacy of the
traditional operation, without adding, and possibly limiting, any
morbidity and/or mortality.
Update on European guidelines in thyroid nodule
R. Paschke
III Medical Department, University of Leipzig, Leipzig, Germany
In borderline iodine sufficient countries like Germany thyroid nod-
ules are detectable by thyroid ultasound in 20% of the general pop-
ulation. About 10% of thyroid nodules in iodine deficient or iodine
sufficient areas are scintigraphically hot. Whereas the malignancy
rate of thyroid nodules in the general population is very low it is 3–
–10% for a selected patient with a thyroid nodule referred to a spe-
cialist clinic for evaluation. Consequently the diagnostic workup
of a thyroid nodule should focus mainly on hyperthyroidism and
malignancy. Therefore, evidence based rational screening strate-
gies are required to detect hyperthyroidism and thyroid carcino-
mas in patients with thyroid nodules.
The recent publication of the revised ETA/AME/AACE thyroid nod-
ule guideline is a considerable step towards evidence based ratio-
nal strategies. This document was prepared as a collaborative ef-
fort between the American Association of Clinical Endocrinologists
(AACE), the Associazione Medici Endocrinologi (Italian Associa-
tion of Clinical Endocrinologists) (AME), and the European Thy-
roid Association (ETA). This guideline covers diagnostic and thera-
peutic aspects of thyroid nodular disease but not thyroid cancer
management The use of high-resolution ultrasonography (US),
sensitive thyrotropin (TSH) assay, and fine-needle aspiration (FNA)
biopsy is the basis for management of thyroid nodules. Thyroid
scintigraphy is not necessary for diagnosis in most cases. Howev-
er, it may be warranted in patients with a low serum TSH value or
a multinodular gland to detect functional autonomy, most com-
mon in iodine-deficient areas. Measurement of serum TSH is the
best initial laboratory test of thyroid function and should be fol-
lowed by measurement of free thyroxine and triiodothyronine if
the TSH value is decreased, and measurement of anti-thyroid per-
oxidase antibodies (TPOAb) if the TSH value is above the reference
range. A single, non stimulated calcitonin measurement can be used
in the initial workup of thyroid nodules and is recommended be-
fore thyroid nodule surgery.
Although thyroid nodules are a common incidental finding, US
should not be performed as a screening test. Most patients with
thyroid nodules are asymptomatic, but the absence of symptoms
does not rule out malignancy; thus, clinical and US risk factors for
malignant disease should always be reviewed. All patients with
a palpable thyroid nodule or with clinical risk factors should un-
dergo US examination.
Thyroid FNA biopsy is best performed under US guidance because
of the increase in diagnostic accuracy of the procedure. US-guided
FNA (UGFNA) biopsy is recommended for nodules smaller than
10 mm if clinical information or US features are suspicious. Cyto-
logic smears or liquid-based cytology should be interpreted by
a pathologist with specific experience. A classification scheme in
5 cytologic diagnostic categories is recommended for the cytologic
report: nondiagnostic, benign, follicular lesion, suspicious, or ma-
lignant. Currently, no single cytochemical or genetic marker is spe-
cific and sensitive enough to replace the morphologic diagnosis of
follicular lesion or suspicious for neoplasm.
Malignant or suspicious nodules should undergo surgery whereas
hot nodules should be subjected to radioiodine therapy or surgery.
For the majority of thyroid nodules classified as benign by FNAB
iodine treatment is an option to prevent further nodules. Nodule
volume reevaluation after one or two years may identify nodules
with significant volume increases for re FNAB. Thyroid hormone
treatment of thyroid nodules is associated with a significant vol-
ume reduction in only a minority (20%) of patients and can lead to
osteoporosis or atrial fibrillation and increased cardiovascular mor-
tality. It should therefore be avoided in most cases.
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A comparison of two groups of patients with
differentiated thyroid carcinoma treated
with radioiodine 131I following endogenous
and exogenous stimulation of TSH
A. Bałdys-Waligórska, F. Gołkowski, A. Krzentowska,
A. Hubalewska-Dydejczyk
Chair and Clinic of Endocrinology UCMJ, Kraków, Poland
Introduction: Radioiodine 131I treatment of patients with differen-
tiated thyroid carcinoma (DTC) aided by rhTSH allows to avoid
poorly tolerated hypothyroidism. For the first time in 2009 all pa-
tients with DTC at our Clinic were treated with 131I following eg-
zogenous stimulation of TSH.
The aim of the study was to compare a group I of patients treated
with 131I in 2008 following endogenous stimulation of TSH with
group II treated in 2009 with the use of rhTSH.
Material and methods: Group I included 76 patients of mean age
54.3 ± 14.9 years (67 female and 9 male). papillary thyroid cancer
was diagnosed 59 patients (77%). follicular in 16 patients (21%).
one patient (2%) was evaluated as papillary-follicular cancer (2%).
Group II consisted of 75 patients (mean age 53.0 ± 15.4 years.
63 female and 12 male). papillary thyroid cancer was diagnosed in
61 patients (81%). follicular cancer in 13 patients (17%). one patient
(2%) was diagnosed as poorly differentiated thyroid cancer. Prior
to radioiodine treatment thyroid volume (VT) was evaluated by
usg and 24 hrs 131I uptake was measured. TSH and Tg concentra-
tions were measured prior to and after endogenous and exoge-
nous stimulation of TSH. Whole body post-therapeutical scintigra-
phy was evaluated. Basic statistics. W Shapiro-Wilk. Wilcoxon and
U Mann-Whitney tests were applied.
Results: Median values of VT in group I and II were 0.45 ml (max
4.7; min 0.0) and 0.3 ml (max 3.9; min 0.0). respectively; median
values of 24 hrs 131I uptake in group I and II were 6.0% (max 15.9;
min 1.4) and 5.0% (max 13.0; min 0.3). respectively and were no
significantly different. The differences between median values of
TSH concentration after stimulation in group
I and II were statistically significant (p < 0.052) and respective me-
dians were 61.6 lU/mL (max 99.1; min 16.6) and 183.5 lU/mL (max
459.9; min 33.2). Median values of Tg concentration in group I and
II following TSH stimulation were 8.1 ng/mL (max 508.8; min 0.1)
and 23.7 ng/mL (max 599.8; min 0.3) respectively.
Conclusion: rhTSH may be safely used for 131I thyroid remnant
ablation in low risk DTC patients.
Estimation of Parathyroid Hormone level in patients
with primary hyperparathyroidism (PHPT)
and negative SPECT scans in the material obtained
during fine needle aspiration biopsy (FNAB)
of the focal neck lesions
Z. Adamczewski, M. Dedecjus, J. Brzeziński, A. Lewiński
Department of Endocrinology and Metabolic Diseases, Medical University, Łódź,
Polish Mother’s Memorial Hospital — Research Institute Department of General,
Oncological and Endocrine Surgery, Medical University, Łódź, Polish Mother’s
Memorial Hospital — Research Institute, Łódź, Poland
Introduction: The presence of a single parathyroid adenoma is
a cause of primary hyperparathyroidism in most cases. Minimally
invasive parathyreoidectomy is a treatment of choice in PHPT pa-
tients and precise localization of the changed parathyroids is cru-
cial for successful removal.
The aim of the study was to assess usefulness of parathormone
level estimation in the material obtained during FNAB of the focal
neck lesions in order to differentiate structures such as enlarged
parathyroid glands from other focal lesions in patients with HPTH
and negative SPECT scans.
Material and methods: 18 female patients with elevated PTH lev-
els (range: 160–617 pg/mL, median, 224 pg/mL), coexisting calcium
and phosphate disorders typical for PHPT and negative SPECT
scans, were prospectively evaluated. Patients age range was from
6 months to 76 years (median, 51 years). All patients underwent
ultrasound examination (Toshiba Aplio XG, 14 MHz transducer).
23 focal changes were qualified for FNAB (the volume range was
from 0,1 cm3 to 3,0 cm3, median: 0,85 cm3). After FNAB examination
the needle was washed out with 1 cm3 of 0,9% NaCl and PTH level
was measured in the obtained material.
Results: PTH levels exceeded 5000 pg/mL in 13 patients and were low-
er than serum PTH levels in the remaining group (range 24–35 pg/mL,
median, 29 pg/mL). Patients with elevated PTH levels were offered min-
imally invasive surgical intervention. In all operated cases parathyroid
adenoma was removed. In 2 cases neck revision, modified by PTH level
intraoperatively determination of the suspected lesions was performed
and retrotracheal parathyroid glands were removed.
Conclusions: PTH level determination in the needle wash-out ob-
tained during FNAB has demonstrated 100% specifity in differen-
tiating parathyroid and nonparathyroid tissues.
Identification of parathyroid lesions using described procedure is
a timesaving and cost-cutting method. Negative-PTH value should
suggest further need for diagnostic imaging or applying modifica-
tions while performing the surgery.
Original thyroid cancer oral abstracts
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Clinical value of intraoperative neuromonitoring
of the recurrent laryngeal nerves in improving
outcomes of surgery for thyroid cancer
M. Barczyński, A. Konturek, S. Cichoń, W. Nowak
3rd Chair and Department of General Surgery, Jagiellonian University,
Medical College, Kraków, Poland
Introduction: Visualization of the recurrent laryngeal nerves (RLN)
and efforts to preserve their anatomical integrity during total ext-
racapsular thyroidectomy in comparis
on to operations without RLN identification, minimizes the risk of
nerve lesions. However, intraoperative nerve monitoring may be
of additional benefit in reducing the risk of iatrogenic RLNs injury.
To evaluate influence of intraoperative RLN monitoring on the
prevalence of temporary and permanent nerve lesions following
total extracapsular thyroidectomy for well-differentiated thyroid
cancer (TC).
Material and methods: Among 249 patients with TC undergoing
surgery from 01/2005 to 06/2007, intraoperative RLN monitoring
was used in 151 operations of total thyroidectomy with central com-
partment of the neck lymph nodes clearance for well-differentiat-
ed thyroid cancer (pT1-3, N0-1, M0). Neurosign 100 equipment with
laryngeal needle electrodes was used. Outcomes of surgery em-
ploying nerve monitoring were compared to results of operations
performed throughout 2003 and 2004 without nerve monitoring in
a control group of 151 carefully age-, gender-, and TNM-stage-
matched (according to TNM 2002 classification) patients. Indirect
laryngoscopy was used to assess the RLNs morbidity (on the first
postoperative day and in a 12-month follow-up). Results were ex-
pressed as percentage of nerve events among the number of all
nerves at risk, and significance was tested with Chi2-test.
Results: Among patients operated with v. without nerve monitor-
ing the early RLN injury rate was 3.0% v. 6.7% (p = 0.02), including
2.0% v. 5.0% (p = 0.04) of temporary nerve lesions, and 1.0% v.
1.7% of permanent nerve events (p = 0.31).
Conclusions: In our experience the employment of intraoperative
RLN monitoring in surgery for thyroid cancer significantly reduced
the prevalence of nerve injuries. This phenomenon was mostly due
to a remarkable decrease of the prevalence of temporary RLN
events, with no significant difference in permanent nerve injury
rate.
The role of miRNA in reduction of type I
5 — iodothyronine deiodinase expression and mRNA
level in renal clear cell carcinoma (ccRCC)
J. Bogusławska, A. Master, A. Piekiełko-Witkowska,
A. Wójcicka, P. Popławski, Z. Tański, A. Nauman
The Medical Centre of Postgraduate Education, Warszawa, Poland
Introduction: Type I deiodinase (D1) catalyses synthesis of triiodot-
hyronine (T3). We previously revealed that the expression of the
whole pool of D1 transcripts was dramatically lowered in ccRCC
tissues. One of the mechanisms resulting in this aberration could
be microRNAs (miRNAs)-mediated repression of target mRNAs.
The aim of the work: was to study the potential regulation of D1
expression by microRNAs in clear cell Renal Cell Carcinoma (ccRCC)
Material and methods: In silico analysis, real-time PCR. Material:
ccRCC samples T (39); control samples C (contralateral pole of
ccRCC kidney, not infiltrated by cancer 39 samples); cell line: HeLa
and Caki-2 (ccRCC).
Results: We observed statistically significant (p < 0.0001) over five
fold increase in the expression of miRNA 224 and the three fold
increase in the expression of miRNA 383, in samples T compared to
control samples C. In order to evaluate whether D1 was effectively
a target of miR-224 and miR-383, the D1 3UTR was cloned down-
stream of a luciferase reporter gene vector; the HeLa cell line were
then transfected with the over expressing vector and the reporter
construct, with the relative luciferase activity showing that miR-
224 and miR-383 led to decreased activity of the reporter gene, thus
indicating binding with the 3UTR and destabilization of produc-
tive translation of luciferase mRNA.
Conclusions: Reduction of type I 5iodothyronine deiodinase ex-
pression and mRNA level in renal clear cell carcinoma (ccRCC) can
partially be a result of the overexpression of miRNA-224 and 383.
We identify the miR-224 and miR-383 as a potential regulator of
the D1 mRNA expression.
Karyometric characteristics of papillary thyroid
carcinoma and its relation to gene expression profile
of tumor tissue
M. Chekan1, M. Świerniak2, M. Jarząb2,
M. Oczko-Wojciechowska2, D. Rusinek2,
M. Śnietura1, B. Jarząb2
1Tumor Pathology Departament, M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
2Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: Papillary thyroid carcinoma (PTC) is based on char-
acteristic morphological features of tumor nuclei. These features
are very specific, but their molecular nature is still unknown.
We hypothesized that these mechanisms may be uncovered by the
analysis of correlations between PTC karyometric parameters and
its gene expression profile.
Material and methods: Karyometric analysis of 100 nuclei from
41 PTC cases was performed and correlated to gene expression pro-
file, analyzed previously using DNA microarray HG-133A. Param-
eters of nuclear size, shape and chromatin texture were calculated
and the permutation Goeman global test (GT) was calculated.
Results: Statistically significant relation with gene expression pro-
file was revealed for two parameters: one anisocaryosis related:
Nuclear Area Coefficient of Variation (NACV) and one PTC nuclei
shape-related: Circular Factor (mean value) (CF(m)). NACV was
chosen for further analysis of correlation with gene expression pro-
file. Significant Pearson correlation with NACV values was obtained
for 111 unique genes. Ten genes with interesting biological func-
tion were selected for validation analysis. The QPCR analysis was
performed on independent group of 36 PTCs. Significant correla-
tion with NACV for the following four of the ten genes: HDAC1,
ITGA4, PEX11A, SELENBP1 (p < 0.05).
Conclusions: We present the first application of correlation analysis
for investigation of interrelationships between cancer nuclei pheno-
type and gene expression. The significant correlation of anisokaryosis
and nuclei shape with gene expression profile was found.
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Occurrence of BRAF mutations in Polish cohort
of PTC patients — preliminary results
A. Czarniecka1, D. Rusinek2, E. Stobiecka3, J. Krajewska2,
M. Kowal2, A. Kropińska2, J. Żebracka2, M. Kowalska2,
J. Włoch1, A. Maciejewski1, D. Handkiewicz-Junak2
1Department of Oncologic and Reconstructive Surgery
2Department of Nuclear Medicine and Endocrine Oncolog
3Department of Tumor Pathology MSC Memorial Cancer Center and Institute
of Oncology, Gliwice Branch
Genetic alternations involving the mitogen-activated protein ki-
nase (MAPK) pathway are frequently demonstrated in PTC.
BRAF(V600E), the most frequent mutation in adult patients, is
present in approximately 50% of PTC. Most clinical studies have
demonstrated an association of BRAF(V600E) mutation with ag-
gressive clinicopathologic characteristics and high tumor recur-
rence, although the results are controversial.
In this study we present preliminary results of BRAF mutation fre-
quency and its prognostic significance in a group of 88 polish pa-
tients with papillary thyroid cancer (PTC). BRAF(V600E) mutation
was diagnosed in 38 (43%) of cases. From all analyzed clinico-patho-
logical factors only older age positively correlated with BRAF mu-
tation frequency (p = 0,0017). Lymph node/distant metastases,
multifocality and extra-thyroid extension did not correlated with
BRAF status.
Although many studies claim BRAF mutation as a prognostic fac-
tor in PTC our results underline that it is too early to consider its as
an routine, clinical predictive factor.
Role of different imaging modalities in diagnosis
of differentiated thyroid carcinoma metastases
R. Czepczyński, M. Gryczyńska, A. Czepczyńska,
M. Stajgis, J. Sowiński
Department of Endocrinology and Metabolism, 2nd Department of General
Radiology Poznań University of Medical Sciences, Poznań, Poland
Introduction: Metastases of differentiated thyroid carcinoma (DTC)
are rare. They mostly localize in lungs and bones. The aim of the
study was to evaluate the role of basic imaging modalities in dis-
tant metastases detection.
Material and methods: 48 patients (37 female, 11 male) with dis-
tant metastases of DTC were retrospectively analyzed. Whole body
scan using 131I (WBS), chest radiography (CXR), computed tomog-
raphy (CT) and bone scintigraphy (MDP) were evaluated.
Results: Patients were treated with 1 to 6 doses of radioiodine.
During the recent radionuclide diagnostics, thyroglobulin concen-
tration under TSH stimulation (endogenous in 31 pts., rhTSH in
16 pts.) varied from 0.5 tp 500 mg/mL (median 23 ng/mL).
WBS was positive in 27 patients (56.2%). Iodine-avid foci were found
in 17 patients, in the thyroid bed in 4, in mediastinum in 3 and in
bones in 4 pts. In the remaining 21 patients the WBS was negative.
CXR showed pathologic changes in lungs in 19 pts. (39.6%). These
were nodules > 1 cm in 13 pts., < 1 cm in 6 pts. In 29 cases CXR did
not disclose any suspicious lesions. In 13 cases radiological find-
ings were negative in WBS (68.4%). On the contrary, CXR failed to
demonstrate iodine-avid lesions present in WBS (52.9%).
CT was performed in 25 patients in whom the available diagnostic
methods did not show metastases. CT revealed lung metastases in
17 cases: nodules > 1 cm in 4 pts., < 1 cm in 11 pts., lymphangiosis
carcinomatosa in 1 pt., miliary carcinosis in 1 pt. Moreover, CT re-
vealed mediastinal lymph node metastases in 2 cases. In 14 cases
lung metastases were occult on WBS (82.4%).
MDP scan was performed in 20 cases. Bone metastases were found
in 11 of them. In 4 pts. MDP confirmed bone metastases diagnosed
in WBS. In 7 cases, the bone metastases were WBS occult.
Conclusions: Due to the high incidence of non-iodine-avid me-
tastases of DTC, and false negative radiological examinations, the
complementary imaging techniques should be applied on the reg-
ular basis.
The clinical value of PET with 18F-fluorodeoxyglucose
in patients with suspected recurrence of differentiated
thyroid carcinoma
A. d’Amico, T. Gawlik, J. Roskosz, A. Kukulska, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: PET-CT with 18F-FDG is indicated in localization of
the recurrent differentiated thyroid carcinoma patients with ele-
vated serum thyroglobulin (TG) and negative radioiodine scintig-
raphy. Aim of the study is to determine the sensitivity and specific-
ity of PET in these patients.
Material and methods: The study included PET-CT examinations
performed in our patients with differentiated cancer and suspect-
ed recurrence/dissemination. Suspicion of recurrence was based
on elevated TG levels (24 pts) or to the presence of radiological
lesions. In 36 patients the examination was carried out under TSH
stimulation.
Results: PET results were compared with the results of subsequent
surveys: histopathological examination (11 patients), radiological
examination confirming (34 patients) or with the results of scintig-
raphy after treatment with iodine 131 (3 patients). Overall, the PET
study showed sensitivity of 71%, specificity of 81%, positive pre-
dictive value of 88% and negative predictive value of 59%. In the
sub-group with radiographic changes these values was respective-
ly 87%, 75%, 92% and 64% and in sub-group with increased TG
75%, 67%, 85% and 54%.
Conclusions: In patients with suspected dissemination/recurrence
of differentiated thyroid carcinoma, PET-CT showed high PPV
while negative predictive value was only 59% (CI: 45–73%).
Vocal cords examination by use of real time, high-
resolution ultrasonography — a prospective pilot
study in patients before and after thyroidectomy*
M. Dedecjus1, Z. Adamczewski2, J. Brzeziński1, A. Lewiński2
1Department of General, Oncological and Endocrine Surgery Medical University
of Łódź, Polish Mother’s Memorial Hospital-Research Institute
2Department of Endocrinology and Metabolic Diseases Medical University of
Łódź, Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland
Introduction: Examination of the vocal cords is most commonly
performed by direct or indirect laryngoscopy, but this may not be
readily approached by some patients and is difficult to register
without advanced equipment. Ultrasound examination is acces-
sible, inexpensive and may be easily registered, so it would be
a perfect tool for vocal cords examination. Therefore, this pro-
spective study was carried out to evaluate the morphology of the
vocal cords and the larynx by real-time, high-resolution US and
to correlate the ultrasonographical features with the laryngolo-
gical examination.
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Material and methods: Fifty patients were included in the study.
All the patients had ultrasound examination (with 10 MHz linear
probe) performed before and two days after thyroidectomy. Simul-
taneously laryngological examination was performed.
Results: In analyzed group laryngological examination revealed
unilateral vocal cord paralysis in two cases. Moreover vocal cord
dysfunction was diagnosed in four cases. Examination performed
after three months follow-up confirmed transitory character of the
above mentioned pathologies. In simultaneously performed US-
examination of the vocal cords we observed changes in vocal cords
function in ten cases. In two cases the vocal cords were not moving
in US examination these were the patient with vocal cord paraly-
sis. In further 8 cases we observed changes in US image in compar-
ison to examination performed before operation. US-scan per-
formed after three months revealed that the image of the vocal
cords returned to the one registered before thyroidectomy
Conclusions: after analysis of obtained results we conclude that la-
ryngeal ultrasound examination is a non-invasive, easily reproducible
and inexpensive method of examining the larynx. Moreover, thanks
to many options of registration it may be a perfect tool for early vocal
cords post operative dysfunction discovery and monitoring. Howev-
er, analysis on the bigger group of patients is necessary.
*Recipient of Polish Thyroid Association — Ipsen Award.
Elastography — new development in ultrasound
in evaluating thyroid nodules
M. Gietka-Czernel1, M. Kochman1, K. Bujalska1,
E. Stachlewska-Nasfeter2, W. Zgliczyński1
1Endocrinology Clinic, The Medical Centre of Postgraduate Education Warszawa,
Poland
2Endocrinological Surgery Clinic, M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Warszawa, Poland
Introduction: Ultrasound elastography (ES) is a new technique for
estimating tissue stiffness. It measures tissue distortion under ex-
ternal pressure. ES is employed in differential diagnosis of thyroid,
breast and prostatic tumors.
The aim of the study was to investigate the clinical usefulness of ES
in differential diagnosis of thyroid nodules.
Material and methods: 52 thyroid nodules in 43 patients: 36 wom-
en, 7 men aged 44 ± 17.2 years were examined. Conventional ul-
trasonography (US), color Doppler fine-flow (CDF) and ES were
carried out with Hitachi Hi-Vision Preirus machine and linear trans-
ducer of 5–13 MHz. ES images were classified into 5 categories ac-
cording to the tissue stiffness: pattern 1–2 represented soft tissue,
pattern 3 showed mixed type of tissue and patterns 4–5 were char-
acteristic for hard nodules. The final diagnosis was obtained from
cytological or histological evaluation.
Results: Cytological data showed thyroid malignancy in 16 nod-
ules, indeterminate results in 13 and benign in 23 of cases. Thyroid
carcinoma: papillary and medullary appeared as a single nodule in
5/16 (31%) of cases and as a part of multinodular goiter in 11/16
(69%) of cases. In 7 cases (44%) thyroid cancer was accompanied
by Hashimoto thyroiditis. In conventional US and CDF thyroid
cancer was a solid tumor in 13/16 (81%) of cases, non homogenous
in 12/16 (75%), hypoechoic in 16/16 (100%), had microcalcifications
in 8/16 (50%), irregular margins in 10/16 (62.5%), central blood flow
in 7/16 (44%). Sensitivity of a single feature indicative for thyroid
carcinoma in conventional US and CDF was 64–100% and specific-
ity was 71–85%. ES showed high stiffness tissue pattern 4 and 5 in
13/16 (82%) of thyroid cancers. In 3 cases of thyroid malignancy ES
scores were soft (pattern 2) or mixed (pattern 3). All benign nod-
ules were classified into patterns 1–3. Pattern 4 and 5 were charac-
teristic for thyroid carcinoma with sensitivity 84%, specificity 100%,
positive predictive value 100% and negative predictive value 92%.
Conclusions:
1. Ultrasound elastography is a highly sensitive and specific meth-
od of diagnosing thyroid nodules.
2. This method can be employed in selecting thyroid nodules to
the fine-needle aspiration biopsy.
Molecular profile of thyroid cancer after exposure
to ionizing radiation
D. Handkiewicz-Junak, M. Świerniak, D. Rusinek,
M. Jarząb, M. Oczko-Wojciechowska, M. Kowal, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department Maria Sklodowska Curie
Memorial Cancer Center and Institute of Oncology
Thyrocytes derived differentiated thyroid cancers in children are
usually sporadic, but in rare cases they can develop after exposure
to ionizing radiation. Thyroid irradiation after nuclear plant catas-
trophe in Chernobyl, was associated with a large peak of papillary
thyroid cancers (PTC) developing in children and initiate a large
number of studies. However, results of this studies are equivocal
and the cancer-initiating role of radiation is debated. At first RET/
/PRC rearrangements, resulting from radiation induced DNA dou-
ble breaks, were believed to be “molecular fingerprint” of radiation
induced thyroid cancer. Yet, soon it was shown that this rearrange-
ments are frequently detected not only in radiation induced child-
hood PTC, but also in sporadic ones. Also genomic data on child-
hood thyroid cancer are very incomplete. The large scale microar-
ray study of expression profile in sporadic and radiation induced
childhood PTC could help us not only to clarify whether radiation
induced PTC show any specific expression profile, but also extend
our knowledge on PTC ethiopathogenesis and carcinogenetic ef-
fect of ionizing radiation.
Microarray study of sporadic and radiation induced PTC was per-
formed as a part of a international GENRISK-T project. Expression
profile of sporadic (cases with PTC born after January the 1st 1986)
and exposed to Chernobyl radiation (cases born between April 1968
and April 1986) were compared. Expression of more than 200 genes
was different between sporadic and exposed to radiation cases.
Statistical difference in expression profile between these two groups
confirming molecular differences between sporadic and radiation
induced thyroid cancer.
Criteria and standards in FNB of thyroid cancer
W. Jakubowski
Polish Ultrasound Society, Warszawa, Poland
Ultrasound examination, with application of electronic, high reso-
lution, wide bandwidth, 5–12 (14–18) MHz frequency probes, is at
present fundamental imaging examination in diagnostics of mor-
phological lesions in thyroid. Despite of many usable programs as
second harmonics, compound ultrasound, color Doppler, power
Doppler, 3D, visualization of microcalcifications, elastography, ul-
trasound contrast agents, do not exist ultrasound criteria enabling
for reliable differentiation of thyroid cancers from benign lesions.
Thus the important position and significance of FNB guided with
ultrasound for subsequent differential diagnostics.
The choice of focal lesions (lesion), visible with ultrasound, for FNB
should be based on following ultrasound criteria: echogenicity,
borders, distribution of echo in the lesion, chaotic distribution of
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microcalcifications, increased vascularization, decreased elasticity
or lack of elasticity on elastography, image in 3D of coronal plane.
Size of the lesion, halo-sign are not useful in designation of focal
lesions in thyroid for FNB, that can be thyroid cancer.
The presentation includes propositions of Polish Ultrasound Soci-
ety for performance of FNB of abnormal morphological lesions in
thyroid gland.
Analysis of genetic predisposition
to papillary thyroid cancer
B. Jarząb, D. Kula, Z. Puch, M. Kalemba,
D. Handkiewicz-Junak, M. Kowalska,
T. Tyszkiewicz, M. Kowal
Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: Papillary thyroid cancer (PTC) is usually sporadic can-
cer. However, it belongs to this kind of solid tumors, where family
occurring is more frequent than in the other groups — it is estimated
that the PTC risk is five fold higher in the relatives of PTC probands.
In contrast to some monogenetic hereditary cancer syndromes,
among which the occurrence of PTC is characteristic, genes respon-
sible for familiar PTC are poorly known. Genome wide association
studies recently revealed the association of single nucleotide poly-
morphism (SNP) on chromosome 9 with PTC (Gudmundsson et al,
2009). At the same time the results were published, which showed
the association of FOXE1 gene (formerly TTF2, Thyroid Transcrip-
tion Factor 2) located on chromosome 9 with PTC (Lande et al, 2009).
The aim of our study was to analyze the association of FOXE1 gene
with PTC in Polish population. DNA was isolated from 910 PTC
patients and 914 controls. Among PTC there were 85,6% women
and among controls 82,0%. Median age for PTC group was 53 years
and for controls 44 years. rs1867277 polymorphism of FOXE1 gene
was analyzed by allelic discrimination technique (7900HT Fast Real-
Time PCR System, Applied Biosystems).
Genotype distribution of FOXE1 SNP differed significantly between
PTC and controls (p = 0.00004). In PTC group the number of AA
homozygotes (25.5%) and AG heterozygotes (49.0%) was higher
than in controls (18.9% and 45.9% respectively). For the presence
of at least one A allele the OR value was significantly increased
(OR = 1.6; 95% CI: 1.30–1.96).
Conclusion: We confirmed the association of FOXE1 rs1867277 with
PTC in Polish population.
The work was supported by MNiSW grant: N N519 579938.
Expression of age-related genes in thyroid and
thyroid neoplasms by oligonucleotide microarray
profiling
M. Jarząb, M. Oczko-Wojciechowska, M. Świerniak,
S. Szpak-Ulczok, D. Handkiewicz-Junak, M. Kowal,
T. Tyszkiewicz, D. Lange, M. Chekan, A. Pfeifer,
A. Czarniecka, B. Jarząb, Z. Krawczyk
M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Gliwice Branch, Gliwice, Poland
Introduction: Differentiated thyroid cancer show age-associated
profile of occurrence and aggressiveness of disease. This phenom-
enon is not unique for thyroid and was described for different
malignancies. The biological rationale for the differences in cancer
occurrence and aggressiveness related to patient age are poorly
understood, despite the fact that the process of aging is quite well
understood for different tissue types, eg. fibroblasts.
The aim of the study was to characterize the changes in gene ex-
pression in thyroid cancer and normal thyroid samples, associated
with the age of cancer diagnosis.
Material and methods: We analyzed samples of papillary thyroid
cancer, collected from 83 patients treated at Maria Skłodowska-
Curie Memorial Cancer Center and Institute of Oncology in Gli-
wice. We applied Affymetrix HG-U133A (n = 49) and HG-U133
Plus 2.0 (n = 34) oligonucleotide microarrays. In 21 patients, there
was normal thyroid sample from contralateral lobe available for
analysis; additionally, 74 samples of normal thyroid from other
patients with benign or malignant tumors were collected. Microar-
ray data were preprocessed with RMA algorithm and analyzed with
stratification according to the microarray platform used.
Results: We have observed a coordinated pattern of gene expres-
sion in a group of transcripts, which was sigificantly associated with
age of patient at diagnosis (global test of association, p = 0.02). We
identified 105 age-correlated transcripts (p < 0.001), four of them
with False Discovery Rate < 10%. 55 genes showed positive corre-
lation with age, while 50 other transcripts were inversely correlat-
ed. Among the identified genes we observed the over-representa-
tion of extracellular matrix genes, migration and developmental
processes genes. Thyroid peroxidase (TPO) showed an inverse cor-
relation (R = –0.54) with patient age.
Conclusions: Age is significantly associated with gene expression
in papillary thyroid cancer. The importance of this fact for the biol-
ogy of thyroid carcinoma, especially the relation to the disease agres-
siveness demands further study.
Procalcitonin — a new marker for medullary
thyroid cancer patients?
K. Kaczka1, S. Mikosiński2, L. Pomorski1
1Department of General and Oncological Surgery, Medical University of Łódź,
Łódź, Poland
2Department of Nuclear Medicine and Oncological Endocrinology,
M. Sklodowska-Curie Memorial Hospital, Zgierz, Poland
Introduction: Calcitonin (CT) is the best known marker for medul-
lary thyroid cancer (MTC), although it has several limitations. In-
creased CT concentration is observed also in other diseases. CT is
rapidly broken down by serum proteases, which can lead to erro-
neous results. It has a biphasic and concentration-dependent half-
life. There are various immunoreactive isoforms of CT, which could
give inaccurate results.
Procalcitonin (PCT), the precursor of CT, is free from these limita-
tions. In contrast to CT, PCT has a concentration-independent half-
life and excellent in vitro stability in serum. Increased concentra-
tion is observed only in patients with bacterial infections or sepsis
and is due to extrathyroid PCT production.
The aim of the study was to check concordance between CT and
PCT in MTC patients in different stages of the disease.
Material and methods: Twenty-five patients were enrolled in the study.
There were 18 patients with MTC (5 with active — MTC, 13 cured
MTC patients) and 7 non — MTC patients (controls). None of our
patients had signs of bacterial infections or sepsis. CT was measured
by an immunochemiluminometric assay (CLIA) using an Liaison ana-
lyzer (DiaSorin Inc, USA). PCT was measured by an immunochemilu-
minometric assay (Liaison Brahms PCT) using an Liasion analyzer.
Results: PCT and CT levels were higher in all active MTC patients
— mean 4.75 ng/mL for PCT and 1220 ng/mL for CT. In all 13 cured
— MTC patients and 7 non MTC patients (control group), the lev-
els of both markers were not increased. A 100% concordance of
PCT and CT levels was observed among our patients in all clinical
stages of the disease.
Conclusion: PCT may be a new surrogate marker for MTC.
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Difficulties in pathological evaluation of thyroid
carcinomas — results of verification by the Polish
Working-Group for Endocrine Tumors
A. Konturek, M. Barczyński, M. Stopa,
P. Richter, W. Nowak
3rd Chair of General Surgery Jagiellonian University College of Medicine,
Kraków, Poland
Introduction: Microscopic pathology of thyroid carcinoma, where
proliferative processes may occur concomitantly with functional
abnormalities, is classified among particularly difficult specialties
of histopathology. The objective of the present study was histolog-
ical assessment of diagnostically dubious microscopic thyroid tu-
mor preparations based on the results of consultations provided
by the Polish Working-Group for Endocrine Tumors to our patients.
Material and methods: A retrospective study included a group of
diagnostically complex cases originating from 66 patients treated
surgically due to thyroid carcinomas at Department of General
Surgery in 2008. The tissue material was represented by hematox-
ylin-stained microscopic preparations of tissue sections collected
from primary tumor foci and lymph node metastases; in selected
patients, histopathology was supplemented by immunohistochem-
istry. The resultant data were analyzed statistically.
Results: Of the total number of 76 patients, in 12 cases the original
final diagnosis was changed. 40 patients were originally diagnosed
as follicular carcinoma and 8 patients with the diagnosis of papillary
microcarcinoma; 12 patients with follicular carcinoma and 1 individ-
ual with Hurthle cell carcinoma, 3 patients with medullary carcino-
ma; 1 with parathyroid carcinoma, 1 with the diagnosis of chronic
thyroiditis; 4 patients with follicular adenoma; 2 individuals diag-
nosed as multinodular goiter, 2 with lymph node metastases of pap-
illary carcinoma and 1 patient each with clear cell carcinoma (metas-
tasizing kidney tumor) and with poorly differentiated carcinoma.
Conclusions: A high degree of differentiation of thyroid tumors is
a source of considerable diagnostics problems, even in referral cen-
ters of thyroid surgery. Any diagnostic doubts should be consulted
by an extensive group of specialists who would take into consider-
ation the clinical symptoms and course of the disease, as well as
additional histological and immunohistochemical test results. This
help is being provided by the Polish Group of Endocrine Tumors.
Only such a management strategy does allow for initiation of an
appropriate and properly selected post-surgical treatment.
Follicular lesion in thyroid FNAB — a study
of histopathologically verified 129 cases
Ł. Koperski, B. Górnicka, M. Bogdańska, E. Wilczek,
A. Wasiutyński
Department of Pathology; Medical University of Warszawa; Department of
Cinical Pathomorphology, Central Clinical Hospital No 1 (Banacha Hospital),
Warszawa, Poland
Introduction: The term follicular lesion has been coined for some
FNAB results years ago, and represents an attempt to specify the
diagnostic difficulties which arise with this type of lesion. In the
literature there are significant discrepancies in an evaluation of risk
of malignancy of these lesions. One of the reasons of these varianc-
es is lack of precise cytological criteria and excessive latitude in us-
ing already established diagnostic standards by cytopathologists.
A fundamental aim of this study is cyto-histological analysis of cas-
es diagnosed in FNAB as follicular lesion depending on the cyto-
logical criteria.
Material and methods: From 2002 to 2005 (period I) in our Depart-
ment follicular lesion (FL) was classified into two categories: neo-
plasma folliculare (NF) — (cell-rich, monomorphic smears almost
entirely consisting of microfollicular structures) and proliferatio fol-
licularis (PF) — (smears which besides microfollicular structures con-
tained other cellular elements and colloid). During this period FL
was detected in 290 patients - NF in 72 and PF in 218 cases. During
period II (2006–2009) FL (without categorization) was diagnosed in
152 patients. During period I the histopathological verification was
possible in 31% patients with FL (90/290) -— in 69.4% with NF (50/72)
and in 18,3% with PF (40/218). During period II histopathological
verification was possible in 25.7% cases wih FL (39/152).
Results: During period I by postoperative histopathological exam-
ination, a neoplasm (with benign and malignant) was diagnosed
in 62% (31/50) with NF and 40% (16/40) with PF. Risk of malignan-
cy in group with NF (histopathology verified) was 16% (8/50),
whereas with PF was 5% (2/40). During period II by histopatholog-
ical examination a neoplasm was diagnosed in 30.7% patients —
carcinomas were diagnosed in 3/39 cases (7.7%).
Conclusions: Accurate cytological criteria and their strict use es-
sentially affect the postoperative profile of histopathological results.
On the basis of our study seems to be important to create subcate-
gories (eg high and low risk) in group of lesions still named as”
follicular lesions”.
The assessment of the efficacy of radioiodine
remnant ablation after radical surgery in patients
with differentiated thyroid cancer (DTC)
J. Krajewska1, M. Jarząb2, A. Czarniecka3, J. Roskosz1,
A. Kukulska1, E. Paliczka-Cieślik1, Z Puch1,
D. Handkiewicz-Junak1, B. Jarząb1
1Nuclear Medicine and Endocrine Oncology Department 2Clinical Oncology
Clinic, 3Oncologic Surgery Clinic M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology Gliwice Branch, Gliwice, Poland
Introduction: The efficacy of 131I has been proved in DTC patients
(pts) with advanced disease (M1,T4 or N1). However, the effects
obtained in subjects with lower disease stage are not so unequivo-
cal. Randomized, prospective studies seem to be extremely diffi-
cult due to the necessity of large number of pts and long follow-up.
Thus, the retrospective analysis in pts T1b-3N0 radically operated
between 1994 and 1997, during the period of limited accessibility to
131I treatment in Poland, was performed. Because the majority of
pts underwent complementary 131I therapy, the analysis was fo-
cused on relation between the efficacy of 131I and time between sur-
gery and its application. It was assumed that 131I treatment was
more effective when applied sooner after the operation.
Material and methods: The analyzed group consisted of 510 pT1b-
4N0-1M0 subjects, treated with 131I up to 24 months after radical
surgery, selected from 1033 DTC pts diagnosed between 1994 and
1997 (73% with papillary and 27% with follicular thyroid cancer,
mean time of follow-up 11,2 yrs). Pts with papillary microcarcino-
ma not demanding 131I therapy (n = 117), as well as pts not treated
with 131I due to lack of 131I uptake after the operation with absent
other risk factors (n = 151), pts treated non-optimally (n = 192)
and pts with DTC persistent after surgery (n = 63) were excluded.
Taking into the consideration the initial stage of disease the analy-
sis was based on comparison between the subjects treated with 131I
up to 9 months after surgery and others. Freedom from progres-
sion (FFP) and time from 131I treatment to progression were assessed.
Results: In pts T1b-3N0, 131I therapy carried out up to 9 months
after surgery was related to significantly lower risk of cancer recur-
rence (98.4% pts with no recurrence after 10 yrs compared to 93.4%
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in subjects treated between 9 and 24 months, p = 0.041). In sub-
jects with more advanced disease (T4 or N1) the frequency of re-
lapses was higher and no significant differences between pts treat-
ed up to 9 and 9–24 months were observed.
Conclusions:
1. Evaluation of putative benefits of 131I remnant ablation in low
risk DTC patients required the exclusion of these subjects in
whom 131I is definitely not necessary.
2. 131I remnant ablation in T1b-3N0M0 patients is related to sig-
nificant reduction of cancer recurrence dependent on time to
its application.
L-thyroxine supressive treatment in patients with
differentiated thyroid cancer (DTC): evaluation
of our clinical practice
A. Kropińska, J. Roskosz, Z. Puch, J. Krajewska,
A. Krawczyk, T. Olczyk H. Lewandowska, A. Antosz,
M. Dobrakowski, E. Gubała, B. Jarząb
Department of Nuclear Medicine and Endocrine Oncology,
Maria Sklodowska- Curie Memorial Cancer Center and Institute of Oncology,
Gliwice Branch, Gliwice, Poland
Introductions: DTC patients need L-thyroxine treatment after total
thyroidectomy and subsequent 131I therapy. Until recently, supres-
sion of TSH serum level was expected, whereas in the last ten years,
with the improvement of DTC prognosis, it is more common to ap-
ply incomplete suppression (0,1–0,4 mU/L) or even to treat substitu-
tively DTC patients (0,5–2,0 mU/L). In our centre most of patients
were treated with an intention of incomplete TSH suppression.
The aim of the study was to analyze how this intention has been
realized and to evaluate if the increase of serum TSH above 2 mU/L
is related to a higher risk of DTC recurrence.
Material and methods: The analysis was carried out in the group
of 200 DTC patients operated primarily in the Institute of Oncology
in Gliwice in 2004–2005 aged 31–63years (median 50 years) among
them 95.6% with papillary histotype. At the diagnosis 3% of patients
had distant metastases. The initial treatment comprised of total thy-
roidectomy in 94.6% cases and radioiodine therapy in 99%. We ana-
lyzed TSH serum levels during the L-thyroxine treatment, after
exclusion of all values of TSH > 20 mU/L due to L-thyroxine with-
drawal necessary for diagnostics or radioiodine treatment.
Results: Median serum TSH was below 0,1 mU/L in 71.7% of pa-
tients, in 18.5% was between 0.1–0.4 mU/L, whereas in 9.8% was
above 0.4 mU/L.
Despite the intention of incomplete suppression of TSH, median TSH
was lower than 0.1 mU/L in 67% of patients what fulfills the criteria
of total TSH suppression. Only in 14% of patients the increased rate
of TSH above 2 mU/L concerned more than 20% of measurements
and was not associated with the risk of DTC recurrence. The overall
risk of disease relapse was 5% within 5 years of follow-up.
Conclusions: The TSH serum levels obtained during L-thyroxine
therapy of DTC patients were slightly lower than desired. On the
other hand, the risk of insufficient L-T4 therapy was minimal and
was not associated by any increased risk of DTC recurrence.
The treatment of differentiated thyroid cancer (DTC)
in children: Evaluation of permanent side effects
A. Kropińska1, J. Roskosz1, J. Włoch1, J. Krajewska1,
A. Krawczyk1, T. Olczyk1, E. Paliczka-Cieślik1, J. Kozielski2,
A. Krzywiecki2, J. Szczasny1, K. Steinhof-Radwańska1,
W. Przeorek1, D. Handkiewicz-Junak1
1M. Sklodowska- Curie Memorial Cancer Center and Institute of Oncology,
Gliwice Branch, Gliwice, Poland
2Department of Lung Diseases and Tuberculosis, Medical University of Silesia,
Zabrze, Poland
Introduction: DTC treatment in children awakes controversy be-
tween proponents of the aggressive treatment who stress the pro-
tection from disease recurrence and of less intensive treatment,
which carries lower risk of complications. Our own experience
points out that the extensive initial therapy consisting of total thy-
roidectomy combined with appropriate extent of lymphadenecto-
my and followed by radioiodine therapy is associated with sub-
stantial decrease of risk of DTC recurrence.
The aim of this study was to analyze the side effects of combined
treatment of DTC in children.
Material and methods: 123 adult DTC patients diagnosed in child-
hood/adolescence at median age of 14 years (5–18), treated with
total thyroidectomy (92%) in different medical centers and radio-
iodine therapy (91%) in our center. Median time of follow up was
12 years (4–36). Lung metastases were found in 30 patients, but
chest X-ray was normal in 97% of patients at the time of the study.
Laryngologic examination, evaluation of parathyroid function and
gonadotropin levels were carried out during the present study.
HRCT and lung function tests were performed in patients with
lung metastases and in a selected control group.
Results: Recurrent laryngeal nerve palsy was observed in 18.7% of
patients, hypoparathyroidism was found in 20% of patients. There
were no signs of lung fibrosis even after repeated radioiodine treat-
ment. Total lung capacity and diffusing capacity was normal in
92.5% and 85% of patients. In 52.5% of patients decrease of peak
expiratory flow (PEF) was observed. Serum gonadotropins were
normal in all women and 74% of men.
Conclusions:
1. The risk of permanent surgical complications is high in DTC
patients operated during childhood/adolescence.
2. Radioiodine therapy of DTC in children does not cause lung
fibrosis and does not disturb lung function. The risk of PEF
decrease is related rather to the surgical technique applied than
to radioiodine therapy.
3. Risk of gonadal insufficiency should be considered in male pa-
tients as the permanent complication of radioiodine therapy,
especially if repeated radioiodine courses are applied.
Radioiodine remnant ablation in patients with
differentiated thyroid carcinoma (DTC): comparison
of long-term outcomes of treatment with 30, 60 and
100 mCi**
A. Kukulska, J. Krajewska, Z. Puch, M. Gawkowska-
Suwińska, E. Paliczka, J. Roskosz, D. Handkiewicz-Junak,
M. Jarząb, E. Gubała, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department, MSC Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
The aim of this study is to compare the effectiveness of 131I therapy
between three groups of DTC patients who received 30, 60 or 100 mCi
608
Streszczenia
M
A
T
ER
IA
ŁY
Z
JA
Z
D
O
W
E
for remnant ablation. The project was designed as a two-stage, pro-
spective randomized clinical trial.
During the initial phase the early effects of the treatment were com-
pared, the next stage presented below concerns the late outcomes.
In 1998–1999 in a randomized prospective study the early compar-
ison of treatment with 30 mCi v. 60 mCi proved the lower activity
to be less effective, whereas in 2002–2003 the comparison between
60 v. 100 mCi showed no significant differences.
The second stage of the study comprises the long-term assessment
of the course of the disease in study groups. A group of 331 DTC
patients (284 women and 23 men) with no clinical signs of persis-
tent disease was analyzed (267 with papillary and 44 with follicular
thyroid cancer). 30 mCi of 131I was applied in 83 patients, whereas
60 mCi in 128 and 100 mCi in 100 patients. The follow-up was
2–12 years for subjects treated with 30 mCi and 60 mCi and 2-6 years
for the patients treated with 100 mCi of 131I. 6–12 years after the
adjuvant 131I treatment the course of the disease and the current
clinical state were assessed by radiological examinations and se-
rum Tg concentration (on LT4-suppressive treatment). Local re-
lapse was stated in 2 (2.4%), 4 (3%) and 3 (3%) patients treated with
131I activities of 30 mCi, 60 mCi and 100 mCi, respectively.
Conclusions: In the analyzed group no significant differences in
long-term efficacy of radioiodine thyroid ablation using 30, 60 and
100 mCi in low-risk patients were observed. However, it should be
emphasized that thus can be also related to the radical surgical
approach applied, as well as to the completion of unsuccessful thy-
roid ablation by the second course of radioiodine administration
which was more frequently performed in patients treated with
30 mCi of radioiodine.
**Recipient of “Thyroid Research” award.
Does second opinion on thyroid fine-needle
aspiration (FNA) cytology change clinical treatment?
D. Lange, E. Stobiecka, A. Stanek-Widera, D. Banaś,
M. Wesołowski
Department of Tumor Pathology M. Skłodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: Secondary review of thyroid gland FNA cytologic
slides in patients referred from other institutions has been the stan-
dard practice at the Institute of Oncology in Gliwice.
The aims of this study were to analyze if our second, additional
cytological examination has an important effect on patient care.
Material and methods: All thyroid gland FNAs referred from Sep-
tember to December 2009 to the Department of Tumor Pathology
for a second cytopathologic opinion were analyzed. According to
Bethesda system FNA results were divided into: non-diagnostic,
benign, atypia of undetermined significance, suspicious for follicu-
lar or oncocytic neoplasm, suspicious for malignancy and malig-
nant. Final results of our consultation and first initial cytologic di-
agnosis were compared.
Results: One hundred sixteen patients had a second opinion of
their thyroid FNA. Our consultations confirm 61% of initial diag-
nosis in the doubtful cases. The highest concordance rate was in
malignant (Papillary cancer) category — 87,5%, and the lowest in
suspicious category — 52%. 11 cases were moved from suspicious
category to malignant one. Almost 20% of specimens were classi-
fied as non-diagnostic ones.
Conclusions: Second opinion of thyroid FNA is very important,
and often changes the diagnosis and finally decision surgical man-
agement.
Tracheal reconstruction with the use of radial
forearm free flap and biodegradative mesh
suspension description of three cases
A. Maciejewski, C. Szymczyk, J. Wierzgoń, M. Grajek,
M. Dobrut, R. Szumniak, S. Półtorak, Ł. Krakowczyk,
P. Jędrzejewski
Department of Oncological and Reconstructive Surgery, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Trachea reconstruction, after a resection of a malignant tumor is
one of the most difficult treatments. Defects longer than 6 cm can-
not be reconstructed with locoregional methods. The main aim of
tracheal restoration is to provide a non-collapsible construction with
a functional epithelial lining and well vascularized coverage. The
authors present three cases of a successful tracheal reconstruction
in patients with recurrent thyroid gland cancer infiltrating the tra-
chea. In each case the free radial forearm flap was formed as a tube
and suspended to the mesh rings placed outside. Currently all the
patients have no problems with respiration. The authors present
the stages of resection and reconstruction and achieved effect on
videos.
Clinical analysis of urinary iodine excretion in
patients with differentiated thyroid cancer (DTC)
B. Michalik1, J. Roskosz1, A. Stanjek-Cichoracka2,
A. Kochańska-Dziurowicz2, B. Jarząb1
1Nuclear Medicine and Endocrine Oncology Department, M.Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
2Department of Isotope Diagnostics and Radiopharmaceuticals, Sosnowiec,
Medical University of Silesia, Katowice, Poland
Introduction: To relate urinary iodine excretion to L-thyroxine ther-
apy and doses applied in DTC patients. To analyze risk of stable
iodine contamination in patients suspected of DTC dissemination.
Material and methods: The analyzed group included 572 DTC
patients who were treated with radioiodine or hospitalized for as-
sessment of its results from April 17 to December 12, 2009 at Insti-
tute of Oncology in Gliwice. Iodine urine concentration was ana-
lyzed with PAMM (Program Against Micronutrient Malnutrition)
method, L-thyroxine therapy and dose, TSH serum level and thy-
roglobulin level were considered. 545 tests were performed under
rhTSH administration and 27 after L-thyroxine withdrawal.
Results: Median L-thyroxine dose was 150 ug/day whereas 24hr
median urinary iodine concentration was 127,55 µg/L. Only 1,2%
samples showed stable iodine contamination (urinary iodine was
≥ 300 µg/L). Urinary iodine did not differ considerably in patients
treated after L-T4 withdrawal (in whom median TSH serum level
was 33 mU/L) and in patients examined during L-thyroxine treat-
ment (medians were respectively 127.1 and 127.5 µg/L). No distinct
relation between urinary iodine and L-thyroxine dose administered
was observed. Only in 1 patient, in whom serum level of stimulat-
ed thyroglobulin indicated on DTC dissemination, high urinary
iodine raised the suspicion of false negative radioiodine scan.
Conclusions: Low risk of distant metastases in DTC patients and
of urine stable iodine contamination allow to resign from low io-
dine diet in patients treated with rhTSH for diagnostic 131I scan or
complementary radioiodine therapy.
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The diagnostic value of PTH concentration in the
needle washout after fine-needle biopsy of foci of
unknown origin localized within thyroid gland
S. Mikosiński1, P. Jarek1, J. Makarewicz1, S. Sporny2,
L.Pomorski3
1Department of Nuclear Medicine and Oncological Endocrinology,
M. Sklodowska-Curie Memorial Hospital, Zgierz, Poland
2Department of Pathology, Medical University, Łódź, Poland
3Department of General and Oncological Surgery, Medical University, Łódź,
Poland
Introduction: Successful parathyroidectomy depends on recogni-
tion and excision of all hyperfunctioning parathyroid glands. Ul-
trasonography (US) is sensitive in detecting foci located within the
thyroid gland, but its specificity is not sufficient. Ultrasound guid-
ed fine needle biopsy increases the specificity, but cytological ma-
terial is not always diagnostic.
The aim of the study was to estimate the diagnostic value of PTH
concentration in the needle washout after fine-needle aspiration
of foci of unknown origin localized within thyroid gland in pa-
tients (pts) with hyperparathyroidism (HP).
Material and methods:18 pts were studied (15 females, 3 males);
16 pts with primary (2 recurrent), 2 with secondary HP, presenting
with one or more intrathyroid foci on US.
Serum PTH (PTH intact; Immulite 2000), total and ionized calcium,
phosphate, alkaline phosphatase concentration were measured in
all pts. 99mTc-sestamibi parathyroid SPECT scintigraphy was per-
formed. Dual tracer parathyroid 99mTc-pertechnetate/99mTc-sestamibi
planar subtraction scintigraphy was recorded (X-Ring Mediso).
Ultrasound guided (AU3 Partner, EsaoteBiomedica; 10 MHz) fine-
needle biopsy was performed and sent for cytology. The needle
(25G) was washed out with 125 µL (first biopsy) and 400 µL (sec-
ond biopsy) of 0.9% saline.
PTH concentrations (using the same PTH intact kit) in the wash-
outs were measured. A positive cutoff value for PTH washout con-
centration was defined as above to the PTH serum level. A preop-
erative map of the intrathyroid lesion was drawn. The drawing
was placed above the patient’s head to serve as a guide for the
surgeon performing open, focused surgery.
Results: All pts revealed parathyroid lesions. Hyperplasia was
found in 11 pts (11/18; 61.1%), adenoma in 6 pts (6/18; 33.3%) and
in one case (1/18; 5.6%) parathyroid cancer was suspected in pa-
thology, but no metastatic foci have been diagnosed so far. All but
one patient had elevated PTH washout concentrations-sensitivity
94.4%; positive predictive value (PPV) 100%.
Positive scintigraphy (visible parathyroids) was found in 9 pts
(9/18; 50.0%), positive cytology (detected parathyroid cells) was con-
firmed in 12 pts (12/18; 66.7%).
Conclusions: An elevated PTH washout concentration identifies
an intrathyroid focus as enlarged parathyroid gland with high PPV
and high sensitivity. With this diagnostic technique, minimally in-
vasive surgery can be implemented even in negative scintiscan cas-
es, thus sparing the unchanged thyroid gland.
Usefulness of biomarkers of thyroid neoplasm
(RET/PTC-1, RET/PTC-3, AKAP9/BRAF, PAX8/PPARg,
BRAF) in analysis of aspirates from biopsy of thyroid
nodules in children
M. Niedziela, J. Maceluch
Department of Pediatric Endocrinology and Diabetology, Poznań University
of Medical Sciences, Poznań, Poland
Introduction: Pathogenesis of thyroid cancer in children is differ-
ent than in adults and therefore it requires to search the other can-
didate genes as diagnostic markers of cancer. Preoperative materi-
al from fine-needle biopsy (aspirates) of childhood thyroid nod-
ules was studied.
The analysis of usefulness of selected markers of thyroid neoplasm.
Material and methods: Both, RNA (for expression analysis of RET/
/PTC-1, RET/PTC-3, AKAP9/BRAF, PAX8/PPARg) and DNA (to de-
tect mutation in BRAF gene) were isolated from thyroid nodules.
Total RNA underwent reverse-transcription and polymerase-chain-
reaction (RT-PCR) to obtain cDNA and to analyse the expression
of markers of thyroid cancer (candidate genes). In all samples the
analysis of control genes: GAPDH (for the qualitative and quanti-
tative evaluation of RNA) and thyroglobulin (control marker of
thyroid cells) were performed. From the total DNA, the exon 15 of
BRAF gene was amplified to investigate the T1799A (V600E) muta-
tion based on PCR-sequencing technique. Aspirates used for stud-
ies were in vast majority verified histologically and represented all
histological types of thyroid disease.
Results: 119 samples were analysed for the expression and BRAF
mutation. Among fusion oncogenes the positive result for RET/PTC-1
was seen in 3 samples of 119 (only in PTC), in 4 samples/119 it was
positive for RET/PTC-3 [PTC, follicular adenoma and in 2 aspirates
were verified postoperatively as colloid goiters (benign non-neo-
plastic)]. AKAP9/BRAF was negative in all analyzed aspirates. PAX8/
/PPARg was positive in only 1 patient with congenital hypothy-
roidism and coexisting thyroid nodules in both lobes (histological-
ly dyshormonogenetic goiter). Analysis for T1799A (V600E) BRAF
mutation was negative in all, too.
Conclusions:
1. The incidence of RET/PTC rearrangements is in agreement with
previous published data and more common RET/PTC-1 rear-
rangements prove the sporadic nature of this type of thyroid
cancer in the studied group.
2. BRAF gene mutation are not responsible for thyroid cancer in
the studied children.
Transcriptome of microdissected papillary thyroid
cancer cell
M. Oczko-Wojciechowska1, A. Rusin2, D. Rusinek1,
M. Kowalska1, M. Kowal1, T. Tyszkiewicz1, M. Chekan3,
A. Czarniecka4, E. Gubała1, B. Jarząb1
1Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
2Department of Tumor Biology, M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
3Department of Tumor Pathology, M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
4Oncologic Surgery Clinic, M. Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: The transcriptome of papillary thyroid cancer has
been well characterized by microarray studies, however, analysis
of gross specimens, with significant contribution of stromal tissue,
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lymphocytic infiltrate and normal thyrocytes makes the interpre-
tation of gene expression profile difficult. Until now only scarce
data on pure tumor cell populations are available.
Material and methods: Microdissection was performed on tumor
fragments taken intraoperatively from papillary thyroid cancer
(PTC) and normal thyroid tissue of 26 patients with PTC by PALM
laser microdissection system. PTC cells, normal thyrocytes, strom-
al tissue, lymphocyte infiltrates and medium-sized vessel popula-
tions were obtained, in total more than 80 samples. From 41 sam-
ples cRNA was synthetised by IVT Express Kit (Affymetrix). Up to
now, 27 microarray hybridizations were performed. Quantitative
real-time PCR was carried out in 18 independent microdissected
samples and 25 macrodissected fragments.
Results: Both RNA and cRNA showed significant degradation.
Normalization of highly divergent microarray studies, as those
obtained by analysis of pure microdissected populations, was
a challenging task. From preliminary data we selected 12 genes to
be verified by QPCR performed also in microdissected PTC cell
populations, 5 previously known PTC markers, (up-regulated in
PTC — FN1, MET, RXRG, ADORA1 and down-regulated TFF3)
and 7 new candidates (MPPED2, TACSTD2, KCNJ2, LRP4, EVA1,
CDH3, GALE).QPCR confirmed the significant overexpression of
4 known PTC markers, but not ADORA1. MPPED2 was the top
gene from our previous ranking of PTC genes performed in silico
(Fujarewicz et al, 2007) and QPCR confirmed its down-regulation
in PTC. The significant differences were also shown for KCNJ2,
TACSTD2 (up-regulated in PTC thyrocytes).
Conclusions: We indicate on the characteristic down-regulation
of MPPED2 and up-regulation expression of FN1, MET, RXRG and
the down-regulation of TFF3 in PTC thyrocytes.
Disturbances of expression of thyroid hormone
receptor TR-beta-1 in human renal cancer
A. Piekiełko-Witkowska1, A. Master1, A. Wójcicka1,
J. Bogusławska1, P. Popławski1, H. Wiszomirska1,
Z. Tański2, V.M. Darras3, G.R. Williams4, A. Nauman1
1Department of Biochemistry and Molecular Biology, The Medical Centre of
Postgraduate Education, Warszawa, Poland
2Regional Hospital Ostroleka, Poland
3Laboratory of Comparative Endocrinology, Division of Animal Physiology and
Neurobiology, Katholieke Universiteit Leuven, Leuven, Belgium
4Molecular Endocrinology Group, Division of Medicine & MRC Clinical Sciences
Centre, Imperial College London, Hammersmith Hospital, London, UK
Introduction: Thyroid hormone receptor beta1 (TR-beta1) is
a ligand dependent transcription factor whose activity is regulated
by thyroid hormone, triiodothyronine (T3). Untranslated regions
(UTRs) of mRNA molecule and miRNAs participate in postranscip-
tional regulation of expression.
Aim of work to identify and analyze UTRs role in regulation of
TRbeta1 in clear cell renal cell cancer (ccRCC).
Material and methods: samples of ccRCC (samples T), control kid-
ney samples (samples C), Caki-2 cell line (derived from ccRCC).
Methods: molecular cloning, transfection, real-time PCR, Western-
blot, in vitro translation, computational modeling.
Results: We identified one new 3’UTR and multiple new 5’UTRs
that differed by their biophysical properties and differently regu-
lated receptor’s translation. In T samples disturbances of expres-
sion of TRbeta1 protein, UTR variants, hsa-miR-204, iodothyronine
deiodinase type 1, and lowered level of T3 were found.
Conclusions: The observed disturbances lead to local tumor hy-
pothyroidism resulting from low level of tissue T3, TRbeta1 and
Dio1.
The work was supported by CMKP grant: 501-2-25-01/09.
The risk of inadvertent parathyroid excision during
thyroid cancer surgery
L. Pomorski1, K. Paduszyńska1, S. Mikosiński2,
E. Rogowska3, K. Kaczka1
1Department of General and Oncological Surgery, Medical University of Łódź,
Poland
2Department of Nuclear Medicine and Oncological Endocrinology,
M. Sklodowska-Curie Memorial Hospital, Zgierz, Poland
3Department of Pathology, M. Sklodowska-Curie Memorial Hospital, Zgierz,
Poland
Introduction: The aim of the study was to assess the risk of inad-
vertent parathyroid excision in patients undergoing primary thy-
roid cancer surgery.
Material and methods: Thirty-three patients — 30 (91%) female
and 3 (9%) male — were operated for thyroid cancer. The opera-
tions were performed by a surgical team in accordance with cur-
rent guidelines. In all cases of thyroid cancer, complete thyroid
excision with removal of central lymph nodes compartment were
carried out. If indicated, the procedure was extended to involve
ipsilateral lymph nodes or other lymph node compartments. Thir-
ty patients underwent primary surgery and 3 were reoperated due
to lymph node recurrence. In all patients, careful attention was paid
to detect the presence of parathyroid tissue in the pathology spec-
imens.
Results: Pathology results found 26 (79%) cases of papillary carci-
noma (PC), 3 (9%) cases of follicular carcinoma (FC), 2 (6%) cases of
medullary carcinoma (MC), a single case of lymphoma (3%) and
one metastatic lesion (3%). Parathyroid tissue was identified in
6 cases (20%) per 30 primary operations. Not more than one par-
athyroid was found to be removed at any one time. Evidence of
parathyroid tissue was found more frequently in cases of extensive
lymph node excision (more than 8) and in specimens of the central
compartment and upper mediastinum.
Conclusions: Complete thyroid excision due to cancer carries
a substantial risk of incidental parathyroid removal. The risk
increases in patients undergoing extensive regional lymph node
dissection.
Effects of Fenton reaction on oxidative damage to
membrane lipids and nuclear DNA in porcine thyroid
potential role in cancer initiation
J. Stępniak1, A. Kokoszko1,3, K. Zasada1,3, J. Szosland1,
M. Milczarek1, A. Gesing1,3, A. Lewiński2,3,
M. Karbownik-Lewińska1,3
1Department of Oncological Endocrinology, Medical University, Łódź, Poland
2Department of Endocrinology and Metabolic Diseases, Medical University,
Łódź, Poland
3Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland
Introduction: Oxidative stress participates in all steps of cancero-
genesis. The most basic reaction of oxidative stress is Fenton reac-
tion (Fe2+ H2O2ÆFe
3+ + OH + OH–). Hydroxyl radical (æOH), pro-
duced in Fenton reaction, may damage all biological macromole-
cules, leading to cancer initiation. Of special meaning is Fenton
reaction in the thyroid gland, as both H2O2 and Fe
2+ are indispens-
able for thyroid hormone synthesis. Fenton reaction is used to ex-
perimentally induce oxidative damage to biological macromolecules
and may serve as experimental model of cancer initiation.
The aim of the study was to evaluate the effects of Fe2+ and/or H2O2
on the level of oxidative damage to membrane lipids and nuclear
DNA in porcine thyroid.
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Material and methods: Thyroid homogenates or nuclear DNA iso-
lated from the porcine thyroid were incubated in the presence of
either H2O2 (0.00001–100 mM) or FeSO4 (1.5-300 µM) or in the pres-
ence of those two agents used together, namely FeSO4 (30 µM) +
H2O2 (in different concentrations) or H2O2 (0.5 mM) + FeSO4 (in
different concentrations). Concentration of malondialdehyde and
4-hydroxyalkenals (MDA+4-HDA), as an index of oxidative dam-
age to membrane lipids (lipid peroxidation), was measured spec-
trophotometrically. Concentration of 8-oxo-7,8-dihydro-2-deox-
yguanosine (8-oxodG), as an index of oxidative damage to nuclear
DNA, was measured by the use of high performance liquid chro-
matography (HPLC).
Results: Whereas Fenton reaction substrates, used alone, did not
affect the level of lipid peroxidation in porcine thyroid homoge-
nates, they did increase the level of oxidative damage to nuclear
DNA: the level of 8-oxodG increased significantly when H2O2 was
used in the highest concentration (100 mM), and Fe2+ did increase
in concentration-dependent manner (for concentrations of 300, 150,
30 and 15 µM) 8-oxodG level.
When Fe2+ and H2O2 were applied together, the level of lipid per-
oxidation increased significantly and further increase of 8-oxodG
level was observed comparing to the effects of particular substrates
used alone.
Conclusion: Excess of exclusively one of Fenton reaction sub-
strates is sufficient to induce oxidative damage to nuclear DNA in
porcine thyroid. Exposure to iron excess or red-ox imbalance lead-
ing to enhanced H2O2 formation may potentially contribute to
increased cancer risk in the thyroid gland, mainly via oxidative
damage to DNA.
Retrospective categorization of diagnoses
by ultrasound-guided FNAB of the thyroid gland
J. Sygut, A. Kowalska, J. Kopczyński, D. Gąsior-Perczak,
R. Mężyk, K. Niemyska
Holycross Cancer Centre, Kielce, Poland
Introduction: Bethesda system outlined the direction of coopera-
tion between doctors in diagnostic process and treatment of thy-
roid nodules. Would the categorization of diagnoses by ultrasound-
guided FNAB facilitate information exchange between specialists?
Evaluation of concordance between physicians allocations of cyto-
logical diagnoses to proposed diagnostic categories.
Material and methods: The material were 571 cytological diagnoses
reached by ultrasound-guided FNAB of the thyroid gland record-
ed in Correlations Database of the Neoplasm Pathology Depart-
ment of The Holycross Cancer Centre in years 2001–2007. All the
cytological diagnoses were correlated with histopathological diag-
noses and were confirmed to be true positive or true negative. The
average number of biopsied sites per one cytological report was 1.8
(1–4), and therefore, the average number of cytological diagnoses
per one cytological report was 1.8.
Every cytological diagnosis from a single biopsied site was retro-
spectively assigned to one of the 5 diagnostic categories: A1 cate-
gory — non-diagnostic aspirate, A2 category — benign lesion, A3
category — follicular neoplasm/oxyphilic tumor, A4 category —
suspected for carcinoma/malignant neoplasm, A5 category — car-
cinoma/malignant neoplasm. Qualification to the above given cat-
egories was performed by doctors engaged in the study, including
two endocrinologists and two pathologists. Acquired data was sub-
jected to statistical analysis.
Results: Full concordance between allocations of cytological diag-
noses to proposed diagnostic categories by all doctors for every
cytological diagnosis in every cytological report was achieved in
90% of the reports. Lack of concordance with possible consequenc-
es for diagnostic and therapeutic process was revealed in 2.1% of
the reports. In 8.2% of the reports, the lack of concordance would
not have any influence on future medical procedures. The concor-
dance between allocations to diagnostic categories made by doc-
tors engaged in the study was evaluated with Chi square test, and
the following values were recorded (p < 0.0001): 96.5% for the pair
Endocrinologist 1 Endocrinologist 2, 94.2% for the pair Pathologist
1 and Pathologist 2, 94.4% for the pair Endocrinologist 1 and Pa-
thologist 1, 95.1% for the pair Endocrinologist 2 and Pathologist 1,
96.9% for the pair Endocrinologist 2 and Pathologist 2, 94.2% for
the pair Endocrinologist 1 and Pathologist 2.
Conclusions: There was high concordance rate in allocations to
diagnostic categories which reached 90% for all FNAB diagnoses
evaluated by all 4 doctors and ± 95% for pairs of specialists.
Prediction of the papillary thyroid cancer distant
metastases risk by gene expression profiling*
S. Szpak-Ulczok1, M. Jarząb2, M. Oczko-Wojciechowska1,
M. Kowalska1, M. Kowal1, T. Tyszkiewicz1, A. Pfeifer1,
A. Czarniecka3, J. Włoch3, B. Jarząb1
1Department of Nuclear Medicine and Endocrine Oncology, M. Skłodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
2Clinical Oncology Clinic, M. Skłodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Gliwice, Poland
3Clinic of Oncological and Reconstructive Surgery, M. Skłodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: Papillary thyroid cancer, a malignancy of a relative-
ly good-prognosis, presents with distant metastasis in 5–10% pa-
tients. The analysis of gene expression by microarray method al-
lows to specify numerous novel molecular markers, potentially as-
sociated with the risk of disseminated disease.
The aim of the study was to assess the feasibility of genomic pre-
diction of metastases in papillary thyroid cancer patients.
Material and methods: Gene expression profiling was carried out
in 78 PTC samples taken intraoperatively (19 from pts with distant
metastases and 59 from pts without dissemination) by HG-U133A
(n = 49) or HG-U133 Plus 2.0 (n = 29) oligonucleotide microarrays.
Microarray dataset was pre-processed by GC-RMA method, class
prediction was carried out by linear discriminant analysis and sup-
port vector machines, with assessment of method accuracy by 0.632 ±
± bootstrap. Quantitative real-time PCR was carried out in a set of
85 PTC samples (18 pts with and 68 pts without distant metastases)
by ABI 7900 HT analyzer (Roche Universal probes; with normal-
ization to the panel of reference genes).
Results: In the first step we analyzed whether microarray-based
prediction of distant metastases is feasible. By bootstrap-assessment
of class prediction accuracy on the subset of best 10 genes, we found
out that the negative predictive value (NPV) of the method was
high (81%), with much weaker positive predictive value (PPV) of
33%. At least 108 genes were significantly associated with the risk
of distant metastases (non-corrected p < 0.001, false discovery rate
approx. 20%). Each of the genes alone was a weak risk predictor,
but the diagnosis could be based on the set of them. We validated
the selected genes on an independent set of 85 samples: the index
built from 28 microarray-based genes confirmed the initial results,
with NPV 85% and PPV 32%. Similar results were obtained by re-
duction of the classifier size to 10 genes.
Conclusion: Prediction of the low risk PTC is feasible, with clinically
relevant negative prognostic value of multi-gene classifier over 80%.
*Recipient of Polish Thyroid Association — Ipsen Award.
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Receptor PET scintigraphy with positon-gallium
labeled somatostatin analogues
in medullary thyroid carcinoma
Z. Wygoda, A. d’Amico, D. Hankiewicz-Junak,
B. Jurecka-Lubieniecka, K. Hasse-Lazar, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: About 50% medullary thyroid carcinoma patients
suffer from hypercalcitoninemia, despite of absence of clinical evi-
dence foci of recurrent/untreated disease. Routine imaging diag-
nostics, either radiological or based on nuclear medicine techniques,
are insufficient to localize cancer foci. In last 3 years a new method
in diagnostics of persistent hypercalcitoninaemia emerged: PET
scan with positon-gallium labeled somatostatin is analogue.
Initial assessment of usefulness of PET exam with positon-gallium
labeled somatostatin analogues for localization of cancer foci in
patients with medullary thyroid carcinoma and persistent hyper-
calcitoninaemia.
Material and method: Group of 21 patients, aged from 28 to
61 years, without radiological symptoms of disease was assessed.
During postoperative observation the serum calcitonin level above
300 pg/mL was stated. PET scan was performed with somatostatin
analogues, labeled with gallium 68Ga, produced from germanium-
gallium generator. Radiotracer activity of 4–7 mCi was adminis-
tered, the whole body acquisition was performed from base of skull
to knee with hybrid scanner PET-CT Philips Gemini 16XL.
Results: In 5 patients (25%) the foci of radiotracer uptake in thy-
roid bed or lateral neck lymph nodes, invisible in ultrasound or
computed tomography, were observed. In one patient there was
radiotracer uptake in thoracic vertebral column.
Conclusions: A preliminary assessment of usefulness of PET exam
with positon-gallium labeled somatostatin analogues for localiza-
tion of cancer foci suggests its potential usefulness in patients with
medullary thyroid carcinoma and serum calcitonin level above
300 pg/mL.
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Elastography based on tissue Doppler in the
diagnosis of thyroid nodules — a pilot study
Z. Adamczewski, K. Krawczyk-Rusiecka, M. Dedecjus,
J. Brzeziński, A. Lewiński
Department of Endocrinology and Metabolic Diseases, Medical University of
Łódź, Polish Mother’s Memorial Hospital — Research Institute Department of
General, Oncological and Endocrine Surgery, Medical University of Łódź, Polish
Mother’s Memorial Hospital — Research Institute, Łódź, Poland
Introduction: Aiming at the highest specifity in differentiating be-
nign from malignant thyroid nodules effects in new diagnostics
developments. Recent technologies such as elastography enable
determination of tissue stiffness difference between focal lesions
and surrounding thyroid tissue  — the reference tissue. This meth-
od is based on quantifying the stiffness of the lesion. The malig-
nant changes show decreased elasticity when compared to adja-
cent tissue. Tissue Doppler used in Toshiba ultrasound system re-
quires external tissue compression made by the researcher by means
of the transducer. Due to individual technique differences, some
artifacts interfering the diagnosis may occur during examination.
Design: The aim of the study was to assess a potential role of elas-
tography based on tissue Doppler in the diagnosis of focal thyroid
lesions.
In this study, 100 thyroid nodules in 76 consecutive patients were
examined (68 women, 15men), using Toshiba Aplio XG ultrasound
with linear PLT 1204 BT transducer. Final diagnoses were obtained
from cytological and, in 54 cases, histological evaluation. There were
5 cases of papillary thyroid carcinoma, 1 case of anaplastic carcino-
ma, and 70 benign nodules. After achieving final results all the con-
ducted examinations were reviewed.
Results: Retrospective evaluation study revealed presence of the
artifacts causing different outcomes. The results interpretation was
more difficult in nodules localized between isthmus and thyroid
lobes, in peripheral thyroid and in cases when the lesion and lobe
transverse parameters were equal.
Conclusions: Elastographic examination based on tissue Doppler
imaging reveal stiffness differences between thyroid lesions and
reference tissue. The awareness of the circumstances of artifacts
appearing and correct examination technique are crucial for prop-
er results interpretation.
Differentiated thyroid carcinoma diagnosed
incidentally in postoperative histopathology
R. Anielski1, S. Cichoń1, A. Hubalewska-Dydejczyk2,
M. Buziak-Bereza2, P. Orlicki1, A. Bałdys-Waligórska2
1Department of Endocrine Surgery, Jagiellonian University Medical College,
Kraków, Poland
2Chair and Department of Endocrinology, Jagiellonian University Medical
College, Kraków, Poland
Introduction: In view of the absence of characteristic clinical presen-
tation that would indicate a neoplastic process in progress, it is often
difficult to differentiate between differentiated thyroid carcinoma
(DTC) and benign goiter, especially multinodular goiter, and thus DTC
is frequently diagnosed only on the basis of postoperative histopa-
thology. Cytological assessment of biopsy specimens or intraopera-
tive evaluation of frozen section in DTC are associated with diag-
nostic problems, which do not allow in all cases for establishing an
appropriate diagnosis of carcinoma, either pre- or intraoperatively.
A comparative analysis of occult thyroid carcinoma (OTC) and DTC
diagnosed pre or intraoperatively.
Material and methods: The retrospective analysis included 9047
surgical patients treated in a single surgical center due to various
types of goiter in the years 1999 2008. The patients were divided
into three groups: 399 (4.4%) patients with DTC diagnosed pre or
intraoperatively, 507 (5.6%) individuals with occult carcinomas
detected only by final histopathology and 8141 (90%) patients with
benign goiter. The mean age of the surgical patients was 51ą14 years.
The entire group consisted of 87.7% of females and 12.3% of males.
The three subgroups were compared with respect to clinical-patho-
logical characteristics, results of intraoperative examinations and
employed treatment. A further detailed analysis included the group
of individuals with OTC.
Results: Occult thyroid carcinoma was detected in 507 patients. In
372 cases (73.4%), papillary carcinoma was diagnosed, in 68 pa-
tients (13.4%) classic follicular carcinoma, in 54 (10.6%) Hürthle cell
carcinoma, and in 13 (2.6%) cases poorly differentiated follicular
carcinoma. No other histological types of thyroid carcinoma were
observed in this subgroup. The mean size of the tumor focus was
16ą18.2 mm (median value — 9 mm), being smaller by 4 mm as
compared to the respective value in the DTC group. In 302 (59.6%)
cases, the tumor did not exceed 10 mm in diameter. In 68 patients
(13.4%), OTC was a multifocal disease. In 10 (2%) cases, histology
confirmed metastases to regional lymph nodes. Only 49 patients
(9.7%) were classified as clinical stage III and IV (UICC 2002). In
106 (20.9%) patients with OTC, total thyroidectomies were per-
Original thyroid cancer poster abstracts
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formed, while in 401 (79.1%) cases, thyroid resections were less
extensive; of this group, 112 (27.9%) patients required secondary
radicalization of the primary subtotal procedure.
Conclusions: Occult thyroid carcinoma is a significant clinical prob-
lem; in comparison to preoperatively diagnosed differentiated thy-
roid carcinoma, upon diagnosis, OTC is characterized by a smaller
size of tumor focus, lower aggressiveness of the neoplastic process
and a lower clinical stage. In consequence of less extensive prima-
ry thyroidectomies, almost 30% of patients with ITC require reop-
eration.
Diagnostic chip based on enzyme inhibitors
— preliminary approach
W. Balcerzak, A. Czernicka, S. Deja,
P. Młynarz, P. Kafarski
First Department and Clinic of General, Gastroenterological and Endocrinological
Surgery, Wroclaw Medical University Department of Bioorganic Chemistry,
Faculty of Chemistry, Wroclaw University of Technology, Wroclaw, Poland
Fast development of civilization results also in development of med-
icine and medical sciences. Studies directed towards production of
new efficient drugs and designing of new therapeutic techniques
are of high priority all over the world but also are extremely costly.
New non-invasive diagnostic methods are becoming of special in-
terest, especially if considering fast, selective and simple procedures.
Simple tests improving diagnostics as well as those for home-diag-
nosis will become soon integral part of prophylactics.
The goal of this study was to construct diagnostic tool helpful in
diagnosis of thyroid cancer types. The library of diaryl aminoben-
zylphosphonates, able to react with proteins and peptides present
in homogenates was chosen for this purpose. Esteric groups of these
compounds were selected in order to provide color or fluorescence,
which are undergoing changes upon reaction with homogenates.
Sice proteinous composition (proteome) of thyroid and cancerous
tissues is different it should enable to differentiate these tissues be-
cause the same library gives different pattern dependent on type
of homogenate.
Preliminary results are promising and indicated that components
of the library react differently with various homogenates, provid-
ing various changes of fluorescence. This was additionally proved
by studies of composition of products of these reactions by means
of 31P NMR technique.
Incidence rate of thyroid cancer in Olsztyn Region
in the years 1993–2008
E. Bandurska-Stankiewicz1, E. Aksamit-Białoszewska1,
A. Stankiewicz2, D. Shafie3
1Clinic of Endocrinology, Diabetology and Internal Medicine Chair of Internal
Medicine Faculty of Medical Sciences University of Warmia and Mazury,
Olsztyn, Poland
2Department of Thoraco-surgery, City Hospital Olsztyn, Poland
3Pathological Anatomy Unit, District Hospital, Olsztyn, Poland
Introduction: Olsztyn Region (OR), the area of moderate iodine
deficiency, was exposed to one of the highest irradiation doses in
Poland during the Chernobyl atomic plant breakdown.
Estimation of thyroid cancer incidence in Olsztyn Region in the
years 1993–2008.
Material and methods: Thyroid cancer register was kept in OR
from 1993 to 2008. The incidence rate was calculated as the number
of newly diagnosed thyroid cancer cases per 100,000 inhabitants in
a calendar year considering sex, age group and histopathological
diagnosis.
Results: In the years 1993-2008 there were diagnosed 799 new cas-
es of thyroid cancer (678 women, average age 52.5 ± 11.4, and
121 men, average age 54.1 ± 12.6) ; and in age group 0–18 in
12 cases. The women to man ratio was 5.6:1. The incidence rate
increased from 1.7 in1993 to 8.37 in 2004, since 2004 IR decreased to
6.3/100 000 in 2008; in women group respectively 3.1 (1993) to 14.8
(2004) and 11.52 in 2008. Papillary carcinoma was the dominating
histopathological type (75.9%).
Conclusions:
1. An increasing trend in the incidence rate of thyroid cancer was
observed in Olsztyn Region between 1993 and 2004, although
decreasing trend was observed to 2008.
2. Thyroid cancer incidence was significantly higher in women
than in men.
3. The highest thyroid cancer incidence rate was found for papil-
lary thyroid carcinoma.
The prevalence of central compartment of the neck
lymph nodes involvement following elective
clearance for papillary thyroid cancer
M. Barczyński, A. Konturek, M. Stopa, P. Richter,
W. Nowak
3rd Chair and Department of General Surgery, Jagiellonian University, Medical
College, Kraków, Poland
Introduction: Clinical suspicion of regional lymph nodes
involvement is present in approximately 10% of patients with pap-
illary thyroid cancer (PTC). Nevertheless, among the remaining 90%
of individuals assessed pre- or intraoperatively as N0, some cases
of metastatic lymph nodes from PTC are found on final pathologi-
cal report. Both quality of life and survival can be influence by even-
tual nodal recurrence in this group of patients.
To evaluate the prevalence of metastatic lymph nodes in patients
with PTC in stage cT1-3N0M0 undergoing elective central com-
partment lymph nodes clearance.
Material and methods: Clinical database of patients with thyroid
cancer undergoing surgery in 2009 was retrospectively analyzed.
48 (77.4%) patients with PTC, with pre- or intraoperatively not sus-
pected lymph nodes were identified (staging: T1 — 50%, T2
— 10.4%, T3 — 39.6%, including Tm — 22.9%). Elective total extra-
capsular thyroidectomy with one-stage clearance of the central
compartment lymph nodes was performed in all patients. The num-
ber of excised and metastatic lymph nodes within the surgical spec-
imen were analyzed.
Results: Mean number of lymph nodes within the surgical speci-
men was 4.5 ± 3.3 (1–17, median 4). Central compartment of the
neck lymph nodes involvement was found in 11 (27.1%) patients.
Mean number of 1 ± 2 metastatic lymph nodes were identified
(0–7, median 1).
Conclusions: More than a quarter of PTC patients with clinically
and intraoperatively non-suspected lymph nodes within the cen-
tral compartment are positive for metastatic nodal deposits in sur-
gical specimen following elective central compartment clearance.
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Thyroid fine-needle aspiration (FNA) cytology versus
frozen section examination (FS) in the experience
of the Surgical Oncology Department
D. Bisz, J. Albiński, S. Borczewski, P. Ciszewski
Gynaeobstetric Holy Family Hospital in Warszawa, Warszawa, Poland
Introduction: The aim of the study was the histopathological ver-
ification of the diagnoses made based upon frozen section exami-
nations (FS) and ultrasound-guided fine-needle aspiration (FNA)
cytologies conducted on patients who underwent thyroid surgery.
The optimal verification of cytology results is a post-operative his-
topathology analysis of the tissue previously diagnosed through
FNA cytology and FS examination.
Material and methods: The studies were carried out from October
2008 up till November 2009 on a population of 161 female and
42 male patients. The age of the patients varied from 20 to 76 years
of age/the average being 36.
This study compiles the results and shows the correlations between
cytology, frozen section and histopathology taken from 203 patients
treated in our department (17 papillary and follicular carcinomas,
47 follicular and oncocytic tumors and 139 nodular goiters).
Results: Verifying the cytology diagnoses histopathologically and
through frozen section results, it was established that in 139 of the
nodular goiters 94.2% of the diagnoses were confirmed, in 8 cases/
/5.8%/papillary carcinomas were diagnosed/from which 6 cases
were diagnosed through frozen section examinations.
Out of the 47 cases of the pre-operative follicular or oncocytic tu-
mor cytology diagnoses, 10 cases/21.2%/finally proved to be nodu-
lar goiters, 32 cases/68%/follicular adenomas and 5 cases/10.7%/fol-
licular carcinomas. In one of the cases, during the frozen section
examination, a metastatic papillary carcinoma to the lymph node
was identified.
In the 5 cases of pre-operative papillary carcinoma FNA cytology
diagnoses, finally 4 cases were confirmed and one case of Hashim-
oto thyroiditis was identified.
Conclusions: The intra-operative frozen section examination of the
thyroid is a fundamental element of surgical management tactics,
especially in the case of thyroid cancer. Frozen section of the thy-
roid is a difficult procedure to carry out, especially in follicular tu-
mors. Hence, in case of any doubts, pathologists should withhold
from making a diagnoses until the final histology.
Role of fine-needle aspiration biopsy in diagnosing
tumor metastases to thyroid gland
— personal observation
G. Buła, J. Waler, A. Niemiec, H. Koziołek,
W. Bichalski, J. Gawrychowski
Department and Hospital of General Surgery, Bytom Silesian Medical University,
Katowice, Poland
Introduction: Malignant metastases are rarely found in thyroid
gland, the incidence reaching approx. 2% of all thyroid malignant
neoplasm. They are most often caused by tumors of kidneys, lungs,
mammary glands, ovary, colon or by melanomas.
Aim: To evaluate the usefulness of fine-needle aspiration biopsy
(FNA) for diagnosing of tumor metastases to thyroid gland.
Material and methods: A total of 15122 patients were operated
between 1990 and 2009 for goiters. Malignant neoplasm was diag-
nosed in 733 (4.8%) patients. Malignant metastases to thyroid gland
were detected in 10 patients namely 2 men and 8 women aged
48–89. The group made 1.4% of all patients operated for malignant
thyroid tumor. Preoperative diagnostic procedure consisted of thy-
roid scintigraphy, thyroid ultrasonography and cytology of the
material obtained through FNA. In addition, hormonal activity of
thyroid gland was examined. The range of operation was estab-
lished through clinical assessment of the tumor, preoperative cy-
tology and intra-operative histopathology.
Results: Among 7 patients with thyroid metastases from renal clear
cell carcinoma, as diagnosed postoperatively, cytology of the thy-
roid material obtained through FNA revealed follicular tumor in
3 (%), patients, tumor cells in 2 and atypical cells in the other 2.
Intraoperative histopathology confirmed the presence of metasta-
sis from renal clear cell carcinoma (1 ×), and indicated thyroid med-
ullary cancer (1 ×), follicular tumor (4 ×) or trabecular adenoma
with necrosis (1 ×). Among 2 patients with thyroid metastases from
breast cancer, cytology confirmed a metastasis from breast cancer
in one (the woman was disqualified for surgical treatment) and
indicated follicular tumor in one. Intraoperative histopathology
suggested thyroid anaplastic cancer. Examination of biopsy speci-
men revealed epithelial cells accompanied by cell atypia in one
patient with thyroid metastasis from lung cancer. Intra-operative
examination also indicated on cellular atypia in the same patient.
Conclusions: Follicular tumor diagnosed by fine-needle aspiration
biopsy in patients after treatment for other cancers, especially re-
nal clear cell carcinoma, should make the surgeon alert to the pos-
sibility that it may be a metastasis of this cancer to thyroid gland.
Assessment of RET/PTC1 and RET/PTC3
rearrangements in fine-needle aspiration
biopsy specimens collected from patients
with Hashimoto thyroiditis
A. Cyniak-Magierska1, 2, K. Wojciechowska-Durczyńska1, 2,
K. Rusiecka-Krawczyk1, 2, A. Zygmunt1,2, A. Lewiński1, 2
1Department of Endocrinology and Metabolic Diseases, Medical University, Łódź,
Poland
2Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial
Hospital Research Institute, Łódź, Poland
Introduction: RET/PTC rearrangements are the most frequent
molecular changes in papillary thyroid carcinoma (PTC). So far,
11 main RET/PTC rearrangements have been described, among
which RET/PTC1 and RET/PTC3 are the most common in PTC es-
pecially in radiation-induced tumors. Recently, RET/PTC rearrange-
ments have been shown not only in PTC but also in benign thyroid
lesions, including Hashimoto‘s thyroiditis.
The aim of study was an assessment of RET/PTC1 and RET/PTC3
rearrangements in patients with Hashimoto’s thyroiditis.
Material and methods: Thyroid aspirates, eligible for the study,
were obtained from 26 patients with Hashimoto’s thyroiditis by
fine-needle aspiration biopsy (FNAB). Each aspirate was smeared
for conventional cytology, while its remaining part was immedi-
ately washed out of the needle. The cells, obtained from the nee-
dle, were used in further investigation. Total RNA from FNAB was
extracted by use of an RNeasy Micro Kit, and Reverse transcription
(RT-PCR) was done. Quantitative evaluation of RET/PTC1 and RET/
/PTC3 rearrangements by real-time PCR was performed by an ABI
PRISM 7500 Sequence Detection System. In the study, PTC tissues
with known RET/PTC1 and RET/PTC3 rearrangements served for
the reference standard (calibrator), while â-actin gene was used ad
endogenous control.
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Results: Amplification reactions were done in triplicate for each
examined sample. No RET/PTC1 and RET/PTC3 rearrangements
were found in the examined samples.
Conclusions: The results of the study indicate that RET/PTC1 and
RET/PTC3 rearrangements in Hashimoto’s thyroiditis are rather rare
events and further investigations seem to be necessary to describe
molecular changes, associating Hashimoto’s thyroiditis with PTC.
Prognostic value of differentiated thyroid cancer
(DTC) lymph node metastases in relation to the
extent of surgical treatment**
A. Czarniecka, M. Jarząb, J. Krajewska, E. Chmielik,
E. Stobiecka, B. Szcześniak-Kłusek, R. Kokot, A. Sacher,
S. Półtorak, J. Włoch
M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Branch, Gliwice, Poland
The analysis of prognostic significance of metastases to the neck
lymph nodes in DTC patients with special emphasis given to cen-
tral lymph node compartment to evaluate the possibility of reduc-
tion of the extent of neck lymphadenectomy depending on stage
of disease stage.
Prognostic value of N1 feature was assessed firstly in retrospective
group of 1141 DTC patients diagnosed and treated in Gliwice in
years 1986–1998, operated in different Polish surgical centers. In
the analyzed group metastases to neck lymph nodes were diag-
nosed in 291 patients (25.5%). Next, the group of 137 DTC patients
operated in Clinics of Oncological Surgery in Gliwice in years 2004-
2005 (c.a. 60% of all patients operated in these years) was analyzed
with aim to search a correlation between pT and N features. In this
group metastases to lymph nodes were stated in 36 patients (26%).
Statistical analysis was carried out with SPSS 12PL statistical pro-
gram. Test chi2, Kaplan-Meier survival analysis and Cox regression
were performed.
In the long-therm analysis, the presence of DTC metastases to the
neck lymph nodes was correlated with a decrease of both overall
survival (p < 0.0001) as well as disease free survival. In N1 patients
10 years overall survival was 80.4%, while in N0 patients it was
94.3%. 10 years disease free survival was respectively 45.4% i 86.9%.
N1 feature was unfavorable, independent prognostic factor influ-
encing overall survival (RR — 3,1) and disease free survival (RR —
4.5). In group of 137 patients operated in 2004–2005 the risk of me-
tastases increased with tumor size. Increase of risk of lymph nodes
metastases was not correlated with multifocal type of tumor growth,
however the risk of metastases occurrence was considerably relat-
ed with extracapsular invasion (p = 0.000).
Conclusions: In this analysis statistically significant increase of lo-
coregional relapse risk in case of isolated central compartment
lymph nodes involvement in DTC was not observed.
**Recipient of “Thyroid Research” award.
Comparison of results of thyroglobulin (Tg) and Tg
autoantibodies (aTg) measurements obtained with
TRACE and ECLIA methods in patients
with differentiated thyroid carcinoma
R. Deja, Z. Kołosza, E. Gubała, B. Masłyk
Department of Analytics and Clinical Biochemistry; Department of Tumor
Epidemiology; Nuclear Medicine and Endocrine Oncology Department M.
Skłodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice
Branch, Gliwice, Poland
Introduction: The aim of the study was to compare results of Tg
and Tg autoantibody determinations obtained with two different
IMA technologies (TRACE and ECLIA).
Material and methods: TRACE technology is a immunofluorescent
assay in which cryptate europium is used as the tracer. ECLIA tech-
nology is a chemiluminescent assay, ruthenium complex is used as
the tracer. Tg concentration and level of anti-Tg was measured in 339
serum samples of patients with differentiated thyroid carcinoma.
Results: The range of Tg levels was 0.17–265 200 ng/mL for TRACE
and 0.10–56 8210 ng/mL for ECLIA (medians: 0.594 and 0.899 respec-
tively). Both methods were significantly correlated with r = 0.99 for
all results, 0,88 for samples with Tg < 2 ng/mL, 0.98 for Tg < 10 ng/mL
and 0.97 for Tg < 30 ng/mL. The range of aTg levels was: 0–
–4000 IU/mL, with significantly higher values for ECLIA then TRACE
with significant correlation between both methods (r = 0.80).
Conclusion: There was a linear correlation between TRACE and
ECLIA results. Tg levels obtained by ECLIA are 2× higher, which
has to be considered at clinical interpretation.
Compliance of pre and postoperative diagnosis
of malignant thyroid neoplasms
P. Furga, J. Łapiński, K. Paśnik
Department of General, Oncological and Thoracic Surgery, Military Institute
of Health Services, Warszawa, Poland
Introduction: Comparison of compliance of pre and postoperative
diagnosis in patients treated surgically due to malignant thyroid
neoplasms.
Material and method: A preoperative diagnosis was established
on the basis of fine needle aspiration biopsy (FNAB). Postopera-
tively a standard histopathologic assessment was carried out. The
final results based on the analysis of both diagnoses.
Results: The study included 58 patients treated surgically due to
a malignant tumor of thyroid gland in the period between 2000
and 2009. Full compliance of FNAB and histopathologic examina-
tion was found in 38 cases. In 8 cases benign lesions in FNAB while
malignant tumors in histopatholgic evaluation were found. Malig-
nant lesions in FNAB but benign in histopathologic examination
were noted in 3 patients. Different types of malignant tumors in
both examinations were revealed in 3 patients, ambiguous FNAB
diagnosis while malignant lesions in histopathologic assessment
were noted in 6 cases.
Conclusion: Although full compliance between pre and postoper-
ative diagnosis of malignant tumors occurs in most cases, inconsis-
tency or discrepancy may be found.
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Prognostic impact of the doubling time of medullary
thyroid carcinoma tumor markers**
T. Gawlik, A. d’Amico, E. Gubała, A. Chorąży,
K. Gorczewski, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
Introduction: Calcitonin (CT) and carcinoembryonal antigen (CEA),
are tumor markers useful to follow-up activity in patients treated
for medullary thyroid cancer (MTC). Their elevated level precedes
morphological localization of the disease. It is estimated that CT
serum level of 1000 pg/mL, which is 100 times higher than upper
limit of normal value, is produced by 1 mL of tumor volume. In
some patients elevated CT serum level remains stable over years,
but in others it raises rapidly. The dynamics of tumor markers con-
centrations in the first years of follow-up can be assessed by the
calculation of the time they need to double. In the literature it has
been suggested, that CT-doubling time (DT) is the major prognos-
tic factor in patients with MTC.
To evaluate the impact of CEA and CT DT in our patients with MTC.
Material and methods: DT for CT and CEA was calculated using
nonlinear regression analysis by fitting single exponential curve to
CT and CEA concentration v. time. Data from 110 patients hospi-
talized in years 2004–2005 were analyzed. In 40 patients the mark-
ers remained within normal range. Taking into account the lower
DT value of one of the marker the remaining 70 patients were di-
vided into Group 1 (0 < DT < 2 years; 25 patients) and Group 2
(DT > 2 years or DT < 0; 45 patients). Overall and disease-free
survival were compared using Kaplan-Meier survival analysis.
Results: There were statistically significant differences in overall
survival and disease-free survival between these two groups
(p < 0.00001 and p < 0.01, respectively). Group 1 was at greater
risk of death and recurrence. After 5 and 10 years after surgery, the
survival rate in group 1 was 60 and 22%, respectively, whereas in
group 2 — 95 and 82%, respectively. Moreover, all patients with
DT < 0.5 year (4 patients) died in less than 5 years from surgery.
Conclusions: The calculation of CT- and CEA-DT in patients with
MTC has significant prognostic value. In order to achieve adequate
precision several measurements are needed, taken over sufficient-
ly long period of time (optimally > 2 years) without therapeutic
interventions, which is an inevitable drawback of this method.
**Recipient of “Thyroid Research” award.
Diagnostic performance evaluation of procalcitonin
measurments during the follow-up of patients with
medullary thyroid carcinoma (MTC)
D. Gąsior-Perczak, A. Kowalska, I. Pałyga, G. Antczak,
A. Słuszniak, S. Góźdź
Holycross Cancer Center, Kielce, Poland
Introduction: Calcitonin is the main MTC marker. However, it has
limitations: rapid in vitro degradation, a concentration-dependent
biphasic half-life, presence of different isoforms and high cost of
a single measurement. Procalcitonin, the prohormone of calcitonin,
is free of these limitations, but its concentration is influenced by bac-
terial infections and is currently used only as a sepsis marker.
The aim of the study was to compare the diagnostic performance
of measuring the levels of procalcitonin to calcitonin in pentagas-
trin test with in patients with MTC.
Material and methods: The study covered a group of 41 MTC pa-
tients (32 women and 9 men, aged 16-79), after the surgery, during
the follow-up. Procalcitonin and calcitonin levels after pentagas-
trin administration were measured in 0, 3, 5 min. The diagnostic
performance of measuring procalcitonin has been compared to cal-
citonin measurements.
Results: Procalcitonin levels in pentagastrin test were significantly
higher in patients with elevated calcitonin level. In 0 min. they
ranged 0.11–3.19 ng/mL average 2.27 ng/mL; in 3 or 5 min. 0.13–
–15.74 ng/mL average 7.45 ng/mL. Calcitonin levels in 0 min. ranged
13.8–518 pg/mL average 149 pg/mL in 3 or 5 min. ranged 35–937
pg/mL average 495 pg/mL. None of the patients. who were consid-
ered to be cured and had normal calcitonin levels in 0 min. ranged
6.16–8.07 pg/mL average 6.64 pg/mL in 3 or 5 min. ranged 6.19–
–9.75 pg/mL average 6.97 pg/mL was found to have elevated levels
of procalcitonin while the respective values of procalcitonin in
0 min. ranged < 0.05 — < 0.05 ng/mL average < 0.05 ng/mL; in
3 or 5 min. ranged < 0.05 — < 0.05 ng/mL average < 0.05 ng/mL.
Analyze of the results indicates a strong correlation of calcitonin
and procalcitonin in the group of patients with increased calcito-
nin levels.
Conclusions: Measuring procalcitonin levels may be a substitute
of calcitonin measurement when the later in not easily available.
Expression of ghrelin and obestatin in human thyroid
gland and thyroid tumors
E. Gurgul1, M. Ruchała1, M. Biczysko2, J. Surdyk-Zasada3,
A. Kasprzak3, A. Łukaszyk3, J. Sowiński1
1Department of Endocrinology, Metabolism and Internal Medicine, Poznań
University of Medical Sciences
2Department of General, Gastroenterological and Endocrinological Surgery,
Poznań University of Medical Sciences
3Department of Histology and Embryology, Poznań University of Medical Sciences
Ghrelin and obestatin belong to the ghrelin gene derived prod-
ucts. Ghrelin is recognized as a circulating hormone expressed in
multiple organs and exerting locally various actions. Expression
and the in vitro modulatory effects of ghrelin have been recorded
in thyroid gland and thyroid cancer cells, while occurrence and
role of obestatin in this endocrine gland remain to be elucidated. In
reason of deficiency in knowledge on the obestatin role in thyroid
the presented study was performed to compare the immunohis-
tochemical expression pattern of ghrelin and obestatin on human
thyroid under physiological and pathological states.
Human thyroid samples were collected from the material obtained
at thyreoidectomy performed due to clinical indications. It includ-
ed 4 cases of normal thyroid tissue derived of healthy area of the
gland suspected of collateral malignancy in solitary nodule and,
moreover, 7 cases of nodular goiter, 2 cases of papillary cancer,
2 cases of follicular adenoma and one case of mixed medullary and
follicular cancer.
Samples were fixed in Bouin fluid, dehydrated and embedded in
paraffin. 5 µm thick sections were mounted on SuperFrost/Plus
microslides, dewaxed, rehydrated and treated according to stan-
dard immunohistochemical procedure. Primary antibodies used in
the study were antihuman ghrelin polyclonal serum and antihu-
man obestatin polyclonal serum (both Phoenix Pharmaceuticals).
Immunohistochemical expression of both ghrelin and obestatin was
documented in parafollicular and follicular cells and cancer cells.
Expression of ghrelin in follicular cells was found mainly in prox-
imity of the neoplastic area. Most often the immunoreactive obesta-
tin was occurred together with ghrelin in the same cells, but the
618
Streszczenia
M
A
T
ER
IA
ŁY
Z
JA
Z
D
O
W
E
reaction for obestatin was less intensive and the intensity was dif-
ferent in the particular cells. Differences in the intensity of reaction
for obestatin among the cells were observed also in follicular and
medullary cancer. At present, it is concluded that obestatin like
ghrelin is involved in local regulatory processes in human thyroid
and the differences in expression among particular cells may re-
flect its functional significance.
Radioiodine treatment of advanced
differentiated thyroid cancer (DTC)
D. Handkiewicz-Junak, E. Paliczka-Cieślik, J. Roskosz,
K. Hasse-Lazar
Nuclear Medicine and Endocrine Oncology Department M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
Introduction: The key characteristic of DTC that contributes to
success of radioiodine treatment in persistent or recurrent disease
is its ability to actively transport and accumulate iodine. Tradition-
ally radioiodine treatment is performed after a 4 to 6 week with-
drawal of thyroid hormone (LT4). Recombinant human TSH (rhT-
SH) was developed to provide TSH stimulation without LT4 with-
drawal and associated hypothyroidism. Additionally, in patients
without or low radioiodine (131I) uptake in cancer foci, pretreatment
with 13 cis-retinoic acid (13cis-Roo) has been tested recently.
The aim of the study was to evaluate effectiveness of 131I treatment
in advanced DTC patients treated according to standard protocol,
rhTSH stimulation or 13cis-Roo pretreatment.
Material and methods: During the years 2001–2008 more than 150
patients with advanced DTC have been treated with 131I. The pa-
tients were divided into 3 groups: a) 45 patients treated mainly
under exogenous stimulation (≥ 3 consecutive treatments were per-
formed with rhTSH stimulation); b) 51 patients treated mainly af-
ter endogenous stimulation and c) 53 patients with non-functional
metastatic disease treated after preatment with 13cis-Roo and rhT-
SH stimulation. Response to treatment (radiological and biochem-
ical), disease free survival (DFS) and overall survival (OS) were
evaluated.
Results: All patients treated under rhTSH had good TSH stimula-
tion: median 154 mUI/L. 5 patients treated after L4 withdrawal had
TSH below 25 mUI/L. The median time of observation for the whole
group was 66 (18-134) months. 55 (37%) were lost from observa-
tion, 25 (18%) died. In group C, where 35 (66%) were lost from
follow-up, only response to treatment was evaluated. Partial re-
sponse was achieved in 8 (18%), 6 (12%) and 0% patients in group
A, B and C. DFS was respectively 37 and 68 months in group A and
B and OS 28 and 50 months. Biochemical response was achieved in
27 (60%) and 29 (56%) patients in group B and C respectively.
Conclusions: Radioiodine treatment results in radiological and bio-
chemical response in respectively 15% and 58% of patients. There
are no differences in therapeutic effectiveness of radioiodine treat-
ment during endogenous or rhTSH stimulation. In case of non-
functional metastases, pretreatment with 13cis-Roo does not induce
clinically relevant response.
Pheochromocytomas in the RET protooncogene
mutations carriers
K. Hasse-Lazar1, A. Krawczyk1, S. Szpak-Ulczok1,
A. Pawlaczek1, J. Ziaja1, B. Jarząb1
1Department of Nuclear Medicine and Endocrine Oncology, M. Skłodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
2Department of General, Vascular and Transplant Surgery, Medical University
of Silesia, Katowice, Poland
Intraduction: Mutations in the RET protooncogene cause heredi-
tary medullary thyroid cancer, which in some cases coexists with
pheochromocytoma and primary hyperparathyroidism as the
MEN2A syndrome.
Evaluation of frequency of pheochromocytomas and their clinical
course in the RET protooncogene mutations carriers.
Material and methods: 179 patients, among them 109 probands
and 70 family members in whom RET germinal mutations were
detected. 90 probands had DNA analysis because of diagnosis of
medullary thyroid cancer and 19 because of pheochromocytoma.
Analyzed DNA was isolated from peripheral blood leukocytes.
Exons 10, 11, 13–16 were analyzed by direct DNA sequencing.
Results: The frequency of pheochromocytoma in the mutations car-
riers was 29% (n = 51). Multiple lesions present at the time of diag-
nosis or occurring during follow-up were present in 34 cases (66%).
In 3 cases malignant tumors were diagnosed. According to the type
of mutation pheochromocytomas were present in 1/1 cases with
codon 534 mutation, 1/1 cases with codon 609 mutation, 1/3 cases
with codon 611 mutation, 2/17 cases with codon 618 mutation, 0/9
cases with codon 620 mutation, 33/66 cases with codon 634 muta-
tions, 0/6 cases with codon 768 mutation, 0/4 cases with codon 790
mutation, 6/30 cases with codon 791 mutation, 0/14 cases with codon
804 mutation, 1/7 cases with codon 891 mutation and 4/14 cases
with codon 918 mutation.
Conclusions: Pheochromocytomas are present in about 1/3 of RET
mutations carriers, mostly multiple and benign tumors located in
adrenal medulla as in the majority of cases. Their frequency de-
pends on the type of mutation and only in patients with codon 634
mutations reaches 50%. The overall frequency in all RET mutation
carriers is 29%.
DNA repair genes in the thyroid cell lines
and human tumors*
J. Janik, K. Hanusek, B. Czarnocka
The Medical Center of Postgraduate Education Department of Biochemistry and
Molecular Biology, Warszawa, Poland
Free radicals and reactive oxygen species (ROS) participate in phys-
iological and pathological processes in the thyroid gland. Oxida-
tive stress caused by ROS is involved in many types of DNA dam-
age that are associated with the initiation or the progression of
numerous human cancers including thyroid tumors. One of the
most mutagenic products of oxygen radical forming agents is 7,8-
dihydro-8-oxoguanine (8-oxoG).
The aim of the current study was to investigate expression of OGG1
and XRCC1 genes which belong to BER system and take part in
the elimination of 8-oxoG from DNA.
We determined OGG1 and XRCC1 expression on both transcript
and protein levels (Q-RT-PCR, Western blot) in the thyroid cancer
cell lines and a series of human thyroid tumors and normal thyroid
tissues. We analyzed expression of these genes in the lines derived
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from papillary carcinomas: BCPAP, ONCO-DG-1, TPC-1; follicu-
lar carcinomas: FTC-133, FTC-238, CGTH-W-1, ML-1 and non-dif-
ferentiated carcinoma — 8505C. The normal human thyroid follicu-
lar epithelial cells — Nthy-ori 3-1 served as a control. Then, thyroid
tumors (42), mostly PTC, and normal thyroid (15), were screened
for the expression of above genes.
In all, but one cell line the OGG1 and XRCC1 mRNAs expression
was on the level similar to that found in the normal thyroid cell
line. Significantly decreased expression of both genes was detect-
ed in the TPC 1 cell line. Q-RT-PCR method showed that mRNA
expression range was similar in cancer and normal tissues.
Although we found that the expression of OGG1 and XRCC1 genes
in the thyroid cancer cell lines and human thyroid tumors do not
differ from the expression in the normal thyroid further studies are
needed to fully investigate DNA modifications and repair mecha-
nisms in the thyroid tumors development.
*Recipient of Polish Thyroid Association — Ipsen Award.
Depressive symptoms, anxiety and quality
of life in young adults, treated in childhood
due to differentiated thyroid cancer
M. Jarząb1, A. Syska-Bielak2, A. Kropińska2,
D. Handkiewicz-Junak2, M. Jarząb3, K. Hasse-Lazar2,
A. Heyda4, A. Król2, P. Gorczyca1, R.T. Hese1
1Department of Psychiatry Tarnowskie Góry, Medical Faculty Zabrze, Silesian
Medical University, Katowice, Poland
2Nuclear Medicine and Endocrine Oncology Department, M. Skłodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland
3Clinical Oncology Clinic, M. Skłodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Poland
4I Radiotherapy Clinic, M. Skłodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Poland
Introduction: Differentiated thyroid cancer (DTC) is one of most
common epithelial tumors in children. The large disease advance-
ment at presentation, characteristic for DTC in childhood, moti-
vates the intensive multi-modality treatment of this disease. It re-
sults in a very good prognosis of DTC in children, significantly bet-
ter in other common childhood neoplasms. However, the good
prognosis context is being realized by the patients even after many
years, when they achieve full remission; thus this population is
fully prone to the cancer stigma phenomenon. It is especially im-
portant, as in opposition to many oncohematological neoplasms,
DTC is often occuring in teenagers, with important effect of their
own disease perception and emotions influencing the adolescence
and personality development.
The aim of the study was to assess the frequency of anxiety and
depressive disorders and quality of life in relation to the factors
determining the disease course in young adults, in childhood treat-
ed due to DTC.
Material and methods: Psychiatric examination was carried out,
with detailed assessment of anxiety and depressive symptoms and
quality of life assessment in 109 patients, aged 18–38 years, treated
or in regular follow-up in Nuclear Medicine and Endocrine Oncol-
ogy Department between 1987 and 2003. These patients were pro-
spectively assessed (both physical and mental health) between the
years 2006–2007.
Results: In 18% of patients we found significant symptoms of anx-
iety or depressive disorders, requiring therapeutical intervention,
while in approx. 40% of patients we found minor symptoms. The
results were analyzed in the context of the aggressiveness of the
oncological treatment (number of surgeries or 131I treatment cours-
es etc), and disease state at the moment of the examination. We did
not found any association between treatment intensity and psy-
chological outcome, with the exception of the number of surgical
procedures influencing the depressive and anxiety symptoms.
Conclusions: The aggressive treatment of DTC does not deeply
enhance the depressive or anxiety symptoms and does not decrease
the quality of life. It does not apply to the surgical treatment, which
shall be planned to limit the number of procedures, negatively im-
pacting the final anxiety and depressive status.
Expression of immunity-related genes in thyroid
cancer — transcriptome analysis
M. Jarząb, M. Oczko-Wojciechowska, M. Kowal,
M. Olakowski, A. Rusin, M. Kowalska, D. Rusinek,
A. Pfeifer, M. Świerniak, A. Czarniecka, E. Chmielik,
E. Stobiecka, D. Lange, J. Jarząb1, Z Krawczyk
M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Branch, Gliwice, Poland, Silesian Medical University, Katowice, Poland
Introduction: The expression of genes specific for immune system
is an important feature of papillary thyroid cancer (PTC) pheno-
type. The ability of normal thyrocytes to present antigens via MHC
molecules was observed in early 80’, only few years later it was
confirmed for malignant thyroid cells. Also by the analysis on gene
expression level it was observed that immune response genes are
the important pattern of variability in the transcriptome of papil-
lary thyroid cancer.
The aim of the study was to charaterize the variability of immune
response genes in papillary thyroid cancer in comparison to nor-
mal thyroid and other cancers.
Material and methods: We analyzed the dataset consisting of mi-
croarray gene expression profiles for 93 PTC, studied by Affyme-
trix oligonucleotide microarray. Simultaneously, we analyzed
95 specimens of normal thyroid. Separately, the set of other malig-
nancies (medullary thyroid cancer, pancreatic cancer) and benign
samples (normal pancreas, chronic pancreatitis) was assessed.
Results: In the first step, we applied unsupervised analysis (singu-
lar value decomposition) to identify the major sources of variabili-
ty in the analyzed dataset of PTCs and normal thyroid samples.
This analysis was carried out on the whole set of transcripts, and
separately only on transcripts of immunity-related genes. We have
confirmed that the variability of gene expression in PTC is highly
depending on the immune transcripts, with different patterns, some
of them clearly originating from lymphocytes. The results were
interpreted in the context of gene expression in microdissection-
derived thyrocytes.
Conclusions: In the gene expression profile of PTC, there is a visible
lymphocyte infiltration-dependent component, and a separate com-
ponents probably associated with inherent expression of immune
genes in thyrocytes. The discrimination of these components is pos-
sible in further genomic studies of separated cellular populations.
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 Detection of bone metastases in differentiated
thyroid cancer
B. Jurecka-Lubieniecka1, A. d’Amico1,
K. Steinhof-Radwańska2, J. Sczasny2,
Z. Wygoda1, B. Bobek-Billewicz2, B. Jarząb1
1Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
2Radiodiagnostics Department, M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: The aim of this study is to optimize imaging proce-
dures in detection of bone metastases in differentiated thyroid can-
cer patients. In this cancer type elevated markers of bone turnover
have not been certified and the diagnosis is established by correlat-
ing of clinical suspicion with imaging. The possibility earliest de-
tection of metastases is crucial for minimization of pathological frac-
tures, spinal cord compression and for institution of appropriate
therapy. PET with 18-F fluoride is an interesting new option for
imaging of bone metastases in thyroid cancer.
Material and methods: Among 1509 investigated patients suffering
from differentiated thyroid cancer who had undergone thyroi-
dectomy, 54 patients with elevated thyroglobulin (Th > 2 ng/mL
during L-T4 therapy) were selected with bone metastases suspi-
cion. 37 (68.5%) and 17 (31.5%) patients had papillary and follicu-
lar carcinomas, respectively. Posttherapeutic 131I whole — body scan,
computed tomography or MRI were performed in all patients.
Among study group 54 patients, 22 patients with TG higher than
100 ng/mL were carried out with 18F NaF PET.
Results: In 5 of 22 patients bone metastases were diagnosed on the
basis of CT or MR. Skeletal system of every patient was divided
into 13 segments. The whole-body 131I-scan confirmed bone me-
tastases only in single segments in 2 patients. In both patients the
result of 18NaF PET was consistent with 131I-scan though revealed
additional bone metastases in 8 segments in those patients. In
3 patients 131I scintigraphy gave negative results while 18NaF PET
scans detected bone metastases in 7 bone segments in all of the
patients.
Conclusions: Previous methods of bone metastases detection in
differentiated thyroid cancer patients are not sufficiently sensitive.
Application of 18F NaF PET is a promising alternative for earlier
diagnosis of bone metastases in case of patients with elevated thy-
roglobulin serum level.
CHEK2 polymorphism and its association with
occurrence and staging of papillary thyroid cancer
M. Kalemba, Z. Puch, D. Kula, M. Kowalska, M. Kowal,
T. Tyszkiewicz, D. Handkiewicz-Junak, J. Roskosz,
K. Drosik, M. Żydek, A. Sikora, A. Chróst, E. Gubała,
B. Jarząb
Department of Nuclear Medicine and Endocrine Oncology M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: CHEK2 participates in repair of the damaged DNA.
It has been associated with the occurrence of various cancers, among
them papillary thyroid cancer, with OR = 6.2 (Cybulski and wsp.
2004). In the Polish population three polymorphic CHEK2
variants were described: IVS2+1G > A, 430T > C and more rarely
1100 delC.
Aim of the study was analysis of CHEK2 IVS2+1G > A and 430T
> C SNPs in our population of patients with papillary thyroid can-
cer (PTC) and evaluation of the possible association of CHEK2 with
PTC staging.
Material and methods: 701 PTC patients were investigated and
compared to the control group of 1106 healthy persons with nega-
tive cancer anamnesis (all sites). DNA was isolated from peripheral
blood with the Genomic Mini AX Blood kit. RFLP-PCR was con-
ducted for the IVS2+1G > A polymorphism and the allele discrim-
ination PCR by the TaqMan SNP Genotyping Assays was per-
formed for 430 T > C. Age at diagnosis, TNM staging and postop-
erative stimulated Tg level were analyzed for association with
CHEK2 polymorphism as well.
Results: Association of CHEK2 variants with PTC accurence was
confirmed. Polymorphism 430T > C was stated in 62 cases PTC
(8.8%) and 60 controls (5.4%) (p < 0,05). IVS2+1G > A was found
in 8 cases (1.59%), and in none control (p = 0.09). There was no
difference with respect to age or postoperative thyroglobulin level.
For 430T > C in 35% of PTC patients higher TNM stage was ob-
served compared to 21% in whom this variant was not present
(p < 0,05). For IVS2+1G > A there was also a difference in staging,
38% to 21% respectively (p < 0,05).
Conclusions: Our study confirms, that CHEK2 SNPs IVS2+1G
> A and 430T > C are associated with the appearance of papillary
thyroid cancer. Moreover, they are associated with the higher stage
of disease at the diagnosis.
Thyroid neoplasms in children and adolescents
operated on due to nodular goiter in a single
institution within the past 40 years
A. Kalicka-Kasperczyk1, G. Drabik2, J. Skirpan3,
W. Mieżyński2, J. Starzyk1
1Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics,
Polish-American Institute of Pediatrics, Collegium Medicum,
Jagiellonian University, Kraków, Poland
2Department of Pathomorphology ,Polish-American Institute of Pediatrics,
Collegium Medicum, Jagiellonian University, Kraków, Poland
3Department of Pediatric Surgery, Polish-American Institute of Pediatrics,
Collegium Medicum, Jagiellonian University, Kraków, Poland
Introduction: Objective of the study was a histopathology-based
assessment of the prevalence and types of neoplastic thyroid le-
sions in children and adolescents subjected to thyroidectomies in
the years 1969–2009.
Material and methods: The analysis was based on data originat-
ing from 366 surgical patients, including 307 girls (83.1%), aged from
neonates to 22.19 years lat (mean age 14.39 ± 3.1 years). Children
up to 12 years of life accounted for 25.4% (n = 93). Group 1 includ-
ed 249 patients referred for strumectomies based on clinical assess-
ment and operated on in the years 1969–1997. In the period 1998–
–2009, thyroid FNAB was performed in 784 cases. A total of 117
Group 2 patients were referred for strumectomies based on clinical
assessment and cytology.
Results: Neoplastic thyroid lesions were detected in 105 (29.2%)
patients. These lesions were represented by 2 (0.5%) teratomas,
72 (20.2%) adenomas and 31 (8.5%) thyroid cancers. In Group 1
patients, thyroid adenomas accounted for 22.1% (n = 55) vs. 16.2%
(n = 19) in Group 2, thyroid cancers for 6.4% (n = 16) vs. 12.8%
(n = 15), and tumor-like lesions and 70.7% (n = 176) vs. 70.9% (n = 83).
Thyroid cancers were diagnosed in 23 of 307 girls (7.49%) and 8 of
59 (13.56%) boys with nodular goiter. Papillary carcinoma was de-
tected in 80.65% patients (n = 25), follicular carcinoma in 12.9% of
621
Streszczenia
M
A
T
ER
IA
ŁY
Z
JA
Z
D
O
W
E
cases (n = 4). Medullary carcinoma as an element of MEN2B was
detected in 1 (3.23%) boy, and poorly differentiated carcinoma in
1 girl (3.23%).
Conclusions:
1. In children and adolescents with nodular goiter, a significant
percentage (30%) of patients demonstrated benign or malig-
nant neoplastic lesions of the thyroid.
2. Thyroid cancers were diagnosed in 6% of children referred to
surgery based on clinical assessment as compared to 12% of
children from the group where nodular goiter diagnostic man-
agement was extended to include FNAB.
Papillary thyroid cancer now and 10 years ago
— the analysis of material of 1st Department of General,
Gastroenterological and Endocrinological Surgery
Medical University of Wroclaw
K. Kaliszewski1,2, T. Łukieńczuk1,2, W. Bednarz1,
W. Balcerzak1, Z. Forkasiewicz1, J. Spodzieja1,2,
M. Kaliszewska3, T. Dawiskiba1, M. Napierała4,
W. Podhorski4
1I Department of General, Gastrointestinal and Endocrinological Surgery
2Faculty of Public Health, Department of Clinical Nursing,
Division of Clinical Procedures
3Clinical Hospital of Wroclaw4Student Scientific Circle at I Department of
General, Gastrointestinal and Endocrinological Surgery, Silesian Piasts
University of Medicine Wroclaw, Poland
Introduction: Despite of progress in detectability, early diagnos-
tics and treatment of papillary thyroid cancer (PTC) we still ob-
serve patients with advanced papillary thyroid cancer. It is often
diagnosed only after surgery what causes necessity of second op-
eration. Therefore we ask the question how advanced is the progress
in detectability, early diagnostics and treatment of papillary thy-
roid cancer during last ten years.
Comparison of two periods of the clinic’s activity (1998–1999 and
2008–2009) in aspects of detectability, diagnostics and treatment of
PTC and patients with all other thyroid pathologies.
Material and methods: We retrospectively analyzed the medical
documentations of the patients.
Results: In 1998–1999 668 goiter operations were performed, 17 of
them because of thyroid cancer. In 2008–2009 836 goiter operations
were performed, 53 because of malignant thyroid tumors. In years
1998–1999 and 2008–2009 the agreement of results of biopsy with
final histopathologic diagnosis was observed adequately in 55%
and 62% of single thyroid nodules and in 15% and 19% multinod-
ular goiter. The primary total strumectomy was performed ade-
quately in 44% and 67% patients with papillary thyroid cancer, and
the second surgery radicalization was performed in 52% and 30%.
Total percentage of patients with PTC in 1998–1999 was 1,8%, but
in 2008–2009 6%. In 1998–1999 PTC was observed in 85% as a single
unilateral lesion localized in one lobe, nowadays 16% of papillary
thyroid cancer appears as a multifocal lesion. In 1998–1999 only
20% of patients had fine needle aspiration biopsy ultrasound guid-
ed, in 2008–2009 100%.
Conclusions: We observed over 3 times increase of the patients
treated in our clinic because of PTC. The percentage of detection of
unifocal papillary thyroid cancer didn’t change. Nowadays, as
10 years ago, the basic investigation in diagnosis of papillary thy-
roid cancer is fine needle aspiration biopsy and cytologic smear
investigation. We noticed differences in choosing of the nodule
which has to be biopsied. We observed decreasing number of late
surgical radicalizations after primary operation, and growth of
number of primary radical operations.
Thyroid cancer treated in emergency mode
— 10 years experience of I Department of General
Gastroenterological and Endocrinological
Surgery Medical University of Wroclaw
K. Kaliszewski1, 2, T. Łukieńczuk1, 2, W. Bednarz1,
P. Domosławski1, B. Knychalski1, M. Kaliszewska3,
K. Sutkowski1
1I Department of General, Gastrointestinal and Endocrinological Surgery
2Faculty of Public Health, Department of Clinical Nursing,
Division of Clinical Procedures
3Clinical Hospital of Wroclaw, Silesian Piasts University of Medicine Wroclaw,
Poland
Introduction: Except of low differentiated cases, which are con-
nected with worse prognosis, also in well differentiated thyroid
cancers are very aggressive cases.
The presentation of own experiences in diagnostics and treatment
of aggressive cases of thyroid cancer that were treated in emergen-
cy mode.
Material and methods: The medical documentations were retro-
spectively analyzed from the last 10 years.
Results: In 2000–2009 169 patients with malignant thyroid tumors
underwent surgery (120 papillary cancers, 22 follicular cancers,
12 medullary cancers, 4 anaplastic cancers, 1 planoepithelial cancer,
1 oncocytic cancer, 5 thyroid’s lymphomas and 3 metastatic tumors.
There was 1 case of aggressive islet thyroid cancer with anaplastic
component. Six patients were treated in emergency mode (islet
cancer, 2 follicular cancers, anaplastic, medullary and clarocellular
metastatic tumors), women in age of 73–91 admitted to the clinic
with advanced respiratory failure symptoms caused by pressure,
dislocation or tracheal infiltration. One of the cases was the female
individual with very aggressive type of islet thyroid cancer, in
whom from the first disease symptoms (hoarseness, tachypnoe)
only few weeks passed to thyroid surgery. The next case was
a patient with large neoplastic tracheal infiltration that coarctated
trachea to 2 mm diameter. In this patient after surgical interven-
tion we diagnosed metastases to thyroid gland from kidney can-
cer. She underwent nefrectomy 20 years earlier because of renal
carcinoma.
None of these patient underwent radical surgical procedure. In two
patients we performed tracheostomy. Unfortunatelly two patients
died because of acute respiratory and circulatory failure, which
appeared just after surgery. In one patient we observed dissemi-
nated intravascular coagulation symptoms that coused severe
haemorrhage.
Conclusions: Thyroid cancer might progress very aggressively and
require surgical treatment in emergency mode. However, during
last 3 years we didn’t observe thyroid cancer that required treat-
ment in emergency mode.
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Expression of LGALS3BP gene in thyroid tissues
and peripherial blood lymphocytes as a potential
prognostic factor for high malignancy type
of papillary thyroid cancer five-year follow up
K. Kaliszewski1,2, T. Łukieńczuk1,2, W. Bednarz1,
W. Balcerzak1, B. Wojtczak1, T. Dobosz3, M. Kaliszewska4,
J. Dawiskiba1
1I Department of General, Gastrointestinal and Endocrinological Surgery, Silesian
Piasts University of Medicine in Wrocław, Poland
2Faculty of Public Health, Department of Clinical Nursing, Division of Clinical
Procedures, Silesian Piasts University of Medicine in Wrocław, Poland
3Department of Forensic Medicine, Molecular Techniques Unit, Medical
University of Wroclaw, Poland
4Clinical Hospital of Wroclaw, Silesian Piasts University of Medicine in Wrocław,
Poland
Introduction: Although papillary thyroid carcinoma has rather
favourable prognosis, we observed some cases that metastasizes
and shows recurrence to lymph node in high incidence even
after radical surgery. Tumor infiltrating lymphocytes (TIL) are
very often identified close to malignant lesions. Lymphocytes
infiltrations occur in 25–30% of papillary thyroid cancers. In the
thyroid gland, the high expression of galectin-3 has been
described in papillary cancer cells. Expression of LGALS3BP is
identified in papillary thyroid cancers and in peripherial blood
lymphocytes.
For detection of papillary thyroid cancer high malignancy types
we estimated correlation between LGALS3BP gene expression in
papillary thyroid carcinoma cells and T activated lymphocytes in
patients with papillary thyroid cancer and the risk of papillary thy-
roid cancer recurrence during 5 years postoperative observation.
Material and methods: Galectin-3 mRNA expression was analy-
sed in the peripheral blood lymphocytes from 90 patients; with
papillary thyroid carcinoma (30), multinodular goiter (27), and
healthy controls (33). We also estimated corellation between level
of galectin-3 expression in papillary thyroid cancer and LGALS3BP
gene expression in peripherial blood lymphocytes in patients with
papillary thyroid cancer (30) and the risk of papillary thyroid can-
cer recurrence during 5 year observation.
Results: Difference of galectin-3 protein expression in papillary
thyroid cancers and multinodular goiters is statistically essential
(p < 0.0001). We did not notice statistically essential difference be-
tween expression of LGALS3BP gene in peripheral blood lympho-
cytes in patients with and without recurrence of papillary thyroid
cancer during 5 years postoperative observation. High level of
LGALS3BP gene expression in peripheral blood lymphocytes was
observed in 4 patients with recurrent papillary thyroid carcinoma.
In all patients with recurrent papillary thyroid cancer we observed
very high galectin-3 expression level in papillary thyroid cancer
cells.
Conclusion: High level of galectin-3 expression in papillary thy-
roid cancer might be helpful presurgery diagnostics of papillary
thyroid cancer type and evaluation of recurrence risk.
Complementary treatment by 131I at patients
with thyroid papillary microcancer
A. Klimowicz1, J. Fischbach1, M. Gryczyńska1,
M. Matysiak-Grześ1, P. Gut1, M. Pisarek1,
B. Więckowska2, J. Sowiński1
1Department of Endocrinology, Metabolism and Internal Medicine, Poznań
University of Medical Sciences, Poznań, Poland
2Department of Computer Science and Statistics, Poznań University of Medical
Sciences, Poznań, Poland
Introduction: Papillary cancer of thyroid gland is the most com-
mon malignant neoplasm of endocrine glands. Standards of the
therapy of thyroid papillary microcancer allow the withdrawal from
complementary treatment by 131I after thyroidectomy.
Evaluation of effectiveness of therapy at patients affected by thy-
roid papillary microcancer who underwent total thyroidectomy and
complementary I131 therapy respectively.
Material and methods: 224 patients were included in the study
(221 females and 23 males, aged 24 to 82, average age 57, SD 11.8)
with histopathologic diagnosis of thyroid papillary microcancer,
post thyroidectomy and complementary 131I therapy, admitted to
our department for control examinations in conditions of endoge-
nous TSH stimulation. Examinations performed in clinical depart-
ment included: serum concentration of thyroglobulin (Tg) and thy-
roglobulin antibodies (aTg), 131I whole body scan, ultrasonography
of the neck and X-ray of chest.
Results: Based on results of control examinations, 90 patients (40%)
didn’t get satisfactory results and were qualified to subsequent 131I
therapy (subgroup A). Effectiveness of complementary 131I therapy
was evaluated as satisfactory at 134 patients (60%) (subgroup B).
No statistical significant difference was shown by comparison of
Tg concentration measured during qualifications to complementa-
ry I131 therapy between groups A and B (p = 0.5752).
During subsequent control examinations mean concentration of
Tg in subgroup A was 2.28 ng/mL and it was statistically higher
(p = 0.0004) than in subgroup B (0.79 ng/mL).
Conclusions: Low stage of papillary thyroid cancer in histopatho-
logical diagnosis combined with concentration of thyroglobulin are
not sufficient prognostic factors during qualification to complemen-
tary 131I therapy and they do not allow predicting the efficiency of
that therapy at patients with thyroid papillary microcancer. Com-
plementary 131I therapy is advisable at all patients with thyroid pap-
illary microcancer.
Immunohistochemical characterization of a primary
papillary thyroid carcinoma and co-existing thyroid
metastases in cervical lymph node
A. Konturek, M. Barczyński, M. Stopa, P. Richter,
W. Nowak
3rd Chair of General Surgery Jagiellonian University College of Medicine, Kraków,
Poland
Introduction: Microscopic pathology of thyroid carcinoma, where
proliferative processes may occur concomitantly with functional
abnormalities, is still difficult. The objective of the present study
was histopathologic and immunohistochemical characterization of
a primary papillary thyroid carcinoma and co-existing thyroid
metastases in cervical lymph node.
Material and methods: A retrospective study included a group of
83 patients with papillary carcinoma treated surgically at Depart-
ment of General Surgery in 2007–2009. The tissue material was
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represented by hematoxylin-stained microscopic preparations of tis-
sue sections collected from primary tumor foci and lymph node me-
tastases and in all this group histopathology was supplemented by
immunohistochemistry. The expression of cytokeratin (CK) 19 and
thyroid transcription factor-1 TTF-1 were examined by immunohis-
tochemistry The resultant data were analyzed statistically.
Results: Of the total number of 83 patients with papillary thyroid
carcinoma, in 6 cases the original final diagnosis was changed. The
group included 77 diagnoses of papillary carcinoma (various types);
4 patients with follicular encapsulated carcinoma; 1 individual with
Hurtle cell carcinoma; and 1 clear cell carcinoma. The size of pri-
mary thyroid tumor was 4 mm to 50 mm. All papillary carcinomas
and metastases (n = 77) showed expression of CK 19. The scores
were +++ in 43 primary tumors and all lymph node metastases.
TTF-1 positivity was noted in 60 patients. 3 patients with follicular
thyroid carcinomas were positive for CK19 and TTF-1.
Conclusions: A high degree of differentiation of morphological
types of thyroid tumors is a source of considerable diagnostics prob-
lems. We conclude the histological and immunohistochemical test
results and characteristic cytokeratin expression profile for thyroid
carcinoma can aid in clinicopathological diagnosis of thyroid carci-
noma and allows for initiation of an appropriate and properly se-
lected post-surgical treatment.
High serum TSH concentration after rhTSH
administration in patients with differentiated
thyroid carcinoma (DTC) and irreversible
renal failure(RF) — 3 cases study
A. Kowalczyk, G. Kamiński
Department of Endocrinology and Radioisotope Therapy, Military Institute
of Health Services, Warszawa, Poland
Introduction: Some of diagnostic procedures in the patients with
DTC, such as 131I whole body scan (WBS) or serum Tg concentra-
tion require intensive TSH stimulation achieved by withdrawing
of thyroxine therapy or rhTSH administration. We demonstrate
3 cases of coexistence of DTC and irreversible renal failure (RF), in
which serum TSH concentration after rhTSH appeared to be ex-
tremely high.
Material and methods: Patient 1. Male of 52 years with papillary
thyroid carcinoma (PTC), after surgery (VI and IX 2008) and radio-
iodine treatment (RIT — IV 2009). RF caused by chronic pyelone-
phritis. Control study performed in IV 2009.
Patient 2. Female of 57 years with PTC, after total thyroidectomy
(TT — X 2008) and RIT (I 2009). RF caused by SLE. Control study in
VII 2009.
Patient 3. Female of 83 years with follicular thyroid carcinoma (FTC,
oxyphilic variant), TT-III 1999, RIT IV 1999 and XII 2004 (thyroid
bed recurrence). RF caused by side effect of Y-90 therapy. Control
study in VII 2009. In all the patients rhTSH (Thyrogen) were ad-
ministrated by intra-muscular injections 0,9 mg for 2 consecutive
days; serum TSH determinations were performed 1 and 3 days af-
ter the second injection. The results were compared with the con-
trol group of 217 patients with DTC treated in our Department from
VIII 2008 to XI 2009: in 115 of them serum TSH concentration was
measured 1 day, in 102 3 days after rhTSH administration.
Results: In the 3 patients with RF serum TSH concentration 1 day
after rhTSH administration were: 570; 449 and 658 (mean 559 uIU/
/mL), and after 3 days: 220; 86.6 and 297 (mean 201.2 uIU/mL). Mean
results in the control group were, respectively:152.8 uIU/mL
(range:25.5–287) and 23,1 uIU/mL (range: 3.6–78.1).
Conclusions: Patients with irreversible renal failure have much
higher serum TSH concentrations after rhTSH administration then
others. Our observation suggests that the smaller doses of rhTSH
may be sufficient in this group of patients.
COX-2 expression in thyroid papillary
cancer in material obtained by FNAB**
K. Krawczyk-Rusiecka1, 2, K. Wojciechowska-Durczyńska1, 2,
A. Cyniak-Magierska1, 2, Z. Adamczewski1,2, A. Lewiński1, 2
1Department of Endocrinology and Metabolic Disease, Medical University, Łódź,
Poland
2Department of Endocrinology and Metabolic Disease, Polish Mother’s Memorial
Hospital Research Institute, Łódź, Poland
Introduction: COX is an enzyme isoform that catalyses the forma-
tion of prostanoids from arachidonic acid. An increased COX-2
expression has been implicated in carcinogenesis. Recent studies
have shown that COX-2 up-regulation is associated with numer-
ous neoplasms, including skin, colorectal, breast, lung, stomach,
pancreas and liver cancers. COX-2 products stimulate endothelial
cell proliferation and its overexpression has been involved in the
mechanism of decreased resistance to apoptosis. Suppressed an-
giogenesis, due to a lowered expression of vascular endothelial
growth factor, was found in experimental animal studies as a con-
seqence of null mutation for COX-2 in mices. The role of COX-2
expression remains a subject on numerous studies, but its partici-
pation in carcinogenesis or thyroid cancer progression remains
unclear.
Material and methods: Patients with cytological findings of papil-
lary thyroid cancer (PTC) were evaluated. After FNAB examina-
tion the needle was washed out with a lysis buffer and the ob-
tained material was used for COX-2 expression estimation. Total
RNA was isolated (RNeasy Micro Kit), based on modified Chomc-
zynski and Sacchi’s method and RT reactions were performed, us-
ing a TaqMan Reverse Transcription Reagents Kit. â-actin was used
as endogenous control. Relative COX-2 expression was assessed in
real-time PCR reactions by an ABI PRISM 7500 Sequence Detection
System.
Results and conclusions: Twelve patients with cytological find-
ings of PTC were evaluated. The obtained results were assessed by
the ABI PRISM 7500 SDS Software, using the ÄÄCT method. COX-2
expression was higher in patients with PTC, when compared to
macroscopically unchanged thyroid tissue. The primary outcome
may indicate COX-2 role in thyroid cancer pathogenesis but the
observed variability in results among particular subjects requires
additional clinical data and tumor progression analysis.
**Recipient of “Thyroid Research” award.
Biochemical detection of relapse of differentiated
thyroid cancer (DTC)
A. Kropińska, E. Gubała, B. Jarząb
Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
Introduction: Determination of thyroglobulin (Tg) in serum is
a key element in the follow up of DTC patients after thyroidectomy
and radioiodine therapy. DTC is characterized with good progno-
sis- the risk of recurrence is only 5%. This implies that the DTC
marker should be highly specific to avoid unnecessary diagnostic
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procedures at most patients. Thyroglobulin measurement provides
a gold standard, but it may be false negative in presence of anti-
thyroglobulin antibodies (TgAb). Further optimalization of Tg mea-
surements is necessary. Ultrasensitive Tg assays did not fulfill this
goal due to their poor specificity.
The aim of the study was to analyze Tg and TgAb in serum speci-
mens of DTC patients taken prior to clinical diagnosis of relapse.
Material and methods: The analysis was carried out in the group
of 100 DTC patients aged 19–84 years (med. 59 years, F/M:66/34)
diagnosed with DTC recurrence in 2007–2009, among them 67.6%
with papillary, 14.7% follicular and 17,6% oxyphylic histotype. The
initial treatment comprised of total thyroidectomy in 85.7% cases
and radioiodine therapy in 83%. At the diagnosis 50% of patients
had lymph node metastases and 11% had distant metastases. There
were 2 cancer related deaths.
Results: The recurrence was diagnosed after 1.2–123.4 months
(median 24 months). 37% patients had more than one recurrence.
In 82% locoregional relapse, in 11,8% distant metastases appeared.
In 60.4% recurrence was preceded by Tg elevation, in 25.6% there
was no increase of Tg serum level (in 13.9% the distinction was not
possible).
In 14.7% of patients TgAb were present. In that group 60% patients
had indeterminable Tg serum level and high level of TgAb. In 40%
relapse was preceded by increase of both Tg and TgAb level. Only
in one case DTC progression was concomitted by an elevation of
TgAb serum level.
Conclusions: The Tg serum rise constitutes the first symptom of
DTC recurrence in 60% cases.
Does the suppressive treatment of L-thyroxine impair
heart function in young patients with differentiated
thyroid cancer (DTC)?
A. Kropińska, J. Krajewska, K. Zawisza, H. Lewandowska,
A. Antosz, M. Dobrakowski, B. Jarząb,
D. Handkiewicz- Junak
Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
Introduction: DTC patients need L-thyroxine treatment after total
thyroidectomy and subsequent 131I therapy. Insufficient L-tyrox-
ine treatment has been reported to be related to the higher risk of
recurrence, especially if TSH levels maintain over 2 mU/L. Howev-
er the degree of TSH suppression required is a matter of consider-
ation in the light of the risk of possible cardiovascular side effects.
The aim of the study was the evaluation of the long term suppres-
sive L-thyroxine treatment on cardiovascular system of patients
diagnosed with DTC when < 18 years of age.
Material and methods:The analysis was carried out in 111 adult
patients diagnosed with DTC at the mean age of 15 years (7–18),
after total thyroidectomy (92%) and radioiodine treatment (91%),
treated with suppressive doses of L-thyroxine for 12 years on aver-
age (4–32). We analyzed TSH serum levels examined during the
L-thyroxine treatment and excluded all values > 20 mU/L on L-thy-
roxine withdrawal necessary for diagnostics or radioiodine treat-
ment. Patients were evaluated by physical examination, ECG,
echocardiography and lipid profile. Patients were subdivided into
three groups on the basis of the geometric mean of their TSH levels
during the whole follow-up: group 1, full suppression, TSH <
< 0,1 mU/L (56%), group 2, incomplete suppression, TSH 0.1 0.4 mU/L
(33%); group 3, lack of suppression, TSH > 0.4 mU/L (11%).
Results: Attributes of non-efficient L-thyroxine substitution (TSH >
> 2 mU/L in more than 20% of measurements) were found in 20,7%
of patients. Analysis of BMI association with TSH serum level was
not significant. Mean level of cholesterol was respectively: 172.86,
177.0, 171.67 mg/dL; HDL cholesterol — 55.81, 54.38, 56.67 mg/dL;
LDL cholesterol — 102.65, 112.54; 108,6mg/dL; triglycerides — 69.91,
77.81; 63.0 mg/dL. There were no statistically significant differenc-
es between the groups.
Mean left ventricular mass was normal: in group 1: 140.3 g and
174.5 g, in group 2: 148.9 g and 183.5 g; in group 3: 159.6 g and
215 g. In ECG only one case of tachycardia was found.
Conclusions: Despite long term suppressive or semi-suppressive
L-thyroxine therapy there were no significant symptoms of car-
diovascular system impairment in our young DTC patients.
Also at appropriate follow up of patients, the risk of insufficient
L-thyroxine treatment was low.
Correlation of metallothionein expression with
antigen Ki-67 in benign and malignant
thyroid lesions
A. Królicka1, P. Domosławski2, B. Wojtczak2,
J. Dawiskiba2, C. Kobierzycki1, A. Piotrowska1,
M. Podhorska-Okołów1, P. Dzięgiel1, T. Łukieńczuk2,
K. Kaliszewski2, J. Daroszawski3
1Department of Histology and Embryology, Medical University, Wroclaw, Poland
2I Department and Clinic of General, Gastroenterological and Endocrine Surgery,
Medical University, Wroclaw, Poland
3Department and Clinic of Endocrinology, Diabetology and Isotope Therapy,
Medical University, Wroclaw, Poland
Introduction: Thyroid nodules appear in 4–8% of adult popula-
tion, among them thyroid neoplasms are found in less than 5%.
Preoperative diagnosis of thyroid neoplasms is difficult, particu-
larly follicular tumors (npl. folliculare). Up to now there is no pos-
sibility, based on preoperative fine needle biopsy to differentiate
follicular adenoma from follicular carcinoma, so there is a need to
look for new biochemical markers.
Metallothioneins are group of proteins represented by 4 isoforms.
They occur in both healthy and neoplasmatically transformed tis-
sues. Expression of these proteins can be observed in nucleus and
cytoplasm of the cells. Expression of antigen Ki-67 is observed in
nucleus of dividing cells. It was shown that index of Ki-67 and
Metallothioneins often correlates with progression of neoplasmatic
process and that these proteins could be used as prognostic markers.
The aim of this work was to analyze the relationship between ex-
pression of MT and Ki-67 and histological type of lesion in studied
thyroid tumors.
Material and methods: Immunohistochemical (IHC) tests were
performed on paraffin sections of 86 thyroid lesions: 62 cancers (34
papillary carcinoma, 16 follicular carcinoma, 9 medullary carcino-
ma, 3 undifferentiated carcinoma), 16 adenomas and 8 goiters. The
presence of MT and Ki-67 was detected in immunohistochemical
tests by use of monoclonal antigens (DAKO, Denmark). Intensity
of MT expression was evaluated in light microscope using semi
quantitative IRS scale. Intensity of Ki-67 expression was evaluated
in light microscope using semi quantitative scale taking into ac-
count number of positive cell nuclei.
Results: Statistic analysis revealed statistically significant increase
of MT expression in follicular carcinoma in comparison to follicu-
lar adenoma and lack of correlation between intensity of Ki-67 ex-
pression and lesion’s type.
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Conclusions: Differences in expression of Metallothioneins may
be useful in differentiation of follicular carcinoma and follicular
adenoma.
The application of SPECT/CT scintigraphy with
MIBI-Tc99m and a comparison with the subtraction
method in the diagnostics of nodular goiter
in the thyroid
M.H. Listewnik1, B. Birkenfeld1, K. Cichoń-Bańkowska1,
K. Niedziałkowska1, L. Iglińska-Wagner2, W. Watrak4,
W. Smolira3, P. Zorga1, H. Piwowarska-Bilska1, B. Elbl1,
M. Sawrymowicz1
1Department of Nuclear Medicine, Pomeranian Medical University, Szczecin,
Poland
2Harbour Independent Public Health Care Institution, Out-patients Thyroid
Clinic, Szczecin, Poland
3Non-Public Health Care Institution „Smol-Med”, Stargrad Szczecin´ski, Poland
4Indpendent Public Integrated Voivodship Hospital, Out-patients Thyroid Clinic,
Szczecin, Poland
Introduction: The diagnostics of the thyroid cancer is based main-
ly on fine needle aspiration biopsy (FNAB) performed under ultra-
sonography guidance. In case of a not conclusive FNAB, or due to
any other reasons which make the decision process difficult, the
patient is followed up or is encouraged to undergo surgery treat-
ment although there is not clear evidence data to support the exist-
ence of a malignant lesion. An additional method to clarify this issue
may be scintigraphy with an oncophilic tracer such as MIBI-Tc99m.
The aim of the study is to evaluate the usefulness of SPECT/CT
scintigraphy with MIBI-Tc99m and to compare it with the subtrac-
tion method in the diagnostics of thyroid nodular goiter in cases
which are difficult from the diagnostic point of view.
Material and methods: The study comprises 18 patients with
a non-conclusive FNAB in the thyroid. In 2009 there were 22 dou-
ble (early and delayed) acquisitions performed with SPECT/CT:
16 using MIBI-Tc99m wash-out method, and an additional 6 pla-
nar studies where the subtraction method was applied with Tc99m
and MIBI-Tc99m. In case of planar studies, the acquisition rules
and software processing was the same as for parathyroid scintigra-
phy: the tumor/background ratio in early and delayed images was
calculated and the wash-out ratio was estimated. In software pro-
cessing of SPECT/CT scintigraphy, the uptake in the thyroid nod-
ule was related to the uptake in the heart.
Results: Abnormal results were obtained in 10 patients and nor-
mal in 8 cases. 3 patients with a normal result underwent surgery
and had a benign histopathology after the operation. One patient
with an abnormal scintigraphy had normal histopathology. Out of
16 studies, in 14 wash-out was observed from the lesion. Two pa-
tients with tracer accumulation are still followed-up, since one does
not agree to surgery and one has contra-indications for surgery. It
was noticed that the images obtained with the wash-out method
were clearer and easier to read.
Conclusions:
1. Thyroid scintigraphy performed with oncophilic tracers may
be helpful for clinicians.
2. The wash-out method performed in SPECT/CT with MIBI-
Tc99m seems to be better for diagnostic purposes than the tra-
ditional MIBI-Tc99m/Tc99m subtraction.
The occurrence of malignant thyroid lesions in
patients after radioiodine treatment due to benign
thyroid diseases
M.H. Listewnik1, B. Birkenfeld1, K. Niedziałkowska1,
M. Chosia2, B. Elbl1, M. Sawrymowicz1
1Department of Nuclear Medicine, Pomeranian Medical University,
Szczecin, Poland
2Department of Pathomorphology, Pomeranian Medical University,
Szczecin, Poland
Introduction: Radioiodine treatment (RT) of benign thyroid dis-
eases is a well-known, safe and effective treatment method. In the
group of patients after radioiodine treatment who remained in our
long-term follow-up, sporadic cases of malignant thyroid lesions
occurred.
The aim of the study is to analyze the frequency of occurrence of
malignant thyroid lesions in patients after radioiodine treatment.
Material and methods: The group of 4314 patients were treated
with radioiodine in the years 2000–2008. They remained on follow-
up for 1–8 years. During the routine checking procedure a fine nee-
dle biopsy aspiration (FNAB) of the thyroid (or neck if needed)
was performed, based on ultrasonography or clinical examination
(if a new palpable nodule occurred). Patients with pathological
FNAB were analyzed and histopathology-reviewed.
Results: In 12 out of 4314 cases (0.3%) suspicious lesions were found
in FNAB. Lesions in the thyroid were found in 9 patients (8 F, 1 M),
aged 46–73 (av. 56 yrs.) and followed up for 3–57 months after RT.
In the remaining 3 cases, metastases in the lymph nodes were found
in FNAB due to other cancers.
Papillary cancer was found histopathologically in one patient with
a toxic nodular goiter (TNG) after 39 months and in one patients
with Graves-Basedow (GB) disease after 48 months since RT.
In one patient with GB 28 months after RT, Huerthle adenoma was
proved histopathologically. In two cases with TNG 4 and 3 months
after RT, in whom FNAB revealed suspicious cells, the histopathol-
ogy examination showed benign lesions. Two patients did not agree
to surgery: one with a suspicion of papillary cancer, TNG 33 months
after RT; the other with suspicious cells in FNAB, TNG 38 months
after RT. A follicular tumour was suspected in two cases. There is
no data about the first one, with TNG 35 months from RT. In the
other case, GB 26 months from RT, the patient was not qualified to
surgery due to a diagnosis of lung cancer.
Conclusions: Although malignant thyroid lesions in patients after
RT due to benign thyroid diseases are seldom detected, a periodi-
cal clinical and ultrasonographic evaluation is recommended.
Case report of the woman with papillary thyroid
carcinoma, which was thyreological diagnosed
because of presence CHEK2 mutation in genetic
examinations
K. Lizis-Kolus1, A. Kowalska1, B. Kozak-Klonowska2,
M. Siołek², J. Słuszniak3, J. Lubiński4, C. Cybulski4
1Department of Endocrinology at the Holy Cross Cancer Center in Kielce, Poland
²Genetic Clinic at The Holy Cross Cancer Centre in Kielce, Poland
3Department of Cancer Surgery at The Holy Cross Cancer Centre in Kielce,
Poland
4International Hereditary Cancer Center, Department of Genetics and Pathology,
Pomeranian Medical University Szczecin, Poland
CHEK2 gene encodes the CHK2 protein which is kinase involved
in DNA repair process. By activating a lot of cell substrates, it can
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regulate the cell cycle, demonstrates suppressive effects as well as
participates in the senescence and apoptosis processes. Mutations
in CHEK2 gene are associated with the increased risk of numerous
cancers. The case described is of a woman with the missense muta-
tion that results in the substitution of isoleucine for threonine at
position 157. This variant of the mutation increases the risk of pap-
illary thyroid carcinoma two times. It is also associated with a two-
fold increased risk cancers of: kidney (10%), colon (10%), ovary
(10% — G1), 1,6-times increased risk of prostate cancer (8% of all of
them and 12% of familiar ones) and 1.5-times increased risk of breast
cancer (7%). The screening procedures were initiated in the carrier
who revealed papillary thyroid carcinoma. Genetic screening of
the family diagnosed her daughter as the carrier of this mutation.
Until now no active cancer disease has been recognized in the
daughter. On the example of presented case we discuss indications
for screening in cases of positive family history. The group espe-
cially predisposed seem to be patients with at least two coexisting
carcinomas. Having diagnosed the mutation, it is necessary to do
genetic screening of family members. Continuous oncologic obser-
vation of the carriers of CHEK 2 mutation is essential.
Ethically-economic aspects of thyroid biopsy
observation from local center
M. Maciejewski, M. Gąsiorek, M. Słomian,
A. Sawicka, K. Marczewski
Department of Nephrology, Endocrinology, Metabolic and Internal Disease with
Dialyses Unit Voivodeship Hospital of Pope John Paul II, Zamos´c´; University of
Management and Administration Zamość, Poland
Introduction: Usually ethical analysis of medical procedure includes
estimation of risk/benefit ratio and cost/effectiveness ratio, eventu-
ally also criteria of selections and/or determination the order of pro-
cedure and also possible potential effects of interactions on psyche
in individual and social dimensions, taking also into consideration
human dignity and public perception. Presented analysis concerned
mainly cost/benefit, but it takes also into consideration other as-
pects in full version.
Early diagnosis of thyroid cancer is essential for effective treatment
and because of it life saved procedure. 40 000 PLN (10 000 Euro) it
is a relatively high for one diagnosis of thyroid cancer. However,
even in an area of relatively low morbidity, it is probably only
a little more than you have to spend for the detection of colon can-
cer by colonoscopy (10 000 PLN estimates MZ) or breast cancer
through preventive mammogram (20 000 PLN), and costs much
less than the detection one kidney cancer (150 000 PLN) or prostate
cancer (more than 200 000 PLN).
Material and methods: From 2007 to 2009, we have performed 1836
ultrasound guided fine needle aspiration biopsies (US-FNAB) of
focal lesions in thyroid, in accordance with recommendations of
the Polish Society of Endocrinology. All results with suspicion of
malignancy are verified in the Institute of Oncology in Gliwice.
Results: In the area of our department with about 300 000 people,
in period of 3 years 5 new thyroid cancers were detected in 1836
US-FNAB and 79 suspicions not confirmed (specificity 95.5%). By
the relative low incidence the cost of operating the BACC to detect
one cancer was 40,878 PLN
Conclusion: US-FNAB is effective method of discovering of thy-
roid cancer even in areas with low morbidity.
Morphological diagnostics of solitary
cystic thyroid nodules
V.N. Marina, V.I. Kolomiytsev, V.I.Vovk,
O.V. Lukavetsky, M.P. Pavlovsky
Lviv National Medical University, Lviv, Ukraine
Introduction: Solitary nodules of thyroid gland occur in 22–43% of
nodular forms of goiter. Among all solitary thyroid nodules malig-
nant tumours present in 12–17% and cystic changes in 15–35% of
cases. Morphological diagnostics of solitary cystic thyroid nodules
(SCTN) is often problematic.
Analysis of effectiveness of different methods of morphological
diagnostics of SCTN especially cytological examination of tissue
compound and cystic fluid from fine needle aspiration biopsy
(FNAB) and frozen section examination.
Material and methods: Analysis of results of morphological diag-
nostics of SCTN of 75 patients was made. Among all cases SCTN in
6(8%) of male and 69(92%) of female patients were presented. Medi-
an age of patients was 40.2 years (from 15 to 78 years). FNAB under
USG guidance was used in all patients. Complete aspiration of fluid
from cyst was made and residual tissue component of nodule was
aspirated. Intraoperative frozen sections examination was used.
Results: Concordance of results of cytological examination of ma-
terial of FNAB and result of final histological examination was found
in 75%. Frozen section examination at suspicion on thyroid cancer
(cytology and/or USG) was made in 40 patients. Results of frozen
section examination in 97.5% were concordant to results of final
histological examination. Among all cases of SCTN by final histo-
logical examination were revealed: colloid goiter in 32 (42.7%), ad-
enoma in 37 (49.3%), thyroid cancer in 6 (8.0%) cases.
Conclusion: Cytological examination of tissue component and fluid
obtained by FNAB before surgery and intraoperative frozen sec-
tion examination is effective method of morphological diagnostics
of SCTN. Among all cases of SCTN colloid goiter and adenoma
predominated, thyroid cancer was diagnosed only in 8.0% of pa-
tients.
Does differentiated thyroid cancer (DTC) staging
change within the last ten years?
B. Michalik1, J. Kern-Bałata2, M. Kalemba1,
B. Włodarczyk-Marciniec2, B. Zemła2
1Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
2Department of Tumor Epidemiology, M. Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: The aim of the study was to compare the stage of
thyroid cancer at diagnosis in patients from Silesian district in years
1999 and 2008.
Material and methods: The analyzed group consisted of Silesian
district patients with thyroid cancer (taking into account adminis-
trative reorganization as well), who were noted by Department of
Tumor Epidemiology in years 1999 and 2008. From group of
186 patients who entered on record in 1999, 167 were qualified for
this analysis. Similarly, from 238 patients registered in 2008 finally
226 were considered. The following factors were analyzed: sex, age
at diagnosis, histotype of thyroid cancer and DTC staging accord-
ing to TNM system (2002).
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In 1999 there were 137 females (82,04%) and 43 males (19,03%) with
thyroid cancer. Age at the diagnosis was 5–81 years. Median age
was 52 years. In 2008 there were 183 females (80.97%) and 43 males
(19.03%) with thyroid cancer diagnosed at 14–80 years of age. Me-
dian age was 51 years.
Results: In year 1999 there were 167 patients registered, 119 (71%)
with papillary thyroid cancer (PTC). In year 2008, 197 (87%) pa-
tients with PTC were diagnosed (p < 0,0001). Relations between
age and sex were similar in these years. The disease staging is shown
below: 1999: pT1a 24 (14.81%), all pT1 73 (45.6%) pT2-pT3 48
(29.59%) pT4 12 (7.41%) Tx 29 (17.9%); 2008: pT1a 52 (23.21%), all
pT1 128 (57.14%) pT2-pT3 75 (33.49%) pT4 4 (1.79%) Tx 17 (7.59%).
Statistically significant decrease of pT4 patients was observed
in 2008.
Conclusions:
1. In 2008 the contribution of papillary histotype to all thyroid
cancer patients (87%) is significantly higher than in 1999.
2. There is some increase in frequency of patients diagnosed with
papillary microcarcinoma, which is however statistically insig-
nificant. Fortunately, the percent of patients diagnosed with
pT4 disease is significantly lower in 2008 than 1999.
Incidence of other malignant neoplasms in patient
with thyroid carcinoma
E. Mikina, J. Sygut, A. Kowalska
Endocrinology and Nuclear Medicine Ward; Pathomorphology Ward Holycross
Center of Oncology, Kielce, Poland
Introduction: The enlargement of incidence of other malignant
neoplasms in patient with thyroid carcinoma is a subject of exten-
sive debate and controversy. Many studies have shown that thy-
roid carcinoma are common among women with breast cancer.
The aim of this study was to demonstrate the frequency of other
malignant neoplasms in patient with thyroid carcinoma and anal-
ysis of morbidity structure in comparison with epidemiology data.
Material and methods: Our study encompasses survey of 801 pa-
tients with thyroid carcinoma treated in our center between 1999–
–2009. There were 80% of women — 641 patients and 20% of men
— 160 patients.
We analyzed retrospectively medical documentation of patients
who received other malignant neoplasms with thyroid carcinoma.
Patients who received both diagnoses were identified and percent-
age morbidity rate were calculated and comparised with epidemi-
ology data.
Results: Among 801 patients with a diagnosis of thyroid carcino-
ma there were 64 patients with coincidence of other malignant neo-
plasms — 50 women, 14 men. The structure of morbidity of other
malignant neoplasms were comparised with epidemiology data
which are in parentheses. We observed the following cancers in
group of women: breast cancer — 30% (21.3%), colorectal cancer
— 4% (10.2%), lung cancer — 2% (7.7%), endometrial cancer — 8%
(6.7%), cervical cancer — 16% (6.4%), ovarian cancer — 8% (5.7%),
kidney cancer — 6% (2.6%), pancreatic cancer — 2% (2.6%). In
group of men: colorectal cancer — 7% (11.1%), prostate cancer —
28.5% (9.0%), laryngeal cancer — 14,2% (3.8%), kidney cancer 7.1%
(3.7%).
Conclusions:
1. The structure of morbidity with other malignant neoplasms in
group of patients with thyroid carcinoma is different than struc-
ture of morbidity in epidemiology data.
2. The incidence of breast cancer, kidney cancer, cervical cancer,
endometrial cancer, ovarian cancer in group of women and
laryngeal cancer, prostate cancer, kidney cancer in group of
men were significantly higher than the expected incidence in
epidemiology data.
3. It seems to be necessary for active searching for other malig-
nant neoplasms in group of patients with thyroid carcinoma.
Analysis of NDRG2 mRNA expression in primary
papillary thyroid carcinoma and in its metastases
to regional lymph nodes
A. Mordalska1, J. Latek2, T. Ferenc1, L. Pomorski3,
A. Zygmunt2, E. Gałecka2, A. Lewiński2
1Department of Biology and Medical Genetics, Medical University, Łódź, Poland
2Department of Endocrinology and Metabolic Diseases, Medical University,
Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland
3Department of General and Oncological Surgery, Medical University,
Provincial Hospital, Zgierz, Poland
Introduction: At present the attention of researchers is focused on
NDRG2 (N-Myc downstream-regulated gene 2) as a new gene can-
didate in the development and progression of papillary thyroid
carcinoma (PTC). NDRG2, together with NDRG1, NDRG3 and
NDRG4 are the members of NDRG family, a new class of genes
inhibited by N-Myc oncogene.
The aim of the present study was to assess NDRG2 mRNA expres-
sion in primary papillary thyroid carcinomas and their metastases
to regional lymph nodes.
Material and methods: Postoperative tumors tissues and macro-
scopically unchanged thyroid tissue, as well as macroscopically
changed lymph nodes of 16 patients with PTC were examined.
Metastases of PTC to regional lymph nodes were confirmed histo-
pathologically in 8 cases. Quantitative evaluation of NDRG2 mRNA
expression was performed using real-time polymerase chain reac-
tion (real-time PCR).
Results: Mean values of NDRG2 mRNA expression in the tissues
of primary tumor were statistically significantly lower compared
to the level of NDRG2 mRNA expression in macroscopically un-
changed thyroid tissue (p < 0.0001). The comparison of the mean
values of NDRG2 mRNA expression between the primary tumor
and its metastases to regional lymph nodes did not demonstrate
any statistically significant differences (p > 0.05). Positive correla-
tion was observed between NDRG2 mRNA expression in primary
tumor cells and NDRG2 mRNA expression in metastases of that
cancer to lymph nodes (RS = 0.7857; p < 0.05). Factors such as:
age, sex, tumor stage in TNM system were of no significance in the
assessment of NDRG2 mRNA expression (p > 0.1).
Conclusion: The results of our study demonstrated decreased lev-
el of NDRG2 mRNA expression in PTC when compared to macro-
scopically unchanged thyroid tissue which may point to the po-
tential role of NDRG2 gene in the development and progression of
the cancer in question.
Acknowledgment This study was supported by the Medical Uni-
versity of Łódź, Poland (project no. 502-17-657).
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The analysis of transcriptome of medullary
thyroid carcinoma
M. Oczko-Wojciechowska1, J. Włoch2, J. Żebracka-Gala1,
A. Pfeifer1, M. Kowalska1, Z. Wygoda1, A. Czarniecka2,
E. Gubała1, B. Jarząb1
1Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
2Oncologic Surgery Clinic, M. Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: The analysis of medullary thyroid carcinoma (MTC)
transcriptome by gene expression profiling encounters difficulties
related to the lack of comparable normal tissue. Para-follicular
C cells are embedded in thyroid parenchyma and are not easily
accessible to RNA isolation in quantities sufficient for analysis. To
omit this difficulty we compared gene expression pattern of MTC
to a wide collection of different thyroid specimens to obtain tran-
scripts specific only for MTC.
Material and methods: Microarray analysis was carried out by HG-
U133A arrays (Affymetrix) in 40 MTC samples: 20 tumors and
20 corresponding normal tissues and compared to 70 different thy-
roid tumor and normal samples (52 papillary, 12 follicular and
6 anaplastic thyroid cancer cases). Statistical comparisons were per-
formed by BRBArray Tools 3.5.0. An independent set of 17 MTC
with paired normal tissues and 17 PTC samples were used for QPCR
validation.
Results: We found 2266 significant genes (p < 0.001) distinguish-
ing MTC from other type of thyroid tumors. Among of them there
were genes characteristic for MTC: RET and CALCA. Up to now,
12 genes were verified by QPCR: EEF1A2, GRP, NEFL1, SCG2,
SCG3, SST, TFF1, TFF3, CALCA, CALCB and chromogranin A and
B (CHGA, CHGB). Comparison of gene expression profile between
hereditary and sporadic MTC did not reveal distinct differences.
Concerning type of RET mutation we were able to select 441 genes
(p = 0.006) differentiating samples with C634R mutation from sam-
ples with other RET mutations.
Conclusion: We present the gene expression signature of medul-
lary thyroid cancer, selected by the degree of differences in RNA
level, not by previous knowledge on its origin, and useful for fur-
ther analysis of its transcriptome.
Prospective analysis of 131I treatment in patients
with papillary microcarcinoma operated
by subtotal thyroidectomy
T. Olczyk, A. Kropińska, A. Krawczyk, J. Krajewska,
D. Handkiewicz-Junak, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department M. Skłodowska-Curie
Memorial Cancer Center and Institute of Oncology Gliwice Branch,
Gliwice, Poland
Introduction: Differentiated papillary thyroid carcinoma accounts
for > 80% of all thyroid cancers. The best prognosis is observed in
papillary micocarcinoma.
The aim of study: To evaluate indications for adjuvant treatment
of 131I in patients with papillary thyroid microcarcinoma.
Material and methods: In the years 2003–2008 we included 124
patients after obtaining informed consent. They were randomly
allocated to complementary 131I treatment with activity of 60 mCi
or to control group not treated by radioiodine after thyroid sur-
gery. In both groups, we evaluated the levels of thyroglobulin (Tg)
and a-Tg antibodies during L-thyroxine withdrawal, ultrasonog-
raphy, 131I scintigraphy 12 months post radioiodine therapy. The
median observation was 54 months.
Results: In the radioiodine-treated group one patient experienced
complications in the form of post 131I therapy thyroiditis, requiring
the use of steroids, antibiotics and NSAIDs. Post 131I therapy in one
patient we detected metastases to mediastinal lymph nodes by whole-
body scan. There was no recurrence in either group of patients. In
the treated group the mean concentration of thyroglobulin post 131I
therapy was 0.2 ng/mL in comparing to 3.7 ng/mL in the control
group. The mean volume of thyroid tissue remaining after treatment
was significantly lower than in the control group and it was 0.51 ml
in the treated group and 2.82 ml in the control group. Radioiodine
neck uptake was less than 0.5% in 80% of patients in 131I treated pa-
tients. In the control studies carried out 24 months after enrollment
the median serum thyroglobulin level was 0.4 ng/mL during L-T4
therapy in the study group and in the control group.
Conclusion: Complementary radioactive iodine treatment does not
confer significant additional benefit in patients with papillary thy-
roid microrcarcinoma after subtotal thyreoidectomy.
The role of gallium-68 labelled somatostatine
analogue PET-CT (68Ga-DOTA-TATE PET-CT)
in diagnosing of patients with disseminated
medullary thyroid carcinoma (MTC)
I. Pałyga, A. Kowalska, D. Gąsior-Perczak, J. Słuszniak.
J. Sygut, M. Tarnawska-Pierścińska, S. Góźdź
Holycross Cancer Center, Kielce, Poland
Introduction: Calcitonin is a very sensitive marker of MTC. High con-
centration of basal or pentagastrin stimulated calcitonin in patients
with MTC is a signal of recurrence or metastatic disease. Detection of
metastatic foci remains a diagnostic and therapeutic challenge.
The aim of the study was to present the examples of the use of 68Ga-
DOTA-TATE PET/CT examinations in diagnosis of patients with MTC
and concomitant elevated serum calcitonin concentration.
Material and methods: Initially the study involved 8 patients with
MTC and elevated basal or stimulated calcitonin in which earlier
diagnostic imaging was negative for metastasis: neck ultrasound,
chest and mediastinal CT scan, liver MRI, bone scintigraphy, and
18F-FDG-PET. A total body scan was performed using 68Ga-DOTA-
-TATE PET/CT. Two patients with positive diagnostic imaging test
were referred to surgery including resection of cervical lymph nodes
with histopathological examination for assessment of metastases.
Conclusions: On the basis of presented cases we conclude that —
PET/CT scan with somatostatin analogue labeled with gallium (68Ga-
DOTA-TATE PET/CT) may be useful in the diagnostic imaging of
patients with disseminated MTC.
Analysis of ultrasound images of thyroid cancers
of diameter less then 15 mm for selection of Fine
Needle Aspiration for patients with multinodular goiter*
J. Pankowski1, E. Kaznowska2, B. Maksymiuk3,
1Department of Pathology, Pulmonary Hospital, Zakopane, Poland
2Department of Pathomorphology, Tubrculosis and Pulmonary Diseases
Specialistic Hospital in Rzeszów, Rzeszow, Poland
3Department of Tumor Pathology M.Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction:The aim of the study was discovery the most charac-
teristic ultrasound features of the small cancer lesions differentiat-
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ing these lesions from other benign nodules of the multinodular
goiters.
Material and methods: All Fine Needle Aspirations (FNA) of the
thyroid performed by the author from 2007 to 2009 were analyzed.
There were 15 130 FNA overall. ALL FNA were performed with
use of the same ultrasound apparatus with linear 10 MHz probe,
with option of Color-Doppler. There were 2-6 FNA/patient per-
formed (mean 2.4). Each nodule was measured and recorded on
the disc of the ultrasound apparatus in JPG format. There were
3 independent pathologist examining all lesions. There were
146 cancers discovered with 110/146 (75%) lesions of the diameter
less than 15 mm included for the current analysis. Diameter,
echogenity, clear borders, shape, presence of calcifications and hy-
poechogenic halo were analyzed.
Results: Diameter of the cancer lesions: less than 5 mm (mean 0.46).
5 (4.5%); 5–10 mm (mean 7.42) — 51 (46.4%); 10 — 15 mm (mean
12.2 mm) — 54 (49.1%). Echogenity : hypoechogenic — 45 (41%);
mixed — 56 (51%); hyperechogenic — 9 (8%). Clear margins: clear
margins — 53 (48%); partial or moderate distict margines — 30
(27%); obscured margins — 27 (25%). External borders of the nod-
ules (only for nodule with clear or partially clear margins): smooth
— 53 (48%); irregular — 21 (19%). Hyperechogenic (with calcifica-
tions): 17 nodules (central 9, peripheral — 8) Hypoechogenic (halo):
17 nodules (15.4%) (10 with diameters 5–10 mm; 12 with diameters
10–15 mm).
Conclusions:
1. In ultrasound vast majority of cancers are small lesions and
have diameter of less than 15 mm.
2. 92% cancers were hypoechogenic or mixed nodule.
3. Small thyroid cancers are characterized of no ultrasonic fea-
tures differentiating them from benign nodule In selection for
FNA 4. FNA should be performed in as many nodules as possi-
ble, including non-dominant nodule.
*Recipients of Polish Thyroid Association — Ipsen Award.
Applying unsupervised analysis to interpret the
variability of gene expression in the set
of follicular tumours
A. Pfeifer1, M. Eszlinger2, T. Musholt3, S. Hauptmann4,
M. Oczko-Wojciechowska1, M. Jarząb5, M. Świerniak1,
D. Lange6, R. Paschke2, B. Jarząb1
1Nuclear Medicine and Endocrine Oncology Department, M. Skłodowska-Curie
Memorial Center and Institute of Oncology, Gliwice Branch, Poland
2Third Medical Departament, University of Leipzig, Germany
3Department of Endocrine Surgery, University Hospital, Mainz, Germany
4Institute for Pathology, University of Halle, Germany
5Department of Tumor Biology, M. Skłodowska-Curie Memorial Center and
Institute of Oncology, Gliwice Branch, Gliwice, Poland
6Tumor Pathology Department, M. Skłodowska-Curie Memorial Center and
Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: Gene expression in follicular tumors may underlie
the differences in their biological aggressiveness and in clinical
course of a disease among patients with follicular adenomas and
carcinomas. The relative rarity of this tumor and subjectivity of his-
topathological diagnosis make this disease relatively hard to be
analyzed in molecular studies. In our analysis, we used the mi-
croarray technology and attempted to analyse the data using un-
supervised methods that don’t use a priori histopathological dis-
tinction between carcinoma and adenoma.
The purpose of the study is to find and interpret the sources of
gene expression variability in follicular tumors by analysing the
microarray data with unsupervised method — Singular Value De-
composition (SVD).
Material and methods: We analyzed 45 microarrays (21 samples
of follicular carcinoma and 24 samples of follicular adenoma) which
were obtained in ZMNiEO laboratory in Gliwice. The tissue sam-
ples were obtained in Gliwice and in collaborating institutes in
Germany. We performed the preprocessing of the data and then
the SVD analysis. To interpret the SVD results we used the gene
signature database MSigDB (Molecular Signatures Database, Broad
Institute, MIT) and the set of microarrays obtained from a set of
various tissues and organs of human (made available by GNF In-
stitute, Genomics Institute of the Novartis Research Foundation).
Results: The main source of variability, described by the first mode
of SVD analysis is responsible for 16% of variance in the data. This
variability probably refers to the difference between transcriptome
of thyrocyte and expression profile typical for immune cells. Ex-
pression of genes of immune response is related to 1st and 4th char-
acteristic modes. In 2nd, 5th and 6th modes we identified significant
differences among genes of cell proliferation. The 2nd mode is also
clearly dependent of mitochondrial genes expression, what can be
related to the proportion of oxyphilic cells.
Conclusions: The main variability in the dataset is related to the
expression of genes of immune response. The important compo-
nent of gene expression variability in follicular tumors is also the
degree of proliferation what can be related to the kinetics of tumor
growth. Further studies are necessary to analyze how expression
of those genes is related to the invasiveness of the tumors.
Skip metastases in papillary thyroid carcinoma
—incidence and impact on surgery
L. Pomorski1, M. Dobrogowski1, S. Mikosiński2, K. Kaczka1
1Department of General and Oncological Surgery, Medical University, Łódź,
Poland
2Department of Nuclear Medicine and Oncological Endocrinology,
M. Sklodowska-Curie Memorial Hospital, Zgierz, Poland
Introduction: The aim of the study was to assess the incidence of
skip metastases in regional lymph nodes of patients with papillary
thyroid carcinoma.
Material and methods: Thirty-three patients — 30 (91%) female
and 3 (9%) male - were operated for thyroid cancer. The operations
were performed by a single surgical team in accordance with ap-
plicable current guidelines. In all cases of thyroid cancer, complete
thyroid excision with removal of central lymph nodes compart-
ment were carried out. If indicated, the procedure was extended to
involve ipsilateral lymph nodes or other compartments.
Results: Pathology results found 26 (79%) cases of papillary carci-
noma, 3 (9%) cases of follicular carcinoma, 2 (6%) cases of medul-
lary carcinoma, a single case of lymphoma (3%) and one metastatic
lesion (3%). Twenty-three patients with papillary carcinoma un-
derwent primary surgery, and 3 were reoperated due to lymph
node recurrence.
The 23 papillary tumors were staged as follows: T1 — 15 (65%), T2
— 26 (26%), T3 — 2 (9%).
In 14/23 (61%) of patients with papillary carcinoma, lymph node
metastases were found during primary surgery. Lymph node me-
tastases were found in 5/15 (33%) of patients with T1, 4/6 (67%) of
patients with T2, 2/2 (100%) of patients with T3. In 5/23 (22%)
of patients with no evidence of metastases in central lymph node
compartment, metastases were present in the lateral or mediastinal
lymph nodes (skip metastases). The latter were found in 1/5 (20%)
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patients with T1, 3/4 (75%) of patients with T2 and 1/2 (50%) of
patients with T3.
Conclusions: Papillary thyroid carcinoma has a high rate of re-
gional lymph node metastases, independently of tumor size. The
rate of lymph node metastases found in this study is particularly
high. The presence of skip metastases regardless of T staging indi-
cates that special care must be taken to monitor the lateral and
mediastinal lymph node compartment in papillary carcinoma at
any stage.
Analysis of usefulness of PTH concentration mea-
surement in the material obtained during fine needle
aspiration biopsy of neck focal lesions in the
identification of parathyroids
B. Popowicz, J. Jankiewicz-Wika, S. Sporny, M. Klencki,
E. Woźniak, E. Sewerynek, J. Komorowski,
D. Słowińska-Klencka
Department of Morphometry of Endocrine Glands, Ist Chair of Endocrinology,
Medical University of Łódź, Poland
Primary hiperparathyroidism frequently causes significant diag-
nostic problems with visualization of the glands that are the source
of overproduction of parathormone (PTH). The aim of the investi-
gation was to assess the usefulness in localization of the changed
parathyroid glands of the measurement of PTH concentration in
the material obtained during fine needle aspiration biopsy of focal
lesions in the neck.
The PTH concentration (FNAB-PTH) was assessed in the material
obtained from 23 patients by flushing the needle after the prepara-
tion of a microscopic smear. The examination was performed in
patients with biochemically proven hyperparathyroidism and also
in patients with incidentally found focal lesion that was suggestive
in US for parathyroid gland. The results were correlated with bio-
chemical indexes of hyperparathyroidism, the output of scinti-
graphic imaging, the outcome of FNAB and also with the results of
histopathological examination.
It was found that mean PTH concentration in the material obtained
during FNAB of lesions that were parathyroids was 4530 pg/mL
(the lowest concentration was 1218 pg/mL) and several fold higher
than the mean concentration of PTH in the material obtained from
the thyroid lesions (the control group) that equaled to 19.0 pg/mL
(the highest concentration 43.05 pg/mL). High PTH concentration
was also observed in the case of non-diagnostic cytological smear.
None false positive result of PTH measurement in material from
biopsy needle was observed.
The incidence and characteristics of thyroid focal
lesions in patients with thyroid hemiagenesis
M. Ruchała, E. Szczepanek, J. Sowiński
Department of Endocrinology, Metabolism and Internal Medicine, Poznań
University of Medical Sciences, Poznań, Poland
Introduction: Thyroid hemiagenesis (TH) is an inborn anomaly,
resulting from one thyroid lobe developmental failure. The research
showed that subjects with TH, despite clinical euthyroidism, present
significantly higher TSH values in comparison to those with prop-
erly developed thyroid gland. Permanent exposure to high TSH
concentration, which is one of the most potent thyroid growth-
promoting factors, may result in nodular goiter development. Lat-
est scientific communications also indicate that initial TSH concen-
tration is an independent risk factor for detection of malignant le-
sion in the thyroid. Similarly, initial TSH value in patients with thy-
roid cancer, positively correlates with its clinical stage. What is sur-
prising, the risk increases along with TSH even within reference
ranges.
The aim of the study was to assess the incidence and describe char-
acteristics of thyroid focal lesions in patients with TH.
Material and methods: The studied group consisted of 47 subjects
with TH. In patients, thyroid ultrasound examination together with
fine-needle aspiration biopsy and cytological diagnostics of detect-
ed focal lesions, were performed.
Results: Thyroid ultrasound examination revealed the presence of
focal lesions in 26 (55%) patients, while in 16 (34%) multifocal chang-
es were detected. In 25 (53%) patients, lesions were predominantly
solid. Each of detected lesions were larger or equal to 6 mm. In
11 (23%) patients, the diameter of largest lesion was between 6-10 mm.
In the remaining 15 (32%) patients, the lesions found were larger
or equal to 11 mm. The cytological examination of specimens ob-
tained by fine-needle aspiration biopsy revealed presence of be-
nign lesions (cysts, colloid and hyperplastic nodules) and in two
cases - oxyphilic nodules. Thyroidectomy was recommended to
6 patients.
Conclusions: Due to high prevalence of thyroid nodular disease
together with increased TSH concentration, in the light of latest
scientific communications, subjects with TH are at higher risk of
developing thyroid cancer. In spite of the fact that in the studied
group no patient was diagnosed with malignant lesion, thyroid
nodular disease often accompanied TH and detected lesions were
frequently multifocal, solid and of size exceeding 11 mm.
Animal model of the papillary thyroid carcinoma
induced by BRAFV600E mutation — preliminary
D. Rusinek1, E. Chmielik2, M. Kowal1,
E. Gubała1, W. Widłak3
1Department of Nuclear Medicine and Endocrine Oncology, M.Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
2Department of Tumor Pathology, M.Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
3Department of Tumor Biology, M.Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: The oncogenic transversion BRAFT1799A is the most
common mutation, described in about 45% of papillary thyroid
carcinoma (PTC). Presence of this mutation both in the papillary
microcarcinomas and the advanced stage of PTC or in dedifferen-
tiated carcinomas arised from PTC indicates that BRAF mutation is
not sufficient to develop aggressive phenotype of carcinoma. Prob-
ably it predisposes tumor cells to acquisition of additional muta-
tions and in this way activates more aggressive signaling pathways.
Aim of the study: Obtaining of the mouse model of the BRAFT1799A
induced papillary thyroid carcinoma for the analysis of
BRAFT1799A influence on the carcinoma phenotype
Material and methods: Mutated human BRAF gene (pMEV-2HA
plasmid; Biomyx) with the bovine thyroglobulin promoter (ob-
tained by courtesy of Prof. Dumont) was injected into the pronu-
cleus of one-cell mouse embryos (FVB/N strain). Detection of PTC
was carried out histopathologically. The expression of the mRNA
transgene was analyzed by the automatic sequencing.
Results: As a result of microinjection we obtained 6 founders in
which the presence of injected transgene was detected on the DNA
level, but on the mRNA level the expression was seen only in two
cases. The histopathological analysis revealed in these two lines of
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transgenic mice tumors with features typical for human PTC: en-
larged overlapping nucleus with irregular shapes, visible pseudo-
inclusions and grooves; predominance of follicular cells
Conclusions: The mouse model of papillary thyroid carcinoma
induced by mutation BRAFT1799A will be used to analyze global
gene expression profile and its relation to different factors of clini-
cal and histological significance.
The analysis of value of ultrasound-guided
fine-needle aspiration biopsy (US-FNAB)
of thyroid nodules patients with nodular goiter
M. Rzeszutko1, W. Rzeszutko1, T. Tomkalski2
1Patology Dep. Medical Academy, Wroclaw, Poland
2Endocrinology Dep. PKP Hospital Wroclaw, Poland
Introduction: Ultrasound-guided fine needle aspiration biopsy
(FNAB) plays a crucial role in the diagnosis of thyroid nodules. In
the case of nodular thyroid lesions the preoperative performance
BAC makes possible the estimation of the change and stating pre-
cisely the range of the thyroid resection.
The aim of study: The analysis of concordance the FNAB with his-
topathologic postoperative results.
Material and methods: Authors put the retrospective analysis of
219 patients at whom nodular lesions of the thyroid (183 female
and 36 male) were diagnosed. US-FNAB was performed on all 219
patients under echo-guidance in accordance with the standard tech-
nique. Each patient had the supplied documentary evidence of ul-
trasonographic research and full clinical diagnostics. All patients
had complete ultrasound and clinical diagnosis.
Results: In all cases diagnosed postoperatively as cancers the cyto-
logical diagnostic obtained from US-FNAB were: cancer or oxyphyl-
ic tumor. The comparative analysis of pre- and postoperative re-
sults showed the entire agreement of results in 79%.
Conclusions: US-FNAB is a valuable method in the pre-operative
assessment of thyroid nodules in order to select patients for surgery.
Advantages and disadvantages of 3D ultrasound
of thyroid nodules including thin slice volume
rendering**
R.Z. Słapa1, W. Jakubowski1, J. Słowińska-Srzednicka2,
K.T. Szopiński1,3
1Department of Diagnostic Imaging, Medical Faculty II, Medical University
of Warszawa, Warszawa, Poland
2Department of Endocrinology, Centre for Postgraduate Medical Education,
Warszawa, Poland
3Interdisciplinary Centre for Mathematical and Computational Modelling,
Warszawa University, Warszawa, Poland
Introduction: Despite numerous studies and the development of
guidelines on the diagnosis and treatment of thyroid nodules, the
management of thyroid carcinoma has yet to be optimized. An
optimal management strategy for thyroid incidentalomas could be
developed using an evidence-based approach in which systematic
evaluation of obtained data, stored in national databases, would
be used. A new imaging modality — 3D ultrasound has not been
studied for potential diagnosis and storage of thyroid nodules vol-
umes yet.
To assess the advantages and disadvantages of 3D gray-scale and
power Doppler ultrasound, including thin slice volume rendering
(TSVR), applied for evaluation of thyroid nodules.
Material and methods: The retrospective evaluation by two ob-
servers of volumes of 71 thyroid nodules (55 benign, 16 cancers)
was performed with a new TSVR technique.
Results: Multiple logistic regression analysis (area under ROC = 0.87)
demonstrated that independent risk factors of thyroid cancers iden-
tified by 3D ultrasound include:
ill-defined borders of the nodule on MPR, a lobulated shape of the
nodule in the c-plane on TSVR, a density of central vessels in the
nodule within 1–25% or 76–100% of area of the nodule on TSVR.
Combination of features provided sensitivity 100% and specificity
60–69% for thyroid cancer.
Calcification/microcalcification-like echogenic foci on 3D ultrasound
proved not to be a risk factor of thyroid cancer.
Storage of the 3D data of the whole nodules enabled subsequent
evaluation of new parameters and with new rendering algorithms.
Kappa statistics showed at least moderate agreement between the
observers.
Conclusion: 3D ultrasound is a practical and reproducible method
for the evaluation of thyroid nodules. 3D ultrasound stores vol-
umes comprising the whole lesion or organ. Future detailed evalu-
ations of the data are possible, looking for features that were not
fully appreciated at the time of collection or applying new algo-
rithms for volume rendering in order to gain important informa-
tion. 3D ultrasound data could be included in thyroid cancer data-
bases. Further multicenter large scale studies are warranted.
**Recipient of “Thyroid Research” award.
Urinary iodine excretion in patients with
differentiated thyroid cancer (DTC) treated
with recombinant human TSH
A. Stanjek-Cichoracka1, B. Michalik2,
A. Kochańska-Dziurowicz1, J. Roskosz2
1Department of Isotope Diagnostics and Radiopharmaceuticals, Sosnowiec,
Medical University of Silesia, Katowice, Poland
2Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Introduction: Low iodine diet has not been routinely administered
in Polish DTC patients, due to the moderate iodine deficiency in
our patients. Now, when iodine deficiency has been compensated,
the question of low iodine diet arises again. The data on iodine
excretion in DTC patients are necessary.
Aim of the study was to analyze urinary iodine concentration in
patients with differentiated thyroid cancer treated at the Institute
of Oncology in Gliwice
Material and methods: The analyzed group consisted of 572 DTC
patients (444 females and 101 males) who were treated from April
14 to December 12, 2009 at Institute of Oncology in Gliwice. Con-
centration of iodine in urine was assessed with PAMM method (Pro-
gram Against Micronutrient Malnutrition) based on measurement
of Sandell-Kolthoff reaction kinetics. This method is based on spec-
trophotometer analysis of catalytic properties of iodine in reaction
Ce(IV) and As(III). Patients were administered L-thyroxine in dos-
es assuring incomplete TSH suppression (median: 150 ug/day) and
investigated before rhTSH administration.
Results: The age range of analyzed group of patients was 10–
–87 years. Median age of both females and males was 51 years.
Concentration of iodine in urine ranged between 10.1–395.2 ng/L.
In both males and females median urinary iodine was the same
(127.55 ng/L). The following distribution of urinary iodine concen-
tration was observed:
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1) < 100 ng/L 29.72% 2) 100–150 ng/L 35.84% 3) 150–200 ng/L 24.83%
4) 200–300 ng/L 8.39% 5) > 300 ng/L 1.22% Urinary iodine < 200
ng/L was observed in over 90% of patients and this cut-off was
chosen for reference range.
Conclusion: In DTC patients treated with thyroxine with inten-
tion of TSH suppression the urinary iodine concentration does not
exceed 200 ng/L in 90,4% of patients.
Analysis of the results of histopathological
examination of the thyroid gland after reoperations
caused by thyroid cancer diagnosed after strumectomy
J. Skrobisz
Surgical Departament B of Regional Hospital in Poznań, Poland
Between 2003 and 2009, 76 patients were diagnosed with thyroid
cancer after strumectomy performed most frequently because of
the multinodular goiter.
Strumectomy was performed in our Department and other neigh-
bouring hospitals.
In the present study we analyzed the results of histopathology
performed after reoperation. The analysis included patients with
differentiated thyroid cancer. In 5 patients (6.5%) cancer was con-
firmed in postoperative mass. In 3 patients papillary carcinoma was
diagnosed in excised tissue. In 2 out of these patients it was diag-
nosed in both lobes. There were no metastases to lymphatic nodes
observed during reoperation of papillary thyroid cancer cases. Two
patients were diagnosed with foci carcinomatosi after diagnosis of
follicular cancer. One of them was also diagnosed also with me-
tastases in lymphatic nodes.
Conclusions: Multifocal differentiated thyroid cancer is rare, but
may occur even in cancers with the diameter below 2 cm.
New ultrasound techniques in visualization of
microcalcifications in diagnostics of focal lesions
of thyroid gland
R.Z. Słapa1, W. Jakubowski1, K.T. Szopiński1,2,
A. Szcześniak3, J. Bierca4, J. Słowińska-Srzednicka5
1Department of Diagnostic Imaging, II Medical Faculty, Medical University,
Warszawa, Poland
2Interdisciplinary Centre for Mathematical and Computational Modelling,
Warszawa University, Warszawa, Poland
3Department of Pathology, Solec Hospital, Warszawa, Poland
4Department of Surgery, Solec Hospital, Warszawa, Poland
5Department of Endocrinology, Centre for Postgraduate Medical Education,
Warszawa, Poland
Introduction: Microcalcifications may be visible on gray-scale ul-
trasound. Microcalcifications in thyroid nodule increase the prob-
ability of cancer about 3 times, calcifications increase about 2 times.
Microcalicifications are considered a specific feature of thyroid can-
cer (85.8–95%) but with low sensitivity (29–59%).
Harmonic imaging, compound ultrasound, 3D ultrasound with thin
slice rendering and new programs, that due to application certain
filters, enable to separate microcalcifications echos are new ultra-
sound techniques that improve visualization of microcalcifications.
Techniques that improve visualization of microcalcifications po-
tentially could increase sensitivity in diagnostics of thyroid cancer.
Evaluation of usefulness of new ultrasound techniques in visual-
ization of calcification/microcalcification-like echogenic foci (CAL)
in diagnostics of focal lesions of thyroid gland.
Material and methods: Retrospective analysis of ultrasound images
of 99 dominant thyroid nodules (81 benign, 18 cancers) verified by
FNB and/or surgery. CAL was evaluated with application of 3D ul-
trasound with implementation of new thin slice rendering method,
with harmonic imaging and compound ultrasound and with applica-
tion of new technique of microcalcification mapping MicroPure.
Results: CAL in 3D ultrasound in MPR presentation were 81–88%
sensitive and 38–44% specific for thyroid cancer. In thin slice ren-
dering sensitivity was 88–94% and specificity 22–25%. On multiple
logistic regression analysis CAL proved not to be a statistically sig-
nificant factor of thyroid cancer.
Correlation of ultrasound with application of new gray-scale tech-
niques and MicroPure with pathology examination after thyroidec-
tomy revealed that most of CAL were the presentation of inspissat-
ed colloid and only a small percentage was due to microcalifica-
tions, calcifications and or fibrosis.
Conclusion: In 3D ultrasound microcalcifications are not a valid
risk factor of thyroid cancer.
Application of Random Forests technique
for discrimination of histological types
of thyroid tumor
T. Stokowy1, 2, M. Jarząb1, K. Fujarewicz2,
M. Oczko-Wojciechowska1, A. Pfeifer1,
R. Paschke3, M. Eszlinger3
1Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
2Systems Engineering Group, Institute of Automatic Control, Silesian University
of Technology, Gliwice, Poland
3III Medical Department, University of Leipzig, Leipzig, Germany
Introduction: Statistical analysis of DNA microarray data is a basic
tool for recognition of patterns in gene expression.
Multigene molecular classifiers can be applied for support of histo-
pathologic diagnosis but at the moment there is no agreement what
techniques can be used for that purpose. Different methods of arti-
ficial intelligence are characterized by high diversification of pa-
rameters, what is more, they give significantly different gene sets.
Random Forests have an advantage over other methods — they
deal well with large data sets and have a good accuracy of classifi-
cation in comparison to other algorithms.
The goal was to determine the quality of classification with Ran-
dom Forests for prepared set of thyroid samples.
Transcriptome was analyzed with oligonucleotide Affymetrix DNA
microarrays in the laboratory of Nuclear Medicine and Endocrine
Oncology Department, Institute of Oncology, Gliwice.
Material and methods: There were chosen 30 representative sam-
ples of papillary thyroid cancer, 30 samples of medullary thyroid
cancer, 30 follicular tumor samples and 30 normal benign thyroid
samples. Methodology of Random Forests is based on the algo-
rithm proposed by Breiman and Cutler (2001) and the analysis was
performed in Bioconductor environment. Unsupervised analysis
was performed by Shi and Horvath (2006).
Results: Both unsupervised and supervised analyses were com-
pared with results coming from other classification methods run
on the same data set. Unsupervised analysis easily distinguished
all 4 classes. By means the supervised technique was performed as
a selection of gene classifiers for two class comparisons. The accu-
racy of classification was determined. A trial of minimization of the
list of genes that distinguish the classes in each of comparisons was
performed. Lists of genes describing the differences were interpret-
ed in the biological function context.
Conclusions: Random Forests is an useful technique of selection of
multigene sets classifying different histological types of thyroid tumors.
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Diagnostic cytology of poorly differentiated thyroid
carcinoma
J. Sygut, W. Rezner, J. Kopczyński, J. Słuszniak,
A. Kowalska
Holycross Cancer Centre, Kielce, Poland
Introduction: Uniform histological criteria for the diagnosis of poor-
ly differentiated thyroid carcinoma (PDTC) were proposed in 2007.
Cytological diagnostic criteria of this entity are still a subject of on-
going discussion.
Aim of the study: To determine cytological features most com-
monly found in fine-needle aspirates of PDTC.
Material and methods: Routine HE-stained cytological preparates
from 6 cases of PDTC diagnosed and treated in HCC in years 2000–
–2008. Histopathological specimens from postoperative specimens
did not contain differentiated or anaplastic carcinomatous compo-
nents.
Thirty six cytological features were evaluated in a single, most rep-
resentative specimen from every case. The features were selected
on the base of literature reviev and contained general information
like: cellularity, background and architectural patterns as well as
specific information including type, size and cytological details of
cells.
Results: The following of the analysed cytological features: high
cellularity (6/6), lack of colloid (6/6), bloody background (5/6), three-
dimensional structures (6/6), rather monomorphic population of
small/medium-sized cells (6/6), well-defined cohesion (6/6), scant
cytoplasm (6/6), oval/round nuclei (6/6), lack of well-defined atypia
(6/6) were present in nearly all (5 to 6 per 6) evaluated smears. Oth-
er features were sparser and were usually observed in no more
than half of the cases.
Conclusions:
1. The above outlined cytological presentation of PDTC distinguish-
es it from other patterns observed in thyroid gland cytology.
2. The nine cytological features are not specific enough for un-
equivocal and unquestionable diagnosis of PDTC derived from
thyroid follicular cell.
3. The features seem to be of no use in differential diagnostics of
so-called follicular neoplasm or aspirates from parathyroid
gland as well as in diagnostics of some medullary carcinomas
and metastases.
Psycho-oncological care over patients suffering from
differentiated thyroid cancer — identification of
crucial points of intervention
A. Syska-Bielak, A. Kropińska, M. Jarząb, A. Heyda,
M. Jarząb, E. Wojtyna, J. Życińska, D. Handkiewicz-Junak,
K. Hasse-Lazar, A. Czarniecka, T. Olczyk, B. Jarząb
Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice
Poland
Department of Psychiatry, Tarnowskie Góry, Medical Faculty in Zabrze, Silesian
Medical University, Katowice, Poland
The Warszawa School of Social Sciences and Humanities, Warszawa, Poland
Introduction: Differentiated thyroid cancers (DTC) are cancers with
relatively good prognosis, however the stigma of cancer and nec-
essary diagnostic and therapeutic procedures are not only a rele-
vant source of distress for the patients but also increase the distress
by causing normal imbalance.
Aim of study: Creating a cohesive scheme of psychological care for
DTC patients involving the most essential points of possible inter-
vention in the course of diagnostics, treatment and control exami-
nations.
Material and methods: A population of DTC patients from the
Department of Nuclear Medicine, Institute of Oncology in Gliwice
have been studied. Evaluation of their psychological health, includ-
ing psychiatric assessment, the quality of life and the comprehen-
sive psychological assessment was performed. Life satisfaction was
measured with the Life Satisfaction Scale — SWLS (E. Diener et al,
the Polish adaptation by Z. Juczyński), level of hope with Cantrilla
Ladder, a Property of Health Behaviours (Z. Juczyński), Draw
a Person Test (DAP) and QLQ-c30 questionnaire form were used.
A psychological interview was carried out in a subgroup of patients.
Results: The crucial areas of possible psycho-oncological interven-
tion were identified. The most common psychological disorders
co-occurring with cancer are depression, anxiety and adaptive dis-
orders. The psychological interview indicates on the need of better
information policy in the scope of both the illness and the treat-
ment methods. The frequency of distress among DTC patients is
high enough to implement effective selection tools for better rec-
ognition of their psychological problems. Distress Thermometer
(DT), a short scale recommended by American Cancer Society and
National Comprehensive Cancer Network (NCCN), may serve for
this goal.
Conclusions: The interdisciplinary team providing care of DTC
patients should integrate their efforts in both the somatic sphere as
well as the psychological one. A differential diagnosis between
symptoms of hormonal disorders and co-occurring negative emo-
tions accompanying cancer disease, such as fear, sadness and an-
ger is necessary
Phenotype of exon 10 RET gene mutations carriers
S. Szpak-Ulczok, E. Gubała, A. Pawlaczek,
M. Oczko-Wojciechowska, B. Jarząb
Nuclear Medicine and Endocrine Oncology Department; M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice,
Poland
Mutations in exon 10 of RET gene are not very often and pheno-
type of these mutations is not well defined. In our center 40 pa-
tients with medullary thyroid cancer (MTC) with exon 10 muta-
tions were diagnosed (14 probands and 26 family members). MEN2a
syndrome was diagnosed in 1 family with 611 codon mutation
(3 pts), in 3 families with RET620 (10 pts) and in 2 RET618 carriers.
The strict criteria of familial medullary thyroid cancer (FMTC) were
fulfilled in 2 families (respectively 4 and 10 carriers of RET618).
Median age of MTC diagnosis in probands was 35 years (20–52)
and in their family members was 30 years (17–62). In 22 probands
relatives thyroidectomy was performed. Prophylactic thyroidecto-
my, performed in 9 patients with normal basal calcitonin level rev-
eled C-cell hyperplasia in 8 pts and MTC in one person. In all pa-
tients with elevated basal calcitonin MTC was diagnosed. Biochem-
ical remission of disease was stated in 5 probands and 17 relatives
(55% of operated pts), persistent hypercalcitoninemia was observed
in 3 probands and 3 family members and dissemination of disease
was diagnosed in 7 pts.
Pheochromocytoma was diagnosed in 7 pts, in all of them after
thyroidectomy. In 4 cases adrenal tumor was bilateral and synchro-
nous. Up to now parathyroid adenomas were not observed in our
group of patients.
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Conclusions:
1. In the analyzed exon 10 RET mutation carriers MTC was diag-
nosed not earlier then in the age of 20 years and pheochro-
mocytoma in the age of 29 years.
2. When prophylactic thyroidectomy is carried out at normal basal
Ct level, the risk of MTC is 10% in our group of exon 10 RET
carriers.
3. The risk of pheochromocytoma is evaluated with 17% up to
40 years of age.
Scale of differences between transcriptomes
of papillary thyroid carcinoma and normal thyroid
— analysis of gene expression profile
M. Świerniak, M. Jarząb, M. Oczko-Wojciechowska,
A. Pfeifer, K. Unger, C. Maenhaut, G. Thomas, B. Jarząb
6th Framework Programme Defining the genetic component of thyroid cancer risk
at low doses Genrisk-T nr 036495
Introduction: Microarray research helps to understand crucial
molecular mechanisms related to differences between subtypes of
carcinomas. However, in the practical use huge differences in gene
expression profile e.g difference in expression between papillary
thyroid carcinoma and normal thyroid, make the bioinformatical
analysis very difficult.
The aim of the study was creating and using bioinformatics algo-
rithms to estimate differences between PTC and normal thyroid
quantitatively and qualitatively.
Material and methods: We analyzed two sets of PTC and normal
thyroid samples arrayed in Department of Nuclear Medicine and
Endocrine Oncology, Centre of Oncology, Gliwice. One set con-
tains samples coming from Ukrainian children (36 PTC and 43 nor-
mal thyroids), another one coming from patients treated in Centre
of Oncology in Gliwice (69 samples).
Results: First step of analysis was comparison of gene expression
profiles in PTC and normal thyroid samples in GC-RMA prepro-
cessed set. Then, influence of preprocessing methods on results
was estimated: the least difference between PTC and normal thy-
roid was observed using methods based on global expression scal-
ing, but on the other hand quantile normalization methods reduced
amplitude of differences. Subsequently, we created a new prepro-
cessing algorithm, tested on a set containing several histological
types of thyroid carcinomas, then used on set contains PTC and
normal thyroid samples. In further work methods of gene set anal-
ysis to estimate difference between PTC and normal thyroid qual-
itatively will be used.
Conclusions: Differences between PTC and normal thyroid are
huge, related to at least 20% of all transcripts. Most of differentiat-
ing genes (about 90%) are genes with large and medium variation.
As the technical aspects strongly influence the degree of observed
differences, the analytical methods shall be further optimized.
Evaluation of specificity of potential papillary thyroid
cancer (PTC) marker genes FN1, KRT19, DPP4, MET
and CDH3
W. Truchanowski1, M. Kowalska2,
M. Oczko-Wojciechowska2, M. Kowal2, T. Tyszkiewicz2,
A. Kukulska2, A. Czarniecka2, J. Włoch2, J. Waler1,
G. Buła1, M. Kucharzewski1, J. Gawrychowski1
1Department and Hospital of General Surgery, Bytom, Silesian Medical
University, Katowice, Poland
2M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Gliwice Branch, Gliwice, Poland
Introduction: Papillary thyroid carcinoma (PTC) is found in ap-
prox. 80% of patients with thyroid malignant tumors. Results of
fine-needle aspiration biopsy (BAC) are specific for PTC in 69–94%.
Should the diagnosis be doubtful (tumor or benign lesion), differ-
ences in gene expression may help to obtain more precise differen-
tial diagnosis. However, specificity of the proposed tumor markers
is rarely evaluated. The genes under discussion include fibronec-
tin gene 1 (FN1), keratin gene 19 (KT19), dipeptidyl peptidase gene
IV (DPP4), proto-oncogene gene MET (MET) and cadherin gene
3 (CADH3).
Material and methods: The study referred to 120 patients treated
between April 2008 and December 2008 for malignant thyroid tu-
mors (20 papillary thyroid carcinomas) or benign lesions (80 prolif-
erative nodules, follicular lesions, colloidal nodules). Diagnosis was
unequivocal by BAC in 20 patients. Tumor fragments were collect-
ed during thyroid surgery. The specimen was divided into two por-
tions of which one was referred to histopathological examination
and the other to molecular analysis. Expression of FN1, KRT19,
DPP4, MET and CDH3 was analyzed by real time Q-PCR. Gene
expression was standardized against reference index obtained from
geometric average of the expression of three selected control genes
EIF3S10, HADHA and UBE2D2.
Results: A significant change in gene expression was observed for
all of them when papillary thyroid cancer was compared to nor-
mal thyroid. The greatest differences were observed for genes FN1
(increase in the expression 74 ×), CDH3 (34 ×), DPP4 (11 ×), KRT19
(8 ×) and MET (7 ×). The differences were statistically significant
(p < 0.001).
Conclusions:
1. QPCR allows to examine many genes at the same time, hence
it can potentially be used to support cytological diagnostics for
thyroid nodules.
2. Careful evaluation of specificity of each candidate gene must
precede any attempt to use it in practice.
The influence of presence distant and/or regional
nodal metastases on frequency of complete
remission at patients with differentiated
thyroid carcinoma (DTC)
T. Trybek, A. Kowalska
Department of Endocrinology, Holycross Cancer Center, Kielce, Poland
Introduction: The presence of regional nodal and/or distant me-
tastases has influence on results of treatment at patients with dif-
ferentiated thyroid carcinoma (DTC).
Aim of the study was to evaluate the frequency of complete remis-
sion at patients with DTC depending on presence in lymph nodes
and/or distant metastases.
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Material and methods: 102 patients (82 females, 20 males) aged
20–86 with N1 or M1 (according to TNM staging) after thyroidec-
tomy and 131I therapy among 625 patients with DTC treated in our
Department. Patients were divided in 3 groups: I group — TxN1M0,
II group — TxN0M1 and III group — TxN1M1.
The documentation was analyzed by classifying the complete re-
mission patients without presence radioiodine uptake in neck and
pathological lesions in the whole body 131I scintigraphy scan after
six month of ablation therapy, with negative serum thyroglobulin
in the absence of anti-thyroglobulin antibodies, ultrasound image
of the neck was normal. We compared frequency of complete re-
mission in 3 group patients.
Results: We recognized complete remission in 57 patients (82.6%)
in the I group (TxN1M0), 4 patients (28.6%) in the II group (TxN0M1)
and 6 patients (31.6%) in the III group (TxN1M1).
Conclusions:
1. The highest percentage of complete remission observed in pa-
tients with lymph nodes but without distant metastases
(I group).
2. In case of presence distant metastases there was not statistical-
ly significant difference in the percentage of complete remis-
sion between patients with or without the presence of metastas-
es in lymph nodes.
The clinical course of poorly differentiated thyroid
carcinoma (insular carcinoma) — own observation
A. Walczyk, A. Kowalska
Department of Endocrinology, Hollycross Cancer Centre, Kielce, Poland
Introduction: Poorly differentiated thyroid carcinoma (PDTC, in-
sular carcinoma) occurs rarely. It is described with more aggressive
behavior, poorer prognosis, higher mortality than well differenti-
ated thyroid carcinoma (WDTC).
The aim of the study was to evaluate the clinical course of patients
with PDTC in addition to frequency, clinical stage at the time of
diagnosis and possibility of radical surgical resection, necessity and
kind of complementary treatment, occurrence of distant metastas-
es and survival of patients.
Material and methods:  The study involved 14 patients diagnosed
and treated of PDTC between 2000 and 2009 (9 females, 5 males),
aged 38 to 78 years.
The medical records of patients with PDTC were analyzed to esti-
mate assumed parameters according to the purpose of the study.
Results: PDTC was diagnosed in 14 among 801 patients with thy-
roid carcinoma (1.75%). Clinical stage (UICC 2002) at the time of
diagnosis — 3 patients: pT1–2No–xMx (21.5%). 10: pT3 4Nx o 1Mx–1(71.4%).
1 was unresectable: TxN1M1 (7.1%). Total thyroidectomy was
achieved in 9 patients (64.3%). 4 patients (28.6%) received non rad-
ical surgery. Complementary radioiodine treatment was given
12 patients (85.8%). Radiation therapy of the neck was applied to
7 patients. palliative radiotherapy of the brain to 1 patient; chemo-
therapy to 1 patient. Distant metastases to the lung and to the brain
at the diagnosis were observed in 2 patients (14.3%). During fol-
low-up of 3-62 months lung metastases were observed in 4 patients
(28.6%). 3 patients were observed above 5 years as disease-recur-
rence free (21.5%). But in one patient after 5 years and 2 months
distant metastases were diagnosed. 3 patients died after 2–30
months (21.5%). 2 patients were lost for control. in the remaining 6:
follow-up lasted < 5 years.
Conclusions: Poorly differentiated thyroid carcinoma is still a chal-
lenge both for the pathologists and the clinicians. Infrequent prev-
alence, more aggressive course and poorer prognosis constitute the
major problem for the clinicians.
Follicular tumors and oxyphilic tumors
of thyroid gland in own experience
J. Waler1, G. Buła1, A. Niemiec1, W. Truchanowski1,
R. Mucha1, N. Waler2, J. Gawrychowski1
1Department and Hospital of General Surgery, Bytom, Silesian Medical
University, Katowice, Poland
2Specialist Hospital No. 2, Bytom, Poland
Introduction: One of the main indications for surgical treatment
in patients with thyroid diseases is thyroid cancer. Basic operation
in case of thyroid cancer consists of total removal of the gland. If
follicular tumor or oxyphilic tumor is diagnosed, at least, total thy-
roidectomy should be undertaken as objective cytological exami-
nation does not allow to distinguish between benign and malig-
nant tumors.
Purpose of the study was to evaluate the incidence of cancer in
patients qualified for surgical treatment when follicular or oxyph-
ilic tumor has been diagnosed by cytological examination.
Material and methods: A total of 3013 patients were operated be-
tween 2005 and 2009 in the Hospital for goiters, including 152 (5.1%)
with thyroid cancer.121 (4.0%) patients showing follicular tumor
by preoperative cytology and 57 (1.9%) patients with oxyphilic tu-
mor were qualified for operation. In most cases, the minimal ex-
tent of surgery consisted of total removal of the lobe with isthmus
on the lesion side. The other lobe was removed totally or subtotally
depending on individual assessment of malignant tumor risk.
Results: The extent of operation in 41 (72.0%) patients with ox-
yphilic tumor, diagnosed preoperatively, included total removal
of the lobe together with isthmus or bilateral lobectomy. Similar
type of operation was performed in 78 (65.0%) patients with follic-
ular tumor. Histopathology on the operative material showed can-
cer in 10 (17.5%) patients referred to operation for oxyphilic tumor
diagnosed by cytology. Among them, eight had papillary thyroid
cancer and two had medullary thyroid cancer. In follicular tumor
group, cancer was detected in 20 (16.5%) patients,-papillary type
in eight, follicular in nine and medullary in three.
Conclusions: The percentage of cancer among follicular and ox-
yphilic thyroid tumors referred to the surgery ranged between 16.5
and 17.5%. The range of operation in such cases should consider
cytological findings, ultrasonography and clinical risk factors eval-
uated both before and during the operation.
Assessment of PIK3CA gene expression in papillary
thyroid cancer
K. Wojciechowska-Durczyńska, K. Krawczyk-Rusiecka,
A. Cyniak-Magierska, A. Zygmunt, A. Lewiński
Department of Endocrinology and Metabolic Diseases, Medical University, Łódź,
Poland; Department of Endocrinology and Metabolic Diseases,
Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland
Introduction: PIK3CA gene mutations are present in the majority
of cancer cells. PIK3CA mutations and amplifications were also con-
firmed in papillary, follicular and anaplastic thyroid cancers. Still,
the data on PIK3CA disturbances in papillary thyroid cancer (PTC)
are rather inconsistent.
The aim of the study was an assessment of PIK3CA gene expres-
sion in PTC.
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Material and methods: Twelve cases of papillary thyroid cancer
were analyzed. Thyroid aspirates, eligible for the study, were ob-
tained from patients by fine needle aspiration biopsy (FNAB). Each
aspirate was smeared for conventional cytology, while the rema-
ing part of aspirate was immediately washed out of the needle.
The cells, obtained from the needle, were used in further investi-
gation. Total RNA from FNAB was extracted by use of an RNeasy
Micro Kit, based on modified Chomczyński and Sacchi’s method.
Total RNA was reversely transcribed into cDNA and investigated
by Real-Time Quantitative PCR (RQ-PCR). Beta-actin gene was
used as endogenous control. The relative expression of PIK3CA
gene was assessed, using the ABI PRISM 7500 SDS Software.
Results: So far, PIK3CA expression in PTC has hardly been inves-
tigated. In the present study, an elevated level of PIK3CA gene
expression was confirmed in PTC. Thus, PIK3CA gene may play
a significant role in the pathogenesis of this cancer type. Further-
more, PIK3CA gene overexpression levels were individually diver-
sified, what may have resulted from its association with different
genetic and clinical prognostic factors. Further studies on this pos-
sible relationship would be appropriate.
The recurrent goiter beyond the typical lateral lobes
localization — the analysis of over 60 cases
E. Woźniak E, M. Klencki, B. Popowicz, S. Sporny,
D. Słowińska-Klencka
Department of Morphometry of Endocrine Glands, 1st Chair of Endocrinology,
Medical University, Łódź, Poland
Introduction: The recurrent goiter is an important clinical prob-
lem among patients who have been operated due to benign le-
sions. An atypical localization of recurrent goiter — nearby hyoid
bone — poses additional difficulties as there are no data available
on the clinical significance of such lesions.
The aim of this study was to analyze if this unusual localization of
recurrence is related to any significant differences in the clinical
course and if it significantly increases the risk of thyroid neoplasm.
Material and methods: The outcomes of ultrasound (US) and cy-
tological examinations of 62 patients, presenting with a goiter re-
currence localised as a focal lesion near hyoid bone, were analyzed
(mean age: 59.4 ± 12.4 years). The analysis included the period
from the operation to the lesion-revealing US, the lesion’s volume,
presence of ultrasound features of malignancy, the volume of re-
sidual thyroid tissue in the thyroid bed, the changes in volumes of
examined structures and the outcomes of cytological examinations.
Results: The mean period from the surgery to the US confirming
the lesion presence was 16 years, the mean volume of lesion was
2.17 cm3, the mean period of observation was 3.2 years (ranging
from 1 to 10). Fine needle aspiration biopsy was performed in
47 (76%) focal lesions. The cytological result was never suspicious
or malignant. In 38% patients in whom control US was done with-
in the observation period the lesions enlarged by 20% or more, in
21% of them — by 50%, and in 15% — by over 100%. The category
of cytological result didn’t imply any significant change even in
the case of significant isolated increase in volume of the lesion near
hyoid bone.
Conclusions: The focal lesions near hyoid bone, revealed in pa-
tients operated previously for benign goiter, are not related to in-
creased risk of thyroid neoplasm and their enlargement does not
imply their malignancy.
The use of transervical approach with elevation of
the sternal manubrium for surgery of mediastinal
ectopic goiter, mediastinal parathyroid tumors and
the mediastinal metastases of the thyroid cancer
M. Zielinski1, J. Pankowski2, M. Skrobot2, L. Hauer1,
T. Nabialek3, A. Szlubowski4
1Department of Thoracic Surgery, Pulmonary Hospital, Zakopane, Poland
2Department of Pathology, Pulmonary Hospital, Zakopane, Poland
3Department of Anaesthesiology and Intensive Care, Pulmonary Hospital,
Zakopane, Poland
4Bronchoscopy Unit, Pulmonary Hospital, Zakopane, Poland
Introduction: The mediastinal tumors (parathyroid tumors, ectopic
goiter and metastatic nodes and the benign thymic lesions) are dif-
ficult for surgical treatment with no standard approach of opera-
tion.
Aim of the study: Presentation of the operative technique and re-
sults of resection of upper mediastinal parathyroid tumors, ectopic
goiter and metastatic nodes and the benign thymic lesions through
the transcervical approach with elevation of the sternum.
Material and methods: 26 patients were operated on from 1.1.2006
to 31.12.2009. Operations were performed through the collar inci-
sion, with elevation of the sternal manubrium with use of the me-
chanical sternal retractor without opening of the mediastinal pleu-
ra and without any mediastinal and pleural drainage. In patients
with exceptionally extensive malignant metastatic thyroid cancer
lesions open median sternotomy approach was used.
Results: The transcervical approach was used in 12 patients with
metastatic mediastinal lymph nodes, in 2 patients with the par-
athyroid lesions (mediastinal adenoma 1, metastatic parathyroid
cancer 1), in 8 patients with ectopic mediastinal goiter. In 4 other
patients median sternotomy approach was necessary to obtain com-
plete resection of the whole cancer lesions. A pathology of the met-
astatic thyroid lesions included papillary cancer in 9 patients, the
medullary cancer in 2 patients and the oxyphylic cancer in 1 pa-
tients. The complete (R0) resection was achieved in all benign tu-
mors and malignant tumors. The diameter of the completely re-
sected tumors was 1–9 cm (mean 5.3 cm). Operative time was 30–
–150 min. (mean — 78 min). There was one conversion for thorac-
otomy (due to adhesions) and one reoperation (transcervical revi-
sion with left videothoracoscopy) for bleeding and no other com-
plications (morbidity 3.8%). Postoperative hospital stay was 3–7
days (mean 4–3 days).
Conclusions:
1. Transcervical approach enables complete resection of the be-
nign tumors and early stage malignant metastatic thyroid can-
cer tumors.
2. More extensive lesions require open operative approach
through the median sternotomy.
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Gene expression profile of follicular adenoma
in comparison to other endocrine adenomas
J. Żebracka-Gala1, M. Oczko-Wojciechowska1,
M. Kowalska1, A. Kukulska2, A. Czarniecka2, E. Gubała1,
D. Larysz3, A. Rudnik3, J. Waler4, J. Gawrychowski4,
A. Pfeifer1, M. Świerniak1, M. Jarząb, E. Chmielik6,
D. Lange6, K. Fujarewicz7, A. Świerniak7, B. Jarząb1
1Department of Nuclear Medicine and Endocrine Oncology
2Oncology Surgeric Clinic MSC Cancer Center and Institute of Oncology,
Gliwice Branch, Gliwice, Poland
3Department of Neurosurgery, Medical University of Silesia, Katowice, Poland;
4Department of General Surgery Bytom, Medical University of Silesia,
Katowice, Poland
5Department of Clinical Oncology
6Tumor Pathology Department, MSC Cancer Center and Institute of Oncology,
Gliwice Branch, Gliwice, Poland
7Institute of Automatic Control, Silesian University of Technology,
Gliwice, Poland
Introduction: The transition of an endocrine cell into benign (ade-
noma) and/or malignant tumor (carcinoma) is the subject of inten-
sive research. In some endocrine glands (pituitary, parathyroids)
malignant transformation is an extremely rare phenomenon while
it is relatively frequent in follicular thyroid cells. Molecular mecha-
nism underlying these differences may be better understood when
adenomas and carcinomas arising in various types of endocrine
cells will be compared by their gene expression profile.
The aim of our study was to compare the gene expression profile
of three groups of adenomas of endocrine tissue: thyroid follicular
adenomas, parathyroid adenomas and pituitary adenomas.
Material and methods: We applied human reference expression
microarray (HumanRef-8, Illumina Inc.) to analyze gene expres-
sion profile in selected samples. Total RNA was extracted from tis-
sue using RNeasy Mini Kit (Qiagen). cDNA synthesis was per-
formed with T7 Oligo (dT) primer, then purified using Illumina
Total Prep Amplification Kit. Next, cRNA was hybridized to Hu-
manRef-8 arrays (Illumina). This study was done in pituitary and
parathyroid adenomas, in thyroid adenomas gene expression pro-
filing was done by Affymetrix HGU133A.
Results The data were analyzed both by unsupervised PCA and
supervised analyses. All three groups of adenomas formed distinct
clusters. The supervised comparison allowed to specify genes char-
acteristic for two-way comparisons and, finally, revealed 227 genes
which were differently expressed in all three groups of adenomas
analyzed.
Conclusions: Gene expression profile analysis enables better char-
acterization of similarities and differences between thyroid ade-
noma and parathyroid and pituitary adenomas, essential both for
their better diagnostic characteristics and for therapeutic-directed
research.
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Case of a patient with acromegaly and
a disseminated follicular thyroid carcinoma
A. Bałdys-Waligórska, F. Gołkowski, A. Krzentowska,
A. Stefańska, O. Halytskyy1, A. Hubalewska-Dydejczyk
Chair and Clinic of Endocrinology CMUJ, Kraków, Poland; 1student of UJCM,
School of Medicine in English, Kraków, Poland
The aim of this work is to present a diagnostically challenging case
of a co-occurrence of acromegaly with follicular thyroid carcinoma.
Case description: A 59-year-old male, post total thyroidectomy
performed in 2005, and histopathologically confirmed metastases
of the follicular thyroid carcinoma to the lungs, was admitted to
the Clinic in April of 2006 for complementary 131I treatment. Ac-
romegaly, diagnosed in 1995, was treated in 1996 by the trans-sphe-
noidal surgery. In December of 2005 a relapse of the pituitary ade-
noma was shown on MRI, what correlated with the increased blood
levels of hGH (25.0 ng/mL) and IGF-1 (762.0 ng/mL), and the lack
of inhibition in the OGTT. Treatment with Sandostatin LAR was
begun with the dose of 20 mg/month, and continued with 30 mg/
/month. The biochemical control of acromegaly was achieved —
present concentration of hGH — 2.2 ng/mL, and IGF-1 — 315.8 ng/
/mL. On neck ultrasound the volume of thyroid remnants was
2.4 ml, with a radioiodine uptake of 13% over the neck. The pre-
-therapeutical whole-body scintigraphy revealed numerous con-
joined hot spots of 131I accumulation in the lungs and in thyroid
remnants. In May and November 2006 the patient received treat-
ment with 131I (a total of 250 mCi). The post-therapeutical scintigra-
phy (WBS) of November revealed a complete ablation of thyroid
remnants and decrease in the number and intensity of the isotope
hot spots in lungs as compare to WBS of May 2006. Laboratory
tests confirmed lowering of thyroglobulin concentration in blood
serum from the initial value of 362.0 ng/mL to 103.0 ng/mL. Since
the endogenous TSH stimulation did not produce levels higher than
25.0 lvU/mL, in the years 2007, 2008 and 2009 the patient was qual-
ified for therapy with 131I aided by rhTSH, achieving a reduction of
the Tg levels to 15.2 ng/mL under TSH suppression and 318.1 ng/
/mL after rhTSH stimulation. A WBS done in 2009 revealed a weak
uptake of the marker in the superior mediastinum and bilaterally
in the lung parenchyma. CT of the chest revealed fibrosis in the
supradiaphragmatic left lung segments with no infiltrative chang-
es. The mediastinal and hilar lymph nodes were not enlarged. The
patient remains under the care of the Endocrinology Clinic of CMUJ
in Kraków.
Conclusions: We believe that patients with a nodular goitre of the
thyroid and acromegaly should be monitored carefully by means
of the fine needle biopsy, and treated with rhTSH after surgery of
the pituitary gland.
Solitary metastasis of the clarocellular renal
carcinoma to the thyroid gland — case report
M. Bilski, G. Kamiński
Endocrinology and Radioisotope Therapy Department, Military Institute of Health
Services, Warszawa, Poland
Introduction: The renal carcinoma accounts for about 3 percent of
all cancers with the 30 percent occurrence of the distant metastasis
at the beginning of the diagnosis. It is estimated that the 5 years
survival rate in IV0 stage of the renal carcinoma is about 10 per-
cent. It is also noted that the prognosis is better for patients with
solitary metastasis to the lung or bones and also in the rare cases of
the single metastasis to the brain or liver. The literature analysis of
the unusual cases of the renal carcinoma with incidental metasta-
sis to the thyroid gland suggests their similar prognosis.
Case description: 60 years old male with familiar incidence of the
bladder and colon cancer. The renal tumor and thyroid goiter were
diagnosed in the imaging studies (CT and USG) performed at the
age of 55. The 4 centimeter clarocellular renal carcinoma without
renal capsule infiltration (II0 stage according the Fuhrman classifi-
cation) was found in the histopathology examination performed
after the left nefrectomy. Two and a half years later patient was
operated due to the euthyroid multinodular goitre. The whole right
and partial left lobe resection was performed. In the histopatholo-
gy examination the single 7 millimeter metastasis of the clarocellu-
lar renal carcinoma was found in the totally removed right lobe.
Up to now no other lesions suspected of the malignant character
were found in the performed examinations (abdomen USG, tho-
racic CT, bone scintigraphy with 99mTc-MDP, PET with 18F-FDG,
gastro and colonoscopy).
Conclusion: It is suggested to take into consideration the possibil-
ity of the distant metastasis to the thyroid gland during the clinical
staging of the clarocellular renal carcinoma.
Coincidence of the clarocellular renal and follicular
thyroid carcinomas: case report
M. Bilski, G. Kamiński
Endocrinology and Radioisotope Therapy Department, Military Institute of Health
Services, Warszawa, Poland
Introduction: The coincidence of two or more malignances occurs
in the small percentage of the patients (about 3 percent) and is
Case reports
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mostly seen in the lung, bowel, prostate, bladder and skin cancers.
In spite of the similar natural history of the clarocellular renal and
follicular thyroid carcinomas (among other metastases to the lung
and bones through the bloodstream) there were only a few cases
of the coexistence of these two malignances described. The new
methods of the systemic therapy for renal cancer which were in-
troduced in the last years brought only limited improvement in
the prognosis for patients with disseminated disease (10 percent in
the five-year survival rate). The prognosis for the patients with the
disseminated follicular thyroid cancer is better which among other
accounts for the possibility of the radioiodine therapy delivery.
Case description: 64 years old female after total thyreoidectomy
due to the follicular carcinoma was referred for the radioiodine
ablation. The status post right nefrectomy and disseminated me-
tastases to the lung and bones in course of the clarocellular renal
cancer were found in her medical history. The accumulation of the
delivered radioiodine not only in thyroid bed but also in the me-
tastases which were visualized previously in other imaging stud-
ies, was visualized in scintigraphy. The radioiodine ablation thera-
py was given two times in doses 85 and 117 mCi (in 8 months inter-
val) with partial morphological and functional regression of meta-
static lesions (by SPECT/CT). The achieved radioiodine treatment
effect suggests the dissemination of the follicular thyroid carcino-
ma instead of the previously suspected dissemination of clarocel-
lular renal carcinoma.
Conclusions: The outcome of the described recalls on the necessi-
ty of careful differential diagnosis and search for second neoplasm
also in cases of disseminated renal carcinoma.
A case of Hodgkin lymphoma of the thymus imitating
retrosternal goiter retrospective analysis of the
diagnostic process
M. Dedecjus1, A. Kędzierska1, J. Kozak1,
G. Stróżyk1, R. Kordek3, J. Brzeziński1
1Department of General, Oncological and Endocrine Surgery Medical University,
Łódź, Polish Mother’s Memorial Hospital-Research Institute
2Department of Thoracic Surgery and Respiratory Rehabilitation, Medical
University, Łódź, Polnad
3Department of Pathology, Medical University, Łódź, Poland
Hodgkin’s lymphoma is the most frequent lymphoid proliferation
in the mediastinum. Symptoms and radiological findings are non-
specific. These tumors must be considered in case of thymus in-
volvement in order to avoid a surgical treatment which could lead
to many complications.
We report a case of primary Hodgkin’s lymphoma of thymic origin
in a 27-year-old woman. She presented with a dyspnoe and chest
pain. Chest radiography showed an anterosuperior mediastinal
mass and echocardiography revealed a mass compressing right
pulmonary artery and right ventricle. Ultrasound examination re-
vealed enlarged left lobe of the thyroid, localized partially subster-
nally Fine needle aspiration (FNA) was not diagnostic.
Thoracic computed tomography revealed heterogeneous tumor
staying in connection with thyroid and the diagnosis of substernal
goiter was suggested. The scintigraphy did not confirmed subster-
nal goiter. Due to increasing compressive symptoms caused by tu-
mor the patient was referred to surgical treatment.
A cervicotomy was performed which did not revealed goiter so
consecutive sternotomy was performed revealing large intramedi-
astinal cystic mass which was resected. The definitive histologic
study revealed a Hodgkin’s lymphoma classified as a nodular scle-
rosing type, which was confirmed by the immunohistochemistry.
The patient received postoperative treatment based on chemother-
apy and radiotherapy. The response was very good with a com-
plete remission without recurrences after a follow up of 3 years.
Differentiated thyroid cancer in pregnant women
— clinical dilemmas
M. Koziołek, E. Wentland-Kotwicka, A. Syrenicz
Department of Endocrinology, Metabolic Diseases and Internal Diseases,
Pomeranian Medical University, Szczecin, Poland
A papillary carcinoma is the most common histological form of dif-
ferentiated thyroid cancer, while follicular carcinoma is the second
most common.
In pregnant women a decision about a surgical treatment of differ-
entiated thyroid cancer is set on basis of the term of pregnancy,
size and dynamics of tumor growth and patients attitude. The most
advantageous period for surgery is the 2nd pregnancy trimester.
The surgery of papillary carcinoma and follicular thyroid tumor
can be postponed to postnatal period if a patient accepts such
scheme of treatment. Disadvantageous influence of pregnancy on
the course of differentiated thyroid carcinoma was not proved,
moreover there are no differences in prognosis between women
who underwent a surgery during pregnancy in comparison to the
group operated after delivery.
In case of papillary thyroid carcinoma or follicular tumor diagnosed
during pregnancy, which surgical treatment was postponed to
a postnatal period, administration of L-thyroxin to obtain a TSH
suppression to values of 01–0,5 mU/L and maintenance of fT4 at
the upper range is recommended.
A case of 23-year old pregnant patient suffering from papillary thy-
roid cancer is presented below.
The patient being in the 4th week of pregnancy noticed a tumor on
the right side of the neck. She visited a physician after three months
thyroid ultrasound examination was performed, after the next
month FAB of tumor in the right thyroid lobe was performed. In
cytopathologic report big groups of follicular thyroid cells were
observed that suggested a papillary carcinoma. The patient visited
the PAM Endocrinology Clinic being in the 27th week of pregnan-
cy. In physical examination a significant anomaly was observed:
composed tumor in right thyroid lobe being 3cm in diameter. In
laboratory tests: TSH 1,37 uIU/mL, fT4 0,969 ng/dL, fT3 2,37 ng/dL,
total and ionized calcium concentration, CEA antigen, antithyreo-
globulin and antimicrosomal antibodies ratios within the normal
range. USG of thyroid gland revealed: in right lobe a focal, solid lesion
of heterogeneous echostructure, with calcifications, of blurred uneven
borders, crossing the upper contour of right thyroid lobe, being 34 ×
× 31 × 17 mm in size, in color Doppler intensified vascularization
within the lesion. Because of the pregnancy period 3rd trimester and
after the conversation with a patient and the child’s father a surgical
treatment was decided to be performed after delivery.
L-thyroxine was administrated to the treatment in initial dose of
75 ug/day, increasing then to 100 ug/day.
A patient had control ultrasound examination of thyroid gland and
thyroid tests in the Endocrinology Outpatient Clinic every 3–4 weeks
performed. In 37th week of pregnancy during a control ultrasound
examination of thyroid gland, a tumor increase of 5 mm in longitu-
dinal dimension was observed. The patient came to Endocrinolo-
gy Outpatient Clinic 3 weeks after delivery and was directed to the
surgery ward.
During the presentation authors present a histopathology exami-
nation and the whole body iodine scintigraphy results.
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Treatment with Sorafenib in advanced thyroid cancer
a case report
J. Krajewska1, T. Olczyk1, J. Roskosz1, A. Śmietana2,
B. Kaczmarek-Borowska2, E. Paliczka-Cieślik1,
S. Szpak-Ulczok1, B. Jarząb1
1Nuclear Medicine and Endocrine Oncology Department M.Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
2Chemotherapy Department Subcarpathian Oncology Center, Rzeszów, Poland
Papillary thyroid cancer (PTC) usually gives a good prognosis. The
treatment including total thyroidectomy and complementary 131I
therapy allows to achieve complete remission in 90% patients.
However, in 10% subjects with metastatic disease, the prognosis is
poor. In the group of patients with disease progression and no 131I
uptake searching for new therapeutical modalities comprising an-
tiangiogenic agents and tyrosine kinase inhibitors is necessary.
Thalidomide inhibits angiogenesis by the influence on vascular
endothelial growth factor (VEGF) and basic fibroblast growth fac-
tor (bFGF). Its immunomodulatory effect is due to repression of
COX-2 and other cytokines. Sorafenib inhibits many targeted en-
zymes and intracellular tumor factors, such as: VEGFR-2, VEGFR-3,
PDGRF, CRAF, BRAF, V600E BRAF, c-KIT, FLT-3. High frequency
of BRAF mutations in thyroid cancer supports sorafenib adminis-
tration in PTC treatment.
The study presents a case of 55-year old male with advanced PTC/
/pT3mNxMo/diagnosed in 1993, treated with antiangiogenic factor
(thalidomide) and multikinase inhibitor (sorafenib). Primary treat-
ment: total thyroidectomy and 131I ablation led to complete remis-
sion. In 2000 surgery due to local recurrence as well as lymph node
metastases was performed. In 2006, because of increasing serum
thyroglobulin level distant lung metastasis was diagnosed and
operated. In 2007 another foci in CNS and vertebral column with-
out 131I uptake were stated. Further progression (bone, CNS and
pterygoid muscle) was confirmed by PET/CT. The patient under-
went neurosurgical metastasectomy twice, palliative CNS and ver-
tebra’s radiotherapy. Liver metastases were diagnosed in 2009.
Treatment with increasing doses of thalidomide (up to 800 mg/d)
was administered for 3 months with a good tolerance. The therapy
was withdrawn due to cancer progression. Next sorafenib (800 mg/d)
was given for 16 weeks. Radiological examination performed after
16 weeks confirmed stable disease, whereas 2 months later (after
sorafenib withdrawal because lack of treatment possibility) further
progression was observed.
PDS gene analysis in family with Pendred’s
syndrome associated with thyroid papillary cancer
K. Łącka1, A. Paradowska2, E. Korman3,
J. Rajewska4, B. Stawny5, J.K. Łącki6
1Department of Endocrinology, Metabolism and Internal Medicine, University
of Medical Sciences, Poznań, Poland
2Department of Biochemistry, Institute of Rheumatology, Warszawa, Poland
3Department of Pediatrics Endocrinology and Diabetology, University of Medical
Sciences, Poznań, Poland
4Department of Connective Tissue Disorders, Institute of Rheumatology,
Warszawa, Poland
Pendred’s syndrome is an autosomal recessive disorder character-
ized by sensorineural deafness, euthyroid or hypothyroid diffuse
goiter and a positive perchlorate test and it is caused by PDS (7q13)
gene mutation (SLC26A4). In the course of Pendred’s syndrome
thyroid cancer was observed, particularly the follicular type. No
PDS gene mutation characteristic for developing thyroid cancer in
these patients was described. We present clinical and molecular
genetics studies in a family with Pendred’s syndrome, in whom
one affected individual developed papillary thyroid cancer.
Two out of five children were affected and displayed the classic
Pendred’s syndrome triad. Because of an enlarged multinodular
goiter, patients were operated on and histopathological findings
showed papillary thyroid cancer in a boy and multinodular goiter
in a girl. Patient with thyroid cancer was treated by total thyre-
oidectomy with lymphadenectomy followed by 131I therapy and
suppressive L-thyroxine therapy.
DNA was isolated from whole blood in all members of family de-
scribed. All exons and exon-intron boundaries of the PDS/SLC26A4
gene were amplified by PCR and sequenced.
The PDS gene analysis in this family revealed a transition of G to A
in the splice donor site of intron 8 (IVS8+1G > A). The two affected
individuals were homozygous for this mutation, whereas both par-
ents and one unaffected daughter were heterozygous for it. The re-
maining two unaffected individuals have no PDS gene mutation.
It seems evident that patients with Pendred’s syndrome coexisting
with thyroid solitary nodule or multinodular goiter shoud be oper-
ated on because of the possibility of malignancy. The question re-
mains whether the specific PDS gene mutation exists, which may
predispose to the development of thyroid cancer.
Familial case of oxyphilic thyroid neoplasm
GRIM-19: gene analysis
J. Maceluch1, B. Rabska-Pietrzak1, A. Rojek1,
J. Harasymczuk2, E. Trejster3, M. Warzywoda4,
D. Bręborowicz5, J. Bręborowicz6, M. Niedziela1
1Department of Pediatric Endocrinology and Diabetes, Poznań University
of Medical Sciences (PUMS), Poznań, Poland
2Department of Pediatric Surgery, Traumatology and Urology, PUMS, Poznań,
Poland
3Laboratory of Pathomorphology, K. Jonscher Children’s Hospital of Poznań
University of Medical Sciences, Poznań, Poland
4Department of Pediatric Radiology, PUMS, Poznań, Poland
5Department of Cancer Pathology, Great Poland Cancer Center, Poznań, Poland
6Department of Oncology, PUMS Department of Cancer Pathology, Great Poland
Cancer Center, Poznań, Poland
Introduction: Familial pattern of oxyphilic thyroid tumor (fOTT)
is rare. Environmental and genetic factors are the underpinnings
of the oxyphilic lesion. GRIM-19, a candidate gene located on chro-
mosome 19p13.2, is responsible for mitochondrial metabolism and
cell death and may play a role in the development of this tumor. It
is indicated by excessive number of mitochondria found in this type
of thyroid tumor and mutations in GRIM-19 gene, detected in some
sporadic cases of Hürtle cell tumor.
Patient’s report: A 10-year old prepubertal boy was admitted to
the hospital because of a positive family history for oxyphilic thy-
roid carcinoma (OTC) (mother — OTC, Hashimoto’s thyroiditis and
endometrial adenocarcinoma). He had a goiter (II°) with multiple
nodules in both lobes, clinical and hormonal euthyroidism, and
waa negative for antithyroid antibodies. The dominant nodule (2.6 ×
× 1.7 × 2.6 cm), solid and hypoechogenic on ultrasound, was lo-
calized in the right lobe. A similar but smaller nodule was present
in the left lobe (LL). Cytological evaluation of the material from
biopsy showed a suspicious lesion. A right lobectomy with the isth-
mus, along with the removal of the nodule in LL, was performed.
Histopathological examination showed an oxyphilic adenoma and
a macro- and microfollicular colloid goiter. He was substituted with
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L-thyroxine. Few years later the reoperation of the LL was per-
formed.
Aim of the study: Analysis of selected neoplastic markers in tumor
‘s tissue and peripheral blood.
Material and methods: Sequence analysis of GRIM-19 on DNA
from blood was performed by PCR amplification of all exons and
sequencing techniques and GRIM-19 gene expression on RNA from
blood was performed by RT-PCR. Biomarkers of thyroid cancer
from tumor’s tissue (FNAB) were analyzed by gene expression anal-
ysis (RT-PCR).
Results: Biomarkers analysis in tumor’s tissue was positive for ga-
lectin 3 and cytokeratin 19. Sequencing of GRIM-19 DNA showed
no abnormalities, however gene expression analysis showed a big-
ger product (~1100 bp) than expected.
Conclusions:
1. Multifocal thyroid nodular lesions in a boy below 10 yrs of age
may indicate the inherited pathology.
2. GRIM-19 gene expression abnormality can influence the func-
tionality of the encoded protein.
Difficulties in diagnosis and therapy of the patient
with chronic autoimmune thyroiditis
and the coexisting thyroid nodule
M. Niedziela1, D. Bręborowicz2, B. Rabska-Pietrzak1,
E. Trejster3, J. Harasymczuk4
1Department of Pediatric Endocrinology and Diabetes, Poznań University
of Medical Sciences (PUMS), Poland
2Department of Cancer Pathology, Great Poland Cancer Center, Poznań, Poland
3Laboratory of Pathomorphology, K. Jonscher Children’s Hospital of Poznań
University of Medical Sciences; Poznań, Poland
4Department of Pediatric Surgery, Traumatology and Urology, PUMS, Poznań,
Poland
Patient’s Report: 15-year-old girl was admitted to the Department
with suspicion of thyroid nodule. Focal lesion was detected on ul-
trasound of the neck done after the neck trauma (with a ball). On
clinical examination she was euthyroid with a palpable nodule in
the upper pole of the right lobe of thyroid. Laboratory tests (thy-
roid hormone levels, TSH, antithyroid antibodies: ATPO and ATG)
were normal. Thyroid ultrasound showed the solid-cystic lesion
with a diameter of 1.3 × 0.4 cm (longitudinal projection) with oth-
erwise hypoechogenic remaining thyroid gland. Scintigraphy was
normal and fine-needle aspiration biopsy (FNAB) was non-diag-
nostic. 8 months later she was admitted to the Department again
for control tests. The lesion (unechogenic) was similar in size (1.2 ×
× 0.5 cm). Thyroid hormones, TSH and ATPO were normal, where-
as ATG titer was positive (87 IU/mL). FNAB was again non-diag-
nostic. 2 years later she was admitted again to the ward (in the
meantime she was in ambulatory care and received 50 ug of
L-thyroxine daily). On clinical examination the palpable nodule was
still present in the right lobe and its diameter was 1.0 × 1.1 × 0.5 cm
on ultrasound. Thyroid hormones, TSH and ATG were normal
whereas ATPO was positive (67 IU/mL). During FNAB of un-
echogenic lesion 0.2 mL of fluid was obtained. The cytological re-
sult of the aspirated material was as follows: atypic cells; based on
cytology the papillary thyroid carcinoma should be suspected; his-
topatological verification is obligatory. Based on the patient‘s his-
tory, clinical examination and cytology the surgical treatment was
advocated (right lobectomy with isthmus). 2 months later she was
operated on. The histopathological (intra- and postoperative) ex-
amination showed features of chronic lymphocytic thyroiditis
(Hashimoto thyroiditis; HT).
Conclusion: HT shares common cytological features with early
papillary thyroid carcinoma and therefore the false positive cyto-
logical result in terms of PTC is possible in a course of HT.
Thyroid lesion as first manifestation of Hodgkin’s
lymphoma
M. Ruchała1, E. Szczepanek1, P. Majewski2, J. Sowiński1
1Department of Endocrinology, Metabolism and Internal Medicine, Poznań
University of Medical Sciences, Poznań, Poland
2Department of Clinical Patomorphology, Poznań University of Medical Sciences,
Poznań Poland
Introduction: Lymphomas account for less than 5% of malignant
lesions diagnosed in the thyroid. Vast majority of them are B-cell
non-Hodgkin’s lymphomas, developing in the course of autoim-
mune thyroiditis, while Hodgkin’s lymphoma, primarily localized
in the thyroid, is a very rare finding.
Case report: 23-year-old woman was referred to the endocrine
outpatient clinic for further diagnostics, with suspicion of thyroid
cancer. On thyroid ultrasound examination, a large, hypoechogenic
lesion, localized at the border between left lobe and isthmus, was
visualized. Unilaterally, enlarged, round and hypoechogenic lymph
nodes were found, suggesting metastatic lesions. On thyroid scin-
tiscan, a large cold nodule was found and its localization corre-
sponded to the lesion revealed during thyroid ultrasound. Thy-
roid hormonal function was normal and thyroid autoantibodies
were negative. Fine-needle aspiration biopsy of the thyroid and
lymph nodes, was twice non-diagnostic. Eventually, third biopsy
allowed to detect carcinomatous cells of undetermined origin. The
clinical picture, together with result of cytological examination,
prompted us to refer the patient for immediate total thyreoidecto-
my and lymphadenectomy. On histopathological examination,
extralymphatic Hodgkin’s lymphoma of the thyroid was diagnosed.
The patient was subsequently referred to the department of hema-
tology for chemiotherapy and radiotherapy. The patient’s obser-
vation period has now reached one year. She is still followed-up in
the endocrine outpatient clinic, reached remission and remains
euthyroid on substitutive dose of L-thyroxine.
Conclusions: Despite extremely rare occurrence, Hodgkin’s lym-
phoma ought to be considered in differential diagnosis of malig-
nant lesions diagnosed in the thyroid.
Metastases of breast cancer to the thyroid gland
in two patients —  a case report
E. Skowrońska-Jóźwiak1, Z. Adamczewski1,
K. Krawczyk-Rusiecka1, A. Gumińska1, S. Sporny2,
A. Kulig3, M. Dedecjus4, J. Brzeziński4, A. Lewiński1
1Department of Endocrinology and Metabolic Diseases Medical University,
Łódź, Poland
2Department of Dental Pathomorphology, Medical University, Łódź, Poland
3Department of Pathology, Institute of Polish Mother’s Memorial Hospital, Łódź,
Poland; 4Department of General and Endocrine Surgery, Medical University,
Łódź, Poland
Introduction: Metastatic cancer is rarely found in the thyroid (only
2–3% of malignant tumors found in this gland), primary sources
usually including breast, kidney and lung tumors.
Patients: Two cases of advanced breast cancer with thyroid me-
tastases in female patients are presented. Similarities between these
two cases included: 1) postmenopausal age, 2) diagnosis based on
result of FNAB (multiple groups of cells with epithelial phenotype
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strongly implying metastasic breast cancer), 3) thyroid function
overt hyperthyroidism in the first woman and subclinical hyper-
thyroidism in the second one, 4) presence of nodular goiter in clin-
ical examination, 5) presence of multiple nodular solid echogenic
lesions with calcifications in both thyroid lobes in US, 6) negative
anti-thyroid antibodies. The main difference was the time of estab-
lishing diagnosis; in the first woman before mammectomy, paral-
lel to diagnostics of breast tumour, in the second woman 4 years
after mammectomy, during metastatic phase of the disease (with
right pleural effusion and lung metastasis). In the first case mam-
mectomy was followed by thyroidectomy in two weeks. The sec-
ond patient was disqualified from thyroid surgery, due to systemic
metastatic disease.
Conclusions:
1. Fine needle aspiration biopsy of the thyroid gland should be
obligatorily performed in patients with breast cancer and nod-
ular goiter, even without any clinical data of metastatic dis-
ease.
2. Clinical assessment of cytological findings is of critical value.
3. In the case of multinodular goiter, accompanying metastatic
neoplastic disease, the biopsy of a greater number of lesions
should be considered.
A case of a patient with secondary
hyperparathyroidism and thyroid cancer
J. Skrobisz1, R. Wieczorek2
Surgical Departament B of Regional Hospital in Poznań, Poland
A young woman with thyroid cancer and hypercalcemia due to ad-
enomas of the parathyroid glands was successfully treated in 2007/
/2008. Total thyroidectomy was performed and two adenomas were
removed. PTH level dropped from 2500 pg/mL to 11 pg/mL.
Columnar cell variant of papillary thyroid carcinoma
in ovarian struma — case report
B. Szcześniak-Kłusek1, E. Stobiecka1,
A. Smok-Ragankiewicz1, J. Krajewska2,
A. Czarniecka3, D. Lange1
1Department of Tumor Pathology, M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Gliwice, Poland
2Nuclear Medicine and Endocrine Oncology Department, M. Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology, Gliwice Branch,
Gliwice, Poland
3Oncologic Surgery Clinic, M. Sklodowska-Curie Memorial Cancer Center and
Institute of Oncology, Gliwice Branch, Gliwice, Poland
Introduction: Ovarian struma is a rare type of mature teratoma
composed predominantly of mature thyroid tissue, which can
present malignant transformation characteristic for normal thyroid.
Case: A 37-year old patient with an ovarian tumor underwent sur-
gery. Postoperative examination revealed two cystic tumors mea-
suring 3 and 4 cm. The smaller one was diagnosed as benign se-
rous cyst and the larger as malignant ovarian struma with colum-
nar cell variant of papillary thyroid carcinoma.
The patient was subsequently treated with total thyroidectomy and
131I therapy. After 10 months of observation there was no evidence
of recurrence or metastases.
Conclusion: Columnar cell variant is extremely rare type of papil-
lary thyroid carcinoma with aggressive biologic behavior and its
presence in ovarian struma has not yet been described in the liter-
ature.
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Identification of immune markers (CD54, CD95,
CD134, CD152) on the thyroid follicular cells in
patients with immune and non-immune thyroid
diseases using cellular culture
A. Bossowski1, E. Iłendo2, K. Ratomski3,
B. Czarnocka4, J Dadan5
1Department of Pediatrics, Endocrinology, Diabetology with the Cardiology
Division. Medical University of Białystok, Bialystok, Poland
2Department of Cytogenetics. University Children’s Hospital in Bialystok,
Bialystok, Poland
3Department of Pediatric Diagnostic Laboratory, Medical University of Bialystok,
Bialystok, Poland
4Department of Molecular Biology and Clinical Biochemistry. Medical Center
of Postgraduate Education, Warszawa, Poland
5Department of Surgery, Medical University of Białystok, Bialystok, Poland
In the pathogenesis of Graves; disease an important role play proin-
flammatory cytokines. They influence on immune system and also
on destination cells by induction of antiapoptotic molecules expres-
sion causing resistance of thyrocytes to apoptosis - the programmed
cells death, coursed by CD 95.
The aim of the study was to detect the expression of CD 54, CD 95,
CD 134, CD 152 in the thyroid tissue in patients with Graves disease
(GD) and patients with non-toxic nodular goiter (NTNG) during the
cellular culture with or without cellular stimulators. Investigated thy-
roid tissue was cleaned and then mechanically and enzymatic frag-
mented using collagenase with HBSS. The obtained suspension of
cells was passed through the nylon- filter. The culture of thyroid
cells was led in 50 mls phials containing: RPMI 1640, 10% FBS, HEPES
buffer, L-the glutamine, penicillin and streptomycin. After isolation
of thyrocytes (3 × 105) the culture was managed into 6-pit plates
through the period of 5 days. TNF-alpha; IL-1beta; and INF-gamma
were added. Identification of CD 54, CD 95, CD 134, CD 152 markers
on thyrocytes, before and after use of cellular stimulators was per-
formed using flow cytometry on apparatus Coulter XP.
The analysis of CD 54, CD 95, CD 134, CD 152 markers expression
on thyrocytes showed their elevation in patients with GD in com-
parison to group of patients with NTNG. During the cellular cul-
ture percentage of cells with CD 95 expression significantly de-
creased. Application of cellular stimulators led to the increase of
the expression of CD54 and CD134 molecules, while CTLA-4 was
unchanged in Graves patients.
In conclusion, changes of the expression of CD 54, CD 95, CD 134
molecules on the thyroid follicular cells suggest the different de-
gree of the activation and stimulation of the cells during the devel-
opment of the pathological process within thyroid gland
The contribution of Pro12Ala PPAR-gamma gene
polymorphism to Graves orbitopathy
J. Daroszewski1, E. Pawlak2, M. Bolanowski1, I. Frydecka2,3
1Department of Endocrinology, Diabetology, and Isotope Therapy,
Medical University, Wroclaw, Poland
2Department of Immunopathology, Institute of Immunology and Experimental
Therapy, Polish Academy of Sciences, Wroclaw; Poland
3Department of Hematology, Blood Neoplastic Diseases, and Bone Marrow
Transplantation, Medical University, Wroclaw, Poland
Introduction: Peroxisome proliferation-activated receptors-gamma;
(PPAR-gamma;) are involved in adipogenesis as well as in immu-
noregulation and inflammation control. Orbital fibroblast differ-
entiation to adipocytes is a PPAR-gamma; dependent process es-
sential for pathogenic tissue remodeling in Graves orbitopathy
(GO).
We studied the occurrence and possible associations of the
Pro115Gln and Pro12Ala in the PPAR-gamma;2 gene with clinical
manifestation of GO.
Material and methods: The Pro12Ala and Pro115Gln polymor-
phisms were examined using PCR-RFLP technique with restric-
tion enzymes: HpaII and HincII, respectively, in 202 Graves dis-
ease patients. There were 168 patients with GO and 34 subjects
without eye changes. Patients with GO were grouped according to
the stage of the disease severity.
Results: Ala allele and (Pro12Ala + Ala12Ala) genotype decreased
the risk of OT by a factor of 3.33 and 3.45 (p = 0.0002, 95% CI: 0.16–
0.59 and p = 0.001, 95% CI: 0.13–0.63, respectively). Moreover, the
Ala12Ala genotype was not observed in the group of patients with
GO. The patients heterozygous at this polymorphic site were sig-
nificantly more frequent in a group without GO as compared to
GO group (38.2% v. 18.5%, p = 0.01, 95% CI: 0.17–0.81). However,
this polymorphism was not associated with a GO stage. The
Pro115Gln mutation was not found in any of subjects examined.
Conclusions: We found that the Ala variant in Pro12Ala polymor-
phism was associated with decreased risk of GO and might be con-
sidered as a protective factor.
Other thyroid-related abstracts
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Thyroid dysfunctions in children detected in mass
screening for congenital hypothyroidism
M. Kumorowicz-Czoch1, D. Tylek-Lemańska2, J. Starzyk1
1Department of Pediatric and Adolescent Endocrinology, Polish-American
Children’s Hospital, Collegium Medicum, Jagiellonian University,
Kraków, Poland
2Division of Screening and Inborn Errors of Metabolism, University Children’s
Hospital, Kraków, Poland
Introduction: To determine the prevalence of primary congenital
hypothyroidism (CHT) and isolated hyperthyrotropinemia (IHT)
in newborns selected in mass screening for CHT and to analyze
the causes of permanent CHT and IHT.
Material and methods: Of 233,120 neonates born in the Małopolska
province in the period 2000-2006, mass screening selected 118 chil-
dren suspected of CHT. Serum TSH and fT4 levels were determined
during 1st confirmation of diagnosis (118 newborns) and re-evalu-
ation (48 children); the patients were subjected to thyroid ultra-
sonography and/or thyroid scintiscan performed in 47 and 30 chil-
dren, respectively.
Results: Of 118 children selected in mass screening, 1st confirma-
tion of diagnosis indicated thyroid dysfunction in 71: CHT in 63,
and IHT in 8. Permanent CHT after 1st confirmation or re-evalua-
tion was noted in 36 children: thyroid dysgenesis in 25 (aplasia in
9, hypoplasia in 3, sublingual ectopy in 13), dyshormonogenesis in
9, unknown etiology in 2. Transient CHT affected 19 children with
normal thyroid. Permanent IHT was detected in 8 children: 6 with
Down s syndrome, one with multiple congenital defects and an-
other one with unidentified cause. The prevalence of CHT was
1:3,700 (permanent 1:6,476, transient 1:12,269) and of permanent
IHT — 1:29,140.
Conclusions:
1.  1st confirmation indicates the diagnosis of CHT or IHT in 60%
of children. Permanent forms are diagnosed in 62% of these
children.
2. Permanent CHT is twice as common as transient CHT. Devel-
opmental thyroid defects are responsible for 69% of perma-
nent CHT cases.
3. IHT is usually permanent and affects children with Down’s
syndrome or congenital malformations.
Evaluation of the results of IL-6 levels in patients with
Graves-Basedow disease without active ophthalmopathy
D. Zalewska- Rydzkowska12, A. Nowicka1,
J. Kwaśniewska-Błaszkowska1, S. Manysiak2,
G. Odrowąż-Sypniewska2, R. Junik1
1Department of Endocrinology and Diabetology CM UMK, University Hospital,
Bydgoszcz, Poland
2Department of Laboratory Diagnostics CM UMK, University Hospital,
Bydgoszcz, Poland
Introduction: Cytokines are peptides and small proteins, affecting
cell functions through specific receptors and conditioning their in-
teraction. In response to the stimulus they are rapidly synthesized
and released in very small quantities. Elevated levels of cytokines
are observed in autoimmune thyroid disease.
The objective of this study was to estimate the IL-6 levels in blood
of patients with Graves-Basedow disease without active ophthal-
mopathy.
Material and methods: The study covered 35 persons with Graves-
Basedow disease. In none of the patients features of active oph-
thalmopathy were observed. The control group was 14 healthy
persons. IL-6 was determined by ELISA Bender MedSystems.
Results: In patients with Graves-Basedow disease, the mean value of
IL-6 was 2.61 pg/mL, SD 0.93 pg/mL. For the control group the mean
value was 2.13 pg/mL, and SD 0.83 pg/mL, p > 0.05. (According to the
producer normal values: mean 1.3 pg/mL, and SD 3.2 pg/mL)
Conclusion: There is no significant difference in the concentrations
of IL-6 between patients with Graves-Basedow disease without
active ophthalmopathy and the control group.
